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Abstract 
 
In recent years, heterologous prime-boost vaccination constructs have emerged as 
a promising strategy to generate broad and protective immunity against a variety of 
pathogens.  The utility of DNA vaccination in priming the immune system, in particular, 
has improved the immunogenicity of vaccines against difficult pathogens such as HIV-
1.  In addition, many vaccine formulations include an adjuvant to augment immune 
responses.  However, the mechanisms and profiles of many adjuvants remain largely 
unknown, particularly in the context of such combination immunization approaches.   
My thesis research studied the effects of several adjuvants, QS-21, aluminum 
hydroxide, MPL, and ISCOMATRIX™ adjuvant in the context of a previously described 
pentavalent HIV-1 Env DNA prime-protein boost vaccine, DP6-001.  In a murine model, 
we quantified HIV antigen-specific humoral and T cell responses, as well as pro-
inflammatory serum cytokine and chemokines, both shortly after immunization and at the 
termination of studies.  Our data indicates that each candidate adjuvant generates a 
unique pattern of biomarkers as well as improved immunogenicity in the context of the 
DP6-001 DNA prime-protein boost vaccine.   
Additionally, we examined the impact of several innate signaling pathways on the 
adaptive immunity raised by DP6-001 and adjuvants, as well as on the unique serum 
cytokine profiles.  These studies provide valuable information in selection of an adjuvant 
for inclusion in future prime-boost strategies, with the goal of enhancing immunogenicity 
while minimizing reactogenicity.  Furthermore, these studies provided insight about the 
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utility of different current adjuvants in a prime-boost formulation, and the unique 
immune environment induced by DNA priming.   
 vi 
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CHAPTER I: 
Introduction 
Since Edward Jenner’s first demonstration of effective human vaccination against 
smallpox in 1796 and the subsequent eradication of smallpox in the human vector, 
vaccine strategies and technologies have continued to develop in the face of new and 
challenging pathogens, as well as the urgent societal need.  Two effective vaccines 
emerged in a rapid response to the public health crisis created by the poliovirus epidemic 
in the mid-20th century: Jonas Salk’s inactivated poliovirus vaccine and Albert Sabin’s 
live-attenuated poliovirus vaccine, released in 1952 and 1958, respectively (133). The 
emergence of new pathogens has always driven optimization and innovation in vaccine 
design, especially where conventional practices fail.   
According to World Health Organization (WHO) reports in 2011, approximately 
34 million people are currently living with human immunodeficiency virus (HIV-1) 
worldwide, with 2.5 million new infections and 1.7 million virus-related fatalities in 2011 
(190).  Since the emergence of HIV-1 and acquired immunodeficiency syndrome (AIDS) 
in 1981, there remains an exigent need for an effective vaccine.  Conventional 
vaccination methods, such as live-attenuated or inactivated viral vaccines, raise 
considerable safety concerns. Development of an effective prophylactic vaccine remains 
the focus of substantial research resources, due both to the overwhelming global need as 
well as the intrinsic obstacles to effective immunity presented by the HIV-1 virus. 
The HIV-1 virus has a high rate of mutation during replication, lacks an effective 
mechanism of proof-reading, and also an error-prone reverse transcriptase enzyme, which 
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results in the substantial diversity of viral subtypes.  These characteristics also allow for a 
high rate of escape from virus-specific adaptive immune responses, and a high level of 
viral diversity within a single host (55).  Subsequently, the global epidemic is 
characterized by a wide distribution of subtypes, or clades, of the major (M) group of 
HIV-1.  Therefore, development of an effective vaccine must address the challenge of the 
large number of circulating viral subtypes even within a single region. 
 A major challenge of designing an HIV-1 vaccine has also been identifying viral 
antigens to include in the vaccine.  The HIV-1 virus is comprised of an RNA genome and 
9 genes encoding 15 proteins with different roles in viral function.  These include the Pol 
enzymatic proteins [protease (PR), reverse transcriptase (RT), integrase (IN)], and several 
accessory proteins in the viral particle (Vif, Vpr, and Nef), gene regulatory proteins (Tat 
and Rev), and the viral assembly protein Vpu.  Viral structural components include Gag 
proteins [matrix (MA), capsid (CA), nucleocapsid (NC) and p6] and two envelope (Env) 
subunits.  The Env trimer is composed of the heavily glycosylated gp120 subunit that 
forms spikes expressed on the virus surface.  gp120 is responsible for the binding of CD4 
on the host cell surface during viral entry, and is covalently linked to the gp41 
transmembrane subunit (55).  Env is the primary viral antigen targeted by neutralizing 
antibodies (NAb) against HIV-1 (20, 113, 197).   
1. HIV-1 Vaccine Trials 
1.1 VaxGen Trial 
Despite the overwhelming success of new subunit recombinant protein-based 
vaccines against hepatitis B (HBV) vaccines in the 1980s (21, 48, 116), these strategies 
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failed in several Phase III clinical efficacy trials conducted by VaxGen conducted 
between 1998 and 2003.  Both the VAX004 trial, conducted in North America and the 
Netherlands, and the VAX003 trial, conducted in Thailand, evaluated the 
immunogenicity of bivalent recombinant HIV-1 envelope gp120 glycoprotein (rgp120) 
vaccines.  The VAX004 study evaluated the immunization of at risk, HIV-1 seronegative 
individuals with the AIDSVAX B/B vaccine, consisting of two clade B rgp120 antigens 
from two different subtypes of clade B viral strains, adsorbed onto an aluminum 
hydroxide gel adjuvant, and administered by intramuscular (i.m.) injection at months 0, 1, 
6, 12, 18, 24, and 30 (52).  Despite the development of binding and neutralizing antibody 
responses (Nab) specific to vaccine strain rgp120, vaccination did not significantly confer 
protection compared to placebo.  Moreover, vaccination did not positively or negatively 
impact disease progression in individuals that became infected during the course of the 
study (52).  The second study, VAX003, evaluated a bivalent vaccine AIDSVAX B/E in 
HIV-1 negative injection drug users in Thailand, which demonstrated a similar lack of 
efficacy (60, 61).   
These clinical results were in disappointing contrast to protection previously 
observed in vaccinated chimpanzees (11, 12, 46), and phase 1 and 2 clinical trials, which 
produced robust vaccine-induced antibody responses after vaccination with AIDSVAX 
(54, 63, 64, 142, 143).  Furthermore, while peak antibody responses were inversely 
correlated with incidence of HIV-1 infection in vaccinees (61), the lack of clinical 
efficacy in the AIDSVAX trials suggest that recombinant protein-based vaccine induction 
of antibody responses may not be sufficient for protection.  Indeed, definitive correlates 
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of protective immunity against HIV-1 remain unclear, and are not limited to the 
generation of humoral immunity.  In light of these observations, alternative strategies 
focused on raising vaccine-specific T cell responses that may be sufficient for protection.   
1.2 STEP Trial 
In an effort to develop an HIV-1 vaccine capable of raising specific T cell 
responses, Merck Research Laboratories developed a recombinant adenovirus serotype 5 
(rAd5) viral vector-based strategy.  The trivalent rAd5 vector vaccine consisted of rAd5 
encoding HIV-1 viral antigens Gag, Pol, and Nef, and was administered in a homologous 
prime-boost regimen at months 0, 1, and 6.  Phase I clinical trials of the rAd5 vector 
vaccine indicated that the regimen was safe and results were encouraging, with the 
induction of HIV-1 Gag-specific T cell responses measured in vaccinees as measured by 
IFNγ ELISpot during weeks 30-78 (147).  While there were concerns regarding pre-
existing adenovirus-specific responses in seropositive individuals previously exposed to 
Ad5, clinical trials of the Merck Ad5 vaccine moved forward.   
The STEP trial, a Phase IIb proof-of-concept study of the rAd5 vector vaccine, 
tested an identical Ad5 viral vector vaccine described above.  As intended, the vaccine 
did induce strong T cell responses, indicated by antigen-specific production of IFNγ as 
measured by ELISpot in 77% of vaccinees (23, 118).  Further analysis by intracellular 
cytokine staining (ICS) demonstrated that 41% of vaccinees produced vaccine-specific 
CD4+ T cells with a polyfunctional profile (production of IFNγ and IL-2), while 73% of 
participants produced specific CD8+ T cell responses (118).  Unfortunately, the positive 
induction of cell-mediated immunity (CMI) was not correlated to protection against 
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infection, or mitigation of viremia in subjects that became infected during the course of 
the study.  In fact, the STEP trial was abruptly halted in September of 2007 due to 
considerable safety concerns.  Not only did the rAd5 vaccine fail to meet expectations of 
protection, but in fact the viral vector vaccine appeared to increase susceptibility to HIV-
1 infection in vaccinees previously exposed to Ad5 adenovirus (95).  Subsequent 
evaluation of samples from vaccinees indicated that CD8+ T cell responses were 
attenuated by pre-existing NAb against Ad5 (196).  Additional reports indicated that 
CD4+ T cells specific for Ad5 vector existed but were not associated with increased 
susceptibility (80, 134).   
In conjunction with safety concerns demonstrated with the viral vector strategy, 
the failure of the STEP trial raised additional questions about correlates of protective 
immunity.  It is unclear whether the inadequate protection conferred by a vaccine 
designed to elicit T cell responses was due to poor induction of cell-mediated immunity 
(CMI), or due to the lack of robust neutralizing antibody responses.  Lessons from the 
VaxGen and STEP trials demonstrate the need for vaccine candidates to induce both 
humoral and cell-mediated immune responses against HIV-1.  
1.3 RV144 Trial 
The Phase III RV144 trial, conducted in Thailand, volunteers were immunized 
with two vaccine strategies that had previously been shown to be ineffective on their 
own.  HIV-1 negative individuals (n=16,402) received the ALVAC recombinant 
canarypox vector.  ALVAC consists of viral vector expressing the circulating 
recombinant forms 01_AE gp120, subtype B transmembrane gp41, and subtype B gag 
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and protease, at weeks 0, 4, 12, and 24 via i.m. injection.  AIDSVAX B/E recombinant 
gp120 boosts were formulated with aluminum hydroxide gel adjuvant and administered 
i.m. at weeks 12 and 24 via i.m.  Vaccinees were followed for HIV infection and immune 
responses over three years following immunization (150). 
Phase I and II clinical trials conducted on a smaller scale demonstrated that the 
ALVAC prime and AIDSVAX B/E boost regimen was safe and tolerable in humans.  In 
addition, 63% of immunized participants demonstrated lymphoproliferation, and 24% of 
vaccinees produced CD8+ T cells.  Almost all vaccinees raised binding and neutralizing 
antibody responses against vaccine strains (132).  These initial results were extremely 
promising, and studies were advanced to phase III trials in the RV144 study. 
Vaccinees in the intent-to-treat group of RV144 demonstrated an overall 31% 
efficacy in protecting against HIV-1 infection in the 3.5 years of study, which was a 
marginal but significant and encouraging outcome (150).  In fact, in a cohort of 
participants considered to be of a lower-risk, protection against infection was as great as 
40% (145).  The vaccine was shown to be safe and tolerable in immunized participants 
(144).  Extensive follow-up studies indicated modest induction of Env-specific T cell 
responses in 41% of vaccinees, predominated by polyfunctional CD4+ T cells producing 
IFNγ and IL-2 (38).  Correlation was observed between subjects producing IL-2 
responses and improved Env-specific antibody titers (38).  Furthermore, antibody-
dependent cellular toxicity was detected in 80% of vaccinees (14, 84).   
Binding IgG antibody responses against the Env epitope V2 were raised in 
vaccinees and were correlated with protection against infection.  In a comparison study 
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against VAX003 study samples, neutralizing antibodies against a Tier 1 panel of viral 
isolates were induced by the RV144 prime-boost, but to a weaker extent than observed in 
VAX003 (83, 125).  However, persistent low levels of neutralizing antibodies generated 
by the RV144 vaccine are at least suggestive of the induction of long-term memory B 
cells (125).  In fact, antibody responses in waned after the 12 months following 
vaccination, a factor that may have contributed to diminishing protection (145).  While 
protection immediately following immunization was estimated at 70%, protection at the 
conclusion of the study (42 months) was more modest, at 31% (5).   
2. Important role of antibodies in HIV-1 vaccines 
2.1 Evidence from passive antibody immunization 
In early preclinical studies focused on protective immunity against HIV-1, 
chimpanzees passively immunized with human neutralizing monoclonal antibodies 
(mAb) specific for HIV-1 Env gp120 epitopes were found to be protected against viral 
challenge by the same HIV-1 variant (49).  Passive inoculation of chimpanzees with NAb 
against Env impacted the course and severity of disease (32).  In non-human primates, the 
combination of HIV-1 immuno globulin and neutralizing human monoclonocal 
antibodies (mAbs) was either protective against subsequent challenge or resulted in a 
more benign disease progression (112, 114).  The advantages of passive immunization 
and the protective importance of neutralizing antibodies were also demonstrated in 
models of maternal-fetal HIV-1 transmission.   Passive immunization of pre-natal 
pregnant macaques, and post-natal immunization of their neonates, with human mAbs 
was observed to be either protective against infection or slowed disease progression 
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following simian HIV (SHIV) challenge (6, 75), even in the absence of a prenatal dose 
(76).  These studies indicate the importance of neutralizing antibody responses in 
effective protection against HIV-1 infection.   
The Env gp120 antigen, exposed on the surface of the virus, was found to be 
superior at generating a viral NAb response compared to the full-length transmembrane 
gp160 (12).  In several studies, immunization with recombinant gp120 (rgp120) protein 
in non-human primates (NHP) resulted in no apparent signs of infection following 
challenge with homologous virus (12, 13, 62).  Immunization of NHPs with rgp120-
based vaccine strategies improved NAb titers against vaccine strains, with elevated 
specific NAb titers correlating to protection against infection during subsequent 
homologous viral challenge (12, 13, 62). In addition, polyvalent multiclade recombinant 
protein vaccine strategies generated NAb responses with improved breadth and potency, 
as well as improved protection and reduced viremia in immunized NHP against 
homologous viral challenge (30, 91).   
However, despite the initial promise of protein vaccines against HIV-1 in 
preclinical trials, these strategies were clinically disappointing.  A Phase I clinical trial of 
rgp120 immunization in healthy human volunteers demonstrated that vaccine-induced 
antibodies were capable of neutralizing laboratory-adapted viral strains, but failed to 
neutralize primary viral isolates (113).  In comparison, HIV-infected individuals were 
characterized by NAb against both laboratory-adapted and primary viral strains, 
indicating a disparity between the vaccine-induced immune response and the immune 
response induced by the natural course of infection (113).  
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Concurrent with the study of NAb raised by protein vaccination, additional work 
in NHP models indicated the critical contribution of cell-mediated immunity (CMI) by 
both CD8+ cytotoxic lymphocytes (CTLs) and CD4+ helper T cells.  In a series of 
publications, Heeney et al. evaluated rgp120 protein-based vaccination in rhesus 
macaques based not only on the induction of humoral immunity, but also vaccine 
antigen-specific CD4+ and CD8+ T cell responses (69-73, 113).  Homologous viral 
challenge of immunized animals demonstrated sterilizing immunity.  Both NAb titer and 
a strong, balanced Th1/Th2 helper response were identified as correlates of long-term 
protective immunity against homologous and heterologous viral challenge in NHP (70, 
73).   The production of pro-inflammatory chemokines RANTES, macrophage 
inflammatory protein 1α (MIP-1α) and MIP-1β produced by cytotoxic T lymphocytes 
(CTLs) were also correlated to protection (71).  In addition, the importance of a vaccine-
induced CTL response was shown to be a critical component in controlling viremia (24, 
72, 164).  To date, there is no human data to support this. 
2.2 Evidence and new data from RV144 
 The modest, but promising, results from the RV144 study provide many lessons 
for the future direction of HIV-1 vaccine strategies, especially considering the substantial 
opposition faced at the inception of the trial rooted in the failure of each vaccine 
component individually.  This study indicated that a prime-boost strategy by heterologous 
modalities are capable of inducing a superior immune response, and in this example, 
improved protection, compared to either component individually.  Despite decades of 
research focused on the immune responses in HIV-infected individuals, and in study 
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participants immunized with evolving vaccine strategies, clear correlates of HIV-1 
immunity towards which to strive remain elusive.  It is clear from this trial, and previous 
failed attempts, the necessity of designing vaccines with the goal of inducing humoral 
responses and CMI, as well as the efficacy of prime-boost strategies in achieving this 
aim.   
Still, questions regarding optimization remain.  Was the modest efficacy and 
quickly waning protection observed in RV144 due to the antigens themselves, the 
vaccination regimen, or the vector chosen for priming?  Alternatively, the choice of 
adjuvant may greatly impact the immunogenicity of a vaccine.  Aluminum salt based 
adjuvants primarily promote antibody responses, and thus inclusion of a more potent and 
balanced immune responses may allow for substantial strides towards an effective 
prophylactic vaccine against HIV-1 (145, 187).  
3. HIV-1 DNA vaccines 
3.1 DNA vaccine history 
After the initial failure of protein-based vaccines against HIV-1 based on raising 
NAb responses, efforts were refocused on generating a strong T cell response.  DNA 
vaccines emerged as a novel immunization modality in the early 1990s, allowing for the 
uptake of antigen-encoding plasmid DNA or viral vector by antigen presenting cells 
(APCs), and subsequent production of vaccine antigen in vivo in its native conformation 
and with post-translational modifications.  Endogenous transcription of a vaccine antigen 
encoded on a plasmid or viral vector makes the antigen available for processing and 
presentation via both major histocompatibility complex (MHC) I and II, effectively 
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targeting both humoral and cell-mediated immune responses to the vaccine (101, 102, 
105).  This approach, in theory, results in an immune response more comparable to 
natural infection, which is a primary objective of an HIV-1 vaccine design strategy (113), 
by effectively inducing the vaccine-specific CTL and helper T cell responses necessary 
for prophylactic immunity against HIV-1. 
The utility of DNA vaccination was initially demonstrated in small animal models 
against a variety of pathogens.  Inoculation of mice with DNA encoding influenza 
hemagluttinin (HA) or nucleoprotein (NP) antigen produced vaccine-specific antibody 
titers and CTL responses, respectively, which were protective against homologous and 
heterologous viral challenge (59, 155, 177).   Immunogenicity of DNA vaccination was 
also demonstrated in small animal models of herpes simplex virus-2 (HSV-2) (117), 
human papillomavirus (HPV) (40), and hepatitis B virus (HBV) (36, 121).  DNA 
vaccination has also been extensively studied in preclinical models of HIV-1.  Mice 
immunized via i.m. inoculation with DNA plasmids encoding HIV-1 Env gp160 
demonstrated potent antigen-specific NAb responses as well as lymphocyte proliferation 
in comparison to a recombinant protein vaccine (184).  Mice immunized with Env DNA 
vaccine also demonstrated broad and potent NAbs concurrent with CD4+ and CD8+ T cell 
responses, with strong neutralizing activity strong even in the absence of high antibody 
titers (58, 104).   
The efficacy and immunogenicity of HIV-1 or simian immunodeficiency virus 
(SIV) Env DNA vaccines was also demonstrated in NHP models, particularly when 
enhanced by administration routes such as electroporation (EP) or gene gun delivery 
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compared to i.m. injection.  Gene gun or i.m. administration of a pentavalent DNA 
vaccine encoding SIV antigens did induce NAb titers as well as persistent CTL responses 
(103).  While protective immunity was not achieved and CD4+ T cell loss was not 
impacted, viremia and signs of acute infection were attenuated in immunized animals 
(103).  Similarly, chimpanzees immunized with a polyvalent DNA vaccine encoding the 
HIV-1 antigens Env, Rev, and Gag/Pol also generated vaccine-specific antibody and CTL 
responses, correlated with partial protection against heterologous viral challenge (17).   
The clinical efficacy of DNA vaccination was first demonstrated in a clinical 
study using a human vaccine against HBV administered using gene gun technology, 
which generated potent vaccine-specific CD4+ and CD8+ T cell responses as well as high 
antibody titers (158).   Unfortunately, despite the promising immunogenicity of DNA 
vaccines in preclinical models and in the context of other pathogens, clinical trials of 
DNA vaccines against HIV-1 were somewhat disappointing.  Immunization of 
asymptomatic HIV-1 seropositive individuals with DNA plasmids encoding HIV-1 
antigens Env and Rev were shown to be safe in humans, but produced low and transient 
levels of specific humoral and cellular immune responses, with no measurable impact on 
viremia or disease progression (108).  DNA-based immunization of HIV+ individuals 
with constructs encoding the HIV-1 regulatory antigens Rev, Nef, or Tat were well 
tolerated and induced positive, albeit transient, vaccine-specific CTL responses; however, 
administration did not result in a therapeutic effect (24-26).  Immunization of HIV-1 
positive individuals with a DNA vaccine encoding Env and Rev was similarly tolerable, 
and it generated vaccine-induced lymphocyte proliferation and CTL responses (15, 16).  
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In addition, the vaccine induced production of IFNγ and β-chemokines MIP-1α, MIP-1β 
and RANTES.  These markers were previously identified as correlates of protective 
immunity by Heeney et al., and are indicative of a pro-inflammatory response (16).  
However, DNA vaccination alone did not appear to be sufficient for protective immunity 
against HIV-1 infection.    
3.2 DNA Prime-protein boost vaccine 
The history of HIV-1 vaccine clinical trials has shown that optimally, an HIV-1 
vaccine should be capable of both producing sterilizing antibodies to prevent viral 
infection, and inducing diverse and specific T cell responses to assist B cell responses, as 
well as control and eliminate infected cells.  While recombinant protein and DNA or viral 
vector-based immunization alone fail to activate both arms of the immune response, the 
combination of these two strategies has proven to be significantly more effective.  A 
landmark 1992 study by Hu et al. established the utility of a prime-boost strategy (78).  
Macaques were primed i.m. with vaccinia vector encoding SIVmne Env glycoprotein at 
weeks 0 and 12, followed by i.m. boosting with recombinant gp160 protein at weeks 62 
and 70.  While weak antibody responses were initially observed, all animals primed with 
vaccinia vector encoding Env antigen demonstrated notable vaccine-specific helper T cell 
function.  Following protein boosting formulated with either an aluminum salts adjuvant 
or incomplete Freund’s adjuvant, primed animals demonstrated a substantial increase in 
Env-specific antibody titers, as well as NAbs against homologous and heterologous viral 
antigens.  Complete protective immunity was confirmed after viral challenge with SIVmne 
in prime-boost immunized animals as compared to control animals (78).   
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While clinical applications of DNA vaccination alone have resulted in weak 
immunogenicity, it is particularly effective at priming the immune system for subsequent 
immunization by a different modality, such as a recombinant protein.  It has been 
generally established that DNA vaccination promotes vaccine-specific CMI (3, 9, 156), 
while protein immunization promotes strong antibody responses (31, 43, 44, 65), and so 
the combination of these two methods in a prime-boost strategy is promising in achieving 
the goal of protective immunity against HIV-1.   
This concept was initially demonstrated in small animal models and NHPs.  Mice, 
guinea pigs, and rabbits immunized with a DNA vaccine encoding HIV-1 Env antigen, 
followed by homologous Env protein boosting, demonstrated superior CTL and NAb 
responses against vaccine strains compared to DNA vaccination alone (8, 153).  In NHPs 
immunized with Env-encoding DNA plasmid and boosted with Env protein, long-lasting 
vaccine-specific CTLs and NAb responses were detected; in addition, animals 
immunized with the prime-boost were protected against homologous SHIV challenge 
(96).     
In recent years, our lab at UMMS has extensively evaluated a pentavalent HIV-1 
Env gp120 DNA prime-protein boost vaccine, called DP6-001.  The DNA vaccine 
encodes five env genes from HIV-1 clades A, B, C, and E as well as a gag gene from a 
single clade.  The protein boost component consists of Env gp120 proteins homologous 
to those encoded by the DNA vaccine, and is formulated with the saponin adjuvant QS-
21.   
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Preclinical studies of DP6-001 and precursor DNA prime-protein boost vaccines 
in small animal models and NHPs established the efficacy of the combination of these 
two modalities.  Rabbits immunized with DNA plasmids encoding gp120, and 
subsequently boosted with rgp120 protein, were found to raise improved NAb against 
primary viral isolates, while either component alone failed to produce a NAb response 
(185).  Immunization of rhesus macaques with DP6-001 induced CD4+ and CD8+ T cells, 
characterized by the production of Th1 cytokines IFNγ and IL-2.  In addition, DNA 
priming prior to boosting with recombinant protein augmented the vaccine induced 
humoral responses compared to protein immunization alone (35).   
In subsequent reports, several immunized macaques rectally challenged with 
SHIV were protected against infection, and those that became infected demonstrated 
reduced viral load (137, 138).  Immunized animals generated NAb against homologous 
and, to a lesser extent, heterologous viral isolates.  Given the lessons from prior clinical 
observations in vaccinees and infected individuals, the DNA prime-protein boost strategy 
appears ideally suited for the generation of the broad and diverse immune response that is 
required for immunity against HIV-1.  Furthermore, toxicology studies of DP6-001 in 
rabbits indicated minimal signs of adverse effects and ruled out DNA integration of 
vaccine plasmids, which supported the further evaluation of DP6-001 in humans (35).   
In phase I clinical trials of DP6-001, participants were immunized either i.m. or 
intradermally (i.d.) with three pentavalent DNA primes at either a high (7.2 mg) or low 
(1.2 mg) dose, followed by two pentavalent homologous rgp120 protein boosts 
formulated with QS-21, as in preclinical studies.  DNA priming followed by protein 
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immunization was shown to enhance the magnitude of cross-subtype Env-specific CMI.  
Robust T cell responses were detected by IFNγ ELISpot in the majority of vaccines 
(186). Follow-up reports identified a T cell response predominated by vaccine antigen-
specific polyfunctional CD4+ T cells, with low positive CD8+ T cells in higher dose 
groups (7).  In addition, vaccinees raised long-lasting antibody titers to levels comparable 
to those observed in infected individuals over the course of the 52-week study.  Antibody 
responses in responders were capable of neutralizing homologous viral isolates, though 
neutralization against a Tier 2 panel representative of more contemporary viral strains 
was more modest (186). 
The choice in adjuvant utilized in the DP6-001 studies is a notable difference 
compared to the RV144 trials.  The saponin QS-21 was chosen for inclusion in DP6-001 
due to its previously demonstrated ability in the clinical context of HIV antigens to 
induce both CMI and humoral arms of the adaptive immune response with a potency 
allowing for antigen dose reduction (50, 183).  However, as a known hemolytic agent, 
QS-21 is not without adverse effects (183).  In the clinical trials of DP6-001, 
reactogenicity predominantly comprised of self-limited injection site reactions were 
observed.  In particular, a case of leukocytoclastic vasculitis, occurring in an individual 
primed with a high dose of DNA prime, was observed following protein and QS-21 
boosting (7).  While this case resolved within 72 hours of corticosteroid treatment, this 
immunization group was halted prematurely due to safety concerns.  This example 
highlights the need to carefully consider the choice of adjuvant in an HIV-1 vaccine 
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strategy not only for immunogenicity, but also for safety and tolerability in a clinical 
setting.     
4. Adjuvants   
 The choice of adjuvant in a vaccine formulation is a critical component of vaccine 
research and development.  Adjuvants are a diverse group of compounds that, when 
formulated with vaccine antigen, improve the immunogenicity of a vaccine or modulate 
the immune response to immunization.  Adjuvants may provide a depot effect, serve as 
an antigen-delivery vehicle, generally stimulate the immune system, or specifically target 
particular immune functions and pathways.  Direct stimulation of innate immune 
responses has been a more recent focus of adjuvant development, with the goal of 
harnessing innate immunity and inflammation in order to enhance vaccine-specific 
adaptive immune responses.   
Adjuvants must be evaluated for safety and efficacy in the context of any novel 
vaccine formulation, as the clinical profile and immunogenicity of adjuvants can vary in 
formulation with different vaccine antigens, vaccination regimens, or delivery methods.  
Furthermore, the choice of adjuvant depends on the type of immune response required for 
prophylaxis.  Aluminum salts, the most clinically established and widely used adjuvant in 
licensed vaccines are known to primarily induce potent antibody responses as opposed to 
CMI.  Lessons learned from clinical trials of HIV-1 vaccines indicate the need for both 
humoral and T cell responses, and thus, the choice of an adjuvant capable of promoting 
both arms of the adaptive immune system.  In addition, we explored several newer 
adjuvant candidates better suited for inclusion in future formulations of HIV-1 vaccines. 
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4.1 Aluminum salt-based adjuvants 
Aluminum salts, typically formulated as aluminum phosphate or aluminum 
hydroxide, are the most widely used adjuvants in vaccines approved for use in humans.  
Generically referred to as “alum,” this term may include aluminum phosphate salts, and 
aluminum hydroxide, which is often used in a gel formulation such as Alhydrogel®.  
Another commonly used aluminum hydroxide-based gel is Imject® alum, a gel 
formulation of aluminum hydroxide and magnesium hydroxide.  For the animal 
experiments described in this dissertation, we employed an aluminum hydroxide gel, and 
will herein refer to the formulation by its chemical formula, Al(OH)3.    
Aluminum salt-based adjuvants are typically well tolerated with minimal adverse 
effects, and induce potent vaccine-specific antibodies and CD4+ Th2 helper responses 
characterized by Th2 cytokines interleukin (IL)-4 and IL-5.  Despite its widespread use, 
alum’s mechanism of action remains largely undefined.  Originally, it was postulated that 
the depot effect was responsible for adjuvanticity.  Adsorption of soluble antigen onto 
aluminum salts would improve uptake of the particulates by antigen-presenting cells 
(APCs) at the vaccination site, and also form a depot at the site for the continuous release 
and presentation of antigen.  However, subsequent studies demonstrated that adsorption 
of antigen onto alum was not required for adjuvant effect (66).  In fact, characterization 
studies of gp120 antigen formulated with a variety of aluminum hydroxide compounds 
showed that gp120 is rapidly desorbed from the adjuvant following immunization of 
guinea pigs, rabbits, and baboons (188).  Furthermore, different formulations of these 
aluminum hydroxide adjuvants were capable of eliciting comparable binding antibody 
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titers specific to gp120 antigen in immunized animals (188).   More recently, the 
activation of innate signaling pathways by either direct or indirect effects of aluminum 
salts have been implicated in their mechanism of action, but the dependence of adaptive 
immune responses on these innate signaling pathways remains controversial. 
 Aluminum hydroxide gel was employed as an adjuvant in the VaxGen and RV144 
HIV-1 vaccine clinical trials discussed above.  Each rgp120 protein immunization in the 
VaxGen trial was adsorbed onto 600 µg of aluminum hydroxide gel.  Similarly, in the 
RV144 prime-boost trial, the AIDSVAX B/E boost component co-administered with the 
final two doses of ALVAC canarypox vector was formulated with 600 µg of aluminum 
hydroxide gel.  While RV144 demonstrated unprecedented protection against HIV-1, 
antibody responses induced by the vaccine were not long lasting, and T cell responses 
were induced at relatively low levels.  The formulation of vaccine with an aluminum salt-
based adjuvant may be one reason for relatively low CMI and short-lived antibody 
responses (125, 145, 187).  Novel vaccine adjuvants described below focus on targeting 
both CMI and humoral responses, and may be better candidates for future HIV-1 vaccine 
formulations. 
4.2 Monophosphoryl Lipid A (MPLA) 
 Monophosphoryl lipid A (MPLA) is a low-toxicity, dephosphorylated derivative 
of Gram-negative bacterial lipopolysaccharide (LPS) from Salmonella Minnesota.  The 
abbreviation of MPLA refers to generic monophosphoryl lipid A, so as to distinguish it 
from clinical grade MPL® produced by GlaxoSmithKline.  While both LPS and MPLA 
are both agonists of Toll-like receptor 4 (TLR4), MPLA has been demonstrated to induce 
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0.1% of the inflammatory effects as compared to its parent molecule, LPS (2, 115).  
Some studies indicated that differently biased signaling pathways downstream of TLR4 
are responsible for the reduced inflammation induced by MPLA, but the exact 
mechanism remains unclear.  MPLA as an adjuvant in vaccine formulations has been 
clinically well tolerated with minimal adverse effects. 
 Due to its ability to stimulated TLR4 but with reduced inflammatory effects, 
MPLA was developed as a novel adjuvant system with improved Th1 responses 
compared to conventional aluminum salt-based adjuvants.  This characteristic is 
advantageous in vaccines against pathogens requiring more robust Th1 immunity, such as 
HIV-1, malaria, and tuberculosis, which require CTL responses as well as improved T 
cell responses against infected cells.  In addition to Th1 immune responses (characterized 
by IFNγ and IL-2), and the Th1-associated IgG2a isotype, MPLA induces a complex 
inflammatory response consisting of neutrophils, antigen-presenting cells (APCs), and 
natural killer (NK) cells following administration (2, 159, 162, 180).  It is becoming 
increasingly evident that all three of these cellular responses are important in the 
development of HIV-1 immunity. 
The extent to which MPLA induces Th1-biased immune responses depends 
largely on the antigen with which it is formulated, the delivery mechanism, and co-
administration with another adjuvant.  Indeed, MPLA is often used in combination with 
other adjuvants, such as in the GlaxoSmithKline (GSK) adjuvant systems.  The licensed 
human vaccines Fendrix™ for protection against hepatitis C virus (HCV), and 
Cervarix™ for protection against human papilloma virus (HPV), include AS04, a 
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combination of aluminum hydroxide and MPL.  MPLA has also been combined with QS-
21 in AS01 and AS02 in anti-malarial vaccines currently being evaluated in clinical trials 
(39, 159).    
4.3 QS-21 
 The QS-21 adjuvant is a purified saponin fraction derived from the Quillaia 
saponaria Molina soap bark tree.  QS-21 is an acylated, water-soluble triterpene 
glyocoside that can be formulated with soluble antigen (87). QS-21 has been extensively 
evaluated in preclinical and clinical studies in formulation with HIV-1 vaccines.  In the 
context of HIV-1 subunit protein-based vaccines, QS-21 is associated with improved 
Th1-biased helper T cells, antigen-specific production of IFNγ and IL-2, as well as the 
Th1-associated IgG isotype IgG2a (34, 87-90, 99, 107, 128, 161).  QS-21 has also been 
shown to enhance NAb (74, 85, 100) and CTL responses (67, 129, 130, 194).  The 
potency of this saponin adjuvant allows for reduced antigen dose in vaccine formulations 
(50).   
However, the potency of QS-21 comes with the risk of local and systemic adverse 
effects.  While toxicity was minimal in preclinical models and veterinary vaccines, the 
use of QS-21 in human vaccines is restricted due to reports of reactogenicity.  A known 
hemolytic agent, QS-21 has been clinically associated with local adverse effects, such as 
mild to moderate tenderness, erythema, and pain at the injection site (7, 50, 183).  
Systemic symptoms after immunization, such as hypotension, fever, myalgia, and 
headache, have also been observed in recipients of QS-21.  Our own clinical experience 
with QS-21 in the context of DP6-001 prime-boost immunization supported prior reports 
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of potent immunogenicity and necessitated the selection of a more tolerable and safe 
adjuvant. 
 QS-21 is included in several Adjuvant Systems (AS) currently being evaluated by 
GlaxoSmithKlein (GSK).  As mentioned above, AS01 and AS02 consist of both QS-21 
and MPL® in liposomes or oil-in-water emulsions, respectively, and have demonstrated 
improved tolerability without compromised potency in clinical trials of anti-malarial 
vaccine candidates (159, 180). 
4.4 ISCOMATRIX™ adjuvant 
 ISCOMATRIX™ adjuvant, produced and trademarked by Commonwealth Serum 
Laboratories (CSL), Ltd. in Australia, is a novel saponin-based adjuvant system that has 
improved upon both the immunogenicity as well as the tolerability of QS-21.  Morein et 
al. first described as ‘immuno-stimulating complexes’ (ISCOMs) in 1984.  The optimized 
formulation of ISCOMATRIX™ adjuvant consists of a highly purified saponin fraction 
(ISCOPREP™) contained within a 40 nm diameter cage-like matrix consisting of 
cholesterol and a phospholipid, dipalmitoyl-sn-phosphatidylcholine (DPPC) (126).  
Prototypical ISCOMs required difficult and complex methods of incorporating a limited 
range of antigens into the structure, and employed a less highly fractionated saponin, 
ISCOPREP™ 703, which is comprised of a mixture of saponin fractions QH-A and QH-
C (171).  Current formulations of ISCOMATRIX™ adjuvant, with ISCOPREP™ 
saponin, are formulated with a wide variety of vaccine antigens by simple mixing, and 
are stable at 4oC for 2-3 years (127, 141).   
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ISCOMATRIX™ adjuvant has been characterized as an ‘integrated adjuvant 
system’ owing to its ability to both act as an antigen delivery vehicle as well as a potent 
immunomodulator (127).  Lymphatic duct cannulation studies performed in sheep 
demonstrated that antigen and ISCOMATRIX™ adjuvant traffic to draining lymph nodes 
(DLN) in two waves, early (2 hours) and late (24-48 hours) following injection, resulting 
in prolonged antigen presentation (192).  At the injection site and in the DLN, antigen 
and ISCOMATRIX™ adjuvant are taken up by dendritic cells (DCs) and APCs.  
Delivery of antigen to the cytosol occurs when ISCOMATRIX™ adjuvant is internalized 
in an actin-dependent manner into endosomes, which are subsequently acidified, 
releasing vaccine antigen into the cytosolic compartment (166, 167).  Antigen is made 
available for processing and presentation via both MHC I and II, for cross-presentation to 
CD8+ and CD4+ T cells, respectively.  As a result, CTLs as well as helper T cells, aiding 
subsequent B cell responses, are effectively induced.  As an immunomodulator, the 
ISCOMATRIX™ adjuvant induces a complex milieu of cytokines and chemokines, 
resulting in the recruitment of immune cells in the DLN while inhibiting efflux of APCs 
and allowing for increased and prolonged T and B cell priming, for up to 48 hours post-
immunization (165, 167).   
ISCOMATRIX™ adjuvant has been evaluated in 16 clinical trials to date, in the 
context of therapeutic vaccines against HPV (57) and HCV (41), as well as in a 
prophylactic vaccine against influenza.  Additionally, in clinical trials ISCOMATRIX™ 
adjuvant has been a component of therapeutic vaccines against NY-ESO-1 positive 
tumors, such as in melanoma (37, 110, 131).  Compiled clinical safety data recently 
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reported by McKenzie et al. indicated that local and systemic adverse effects to vaccines 
formulated with ISCOMATRIX™ adjuvant were mild and self-limited (120).  
Immunization with ISCOMATRIX™ adjuvant and vaccine antigen were demonstrated to 
induce strong CD4+ and CD8+ T cell responses in NHP and human trials of HPV, HCV, 
and anti-tumor vaccines.  In addition, vaccine-induced CMI responses were long lasting 
and suggestive of a strong memory response.  ISCOMATRIX™ adjuvant is also 
associated with the induction of balanced Th1/Th2 T cell and IgG isotype responses (109, 
127, 141).   
5. Innate immune signaling pathways contributing to adjuvant mechanism 
 Despite relatively consistent and well-defined clinical profiles, all of the adjuvant 
systems described herein still lack clearly elucidated mechanisms.  These adjuvants all 
activate innate immune signaling pathways, presumably harnessing the innate immune 
response in order to enhance adaptive immune responses to vaccination.  Here, I will 
expand upon the innate immune pathways demonstrated to play a role in each adjuvant 
mechanism, although their role in generating humoral and CMI responses remains to be 
characterized. 
5.1 Toll-like receptor 4 (TLR4), and its adaptors MyD88 and TRIF 
 As described above, LPS and its derivative, MPLA, are both strong agonists of 
TLR4, a receptor that is present on the surface of DCs and macrophages.  After 
engagement, two adaptor molecules of TLR4 facilitate alternate signaling pathways once 
the receptor has been activated.  Myeloid differentiation primary response gene 88 
(MyD88) is a ubiquitous adaptor molecule utilized by a number of TLR-associated and 
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non-TLR pathways.  Briefly, activation of TLR4 recruits the MyD88 adaptor, which 
results in the “early” phase of activation of the transcription factor NFκB, which upon 
translocation to the nucleus induces pro-inflammatory cytokines.  TLR4 activation may 
also recruit the adaptor molecule TIR-domain-containing adaptor inducing IFNβ (TRIF) 
in a “late” response following receptor-mediated endocytosis, which activates the 
transcription factor interferon regulatory factor 3 (IRF3) resulting in type I IFNs 
production (123).   
 An adoptive transfer mouse model utilizing an OVA antigen formulated with 
MPLA or LPS attempted to determine the differential signaling via MyD88 and TRIF 
(115).  OVA antigen with either MPLA or LPS comparably induced OVA-specific CD4+ 
and CD8+ T cell responses.  Multiplex analysis of serum cytokines induced following 
OVA-MPLA injection were categorized in terms of MyD88-associated (IFNγ, IL-1β, IL-
6, and MIP-1α) or TRIF-associated (G-CSF, IP-10, MCP-1, and RANTES) responses.  
Results indicated that while both LPS and MPLA induce TRIF-associated serum 
cytokines, MPLA only weakly induced the MyD88-associated inflammatory responses in 
comparison to LPS.  In vitro experiments with OVA protein as antigen demonstrated that 
signaling via MyD88 was delayed and reduced in MPLA stimulations as compared to 
LPS.  Adoptive transfer studies in OVA-specific transgenic mice also indicated that 
TRIF, but not MyD88, was required for antigen-specific T cell priming after 
immunization with OVA protein and MPLA (115).   
This bias may be responsible for the reduced toxicity of MPLA, as well as the 
potent Th1 response it induces, however a direct correlation to vaccine and MPLA 
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induced adaptive immune responses remains unclear.  Subsequent comparisons of MPLA 
to LPS suggest that MPLA fails to induce the pro-inflammatory cytokine IL-1β; while 
pro-IL-1β is comparably produced, the MyD88-dependent cleavage product of the bio-
active cytokine is impaired (47).  Still, there is evidence that MPLA action is not devoid 
of MyD88 signaling, indicating that the requirement for TRIF signaling is a bias rather 
than exclusive selective signaling.  However, this requirement may be dependent in part 
on antigen and immunization route.  Recent work has demonstrated that a MyD88-
dependent negative regulator of innate inflammatory responses, SHIP-1 (Src homology 2 
containing inositol phosphatase-1), may be paradoxically responsible for mitigating the 
MPLA-induced TLR4 inflammatory response (28, 29). 
5.2 Inflammasome 
 The inflammasomes are a family of large multicomponent complexes that 
assemble in the cytosol with caspase-1, which cleaves the inflammatory cytokines pro-
IL-1β and pro-IL-18 into their matured and secreted forms.  Two main subtypes of the 
inflammasomes are the NLRs (nucleotide-binding-and-oligomerization domain and 
leucine-rich-repeat-containing) or the PHYINs (pyrin domain and HIN domain-
containing).  While many NLRs have been characterized in humans and mice, NLRP3 is 
the most extensively evaluated in the context of adjuvant mechanisms of action.   
 Activation of the NLRP3 inflammasome occurs when a stimulant induces the 
assembly of NLRP3, and ASC (apoptosis-associated speck-like protein containing a 
caspase recruitment domain), followed by the recruitment of pro-caspase-1.  Pro-caspase-
1 is cleaved into its mature form, which is capable of cleaving the inactive of the 
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inflammatory cytokines IL-1β and IL-18 into a mature state.  An initial priming signal 
through NFκB activation is required but not sufficient for NLRP3 activation (10).  
Known ligands of NLRP3 include endogenous dangers signals released during tissue 
damage, for example ATP and uric acid crystals, as well as several pathogens including 
Klebsiella pneumonia, Listeria monocytogenes, Candida albicans, Staphylococcus 
aureus, and influenza A.  In addition, evidence indicates that potassium efflux, caused by 
pores formed in the cellular membrane, or the presence of reactive oxygen species, or the 
ingestion of certain particulates such as alum or silica, also activate the NLRP3 
inflammasome (22, 149, 169).    
 The potential activation of the NLRP3 inflammasome by aluminum salt adjuvants 
remains controversial.  Initial in vitro studies by Eisenbarth et al., utilizing Imject® alum, 
indicated that the adjuvant indeed acted via ASC-, caspase-1-, and NLRP3-dependent 
pathways to produce IL-1β and IL-18.  In in vivo studies immunizing mice with Imject® 
alum and model antigens, ASC-, caspase-1-, and NLRP3-deficient mice failed to mount 
an antigen-specific antibody response, suggesting that these pathways were also critical 
to adaptive immunity raised by aluminum salt adjuvants (45).  Meanwhile, concurrent 
studies confirm that aluminum hydroxide does activate IL-1β and IL-18 via NLRP3 
inflammasome pathways, but contend that this action is dispensable for its adjuvant 
activity (53, 119).  Furthermore, it remains unclear whether the action of aluminum salts 
on the NLRP3 inflammasome is through direct or indirect interaction.  Whereas some 
evidence supports a direct mechanism involving the phagocytosis of particulates and 
subsequent lysosomal disruption serving as an endogenous danger signal activating 
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NLRP3 (77), others suggest a more indirect action.  Kool et al. speculate that 
administration of Imject® alum causes cell damage and cell death at the injection site, 
releasing the endogenous danger signal uric acid, which itself acts on the NLRP3 
inflammasome (92).  In a novel approach, Marichal et al. suggest that the cell damage 
induced by Imject® alum results in the release of host DNA, which, via inflammasome or 
nucleic-acid sensing pathways, impacts adjuvanticity (111).  Therefore, while it is clear 
both in vivo and in vitro that aluminum salts induce the pro-inflammatory IL-1β response, 
the exact mechanism as well as the impact on adaptive immune response to vaccination 
with aluminum salt adjuvant formulations remains to be defined. 
In contrast to aluminum salts, the TLR4-agonist adjuvant MPLA demonstrates 
impaired signaling via the NLRP3 inflammasome.  The dephosphorylation of LPS to 
produce MPLA appears to substantially reduce the inflammation, including pro-
inflammatory cytokine production, in response to TLR4 stimulation (28, 123).  In fact, 
MPLA was shown to induce mRNA for IL-1β and the pro-form of IL-1β similarly to 
LPS; however, it was defective in the induction of mature IL-1β secretion and defective 
in the activation of caspase-1, which is required for endotoxic inflammation (136).  This 
may or may not be attributable to TRIF-biased signaling, with weaker MyD88 induction 
resulting in the failure of the NLRP3 inflammasome to assemble (47).   
Little is known about how saponin derivative adjuvants harness the innate 
immune system to enhance adaptive immunity to vaccination.  Studies of 
ISCOMATRIX™ adjuvant thus far have not supported a mechanism via TLRs, including 
TLR4.  However, ISCOMATRIX™ adjuvant-based vaccines exhibit variable 
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dependency on MyD88 activation (191).  Mice immunized with a tumor protein antigen 
and ISCOMATRIX™ adjuvant showed that while the recruitment of immune cells and 
maturation of DCs in the DLN after immunization were independent of MyD88, the 
cross-priming by certain DC subsets to generate a CD8+ T cell response, as well as 
natural killer (NK) cell functionality, were significantly compromised in the absence of 
MyD88 (191).  The mechanism by which ISCOMATRIX™ adjuvant activates MyD88 
signaling and other innate pathways remains unclear. 
ISCOMATRIX™ adjuvant, which is by nature both a particulate and a saponin, 
may also function via the NLRP3 inflammasome, especially as it has been observed in 
vivo to induce an IL-1β response.  Recent reports by Duewell et al. observed in vitro that 
the IL-1β response to ISCOMATRIX™ adjuvant occurred in a caspase-1 dependent 
manner, and further investigation into the role of caspase-1-dependent inflammasome 
pathways is currently underway (42).   
Another inflammasome complex that utilizes caspase-1 and ASC is the absent in 
melanoma 2 (AIM2) inflammasome, which produces IL-1β and IL-18 in response to 
double-stranded (ds) DNA.  AIM2 is unlike many other innate nucleic acid sensors, 
which produce type I IFNs in response to activation.  The demonstration by Marichal et 
al. that host DNA released in response to OVA antigen and Imject® alum immunization 
was responsible for Th2-biased adaptive immune responses indicates that AIM2 (111), as 
well as type I IFN-producing nucleic acid sensing pathways, are potentially important in 
the development of future work on adjuvant mechanisms.   
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It is important to note that the AIM2 inflammasome is not the only nucleic acid 
sensing pathway.  TLR9, an endosomal receptor, responds to viral and bacterial DNA 
including unmethylated deoxycytidylate-phosphate-deoxyguanylate (CpG) motifs, 
resulting in the production of type I IFN in a MyD88-dependent and interferon regulatory 
factor 7 (IRF7)-dependent fashion (176).  Cytosolic RNA may be sensed by retinoic acid-
inducible gene (RIG-I) or melanoma differentiation-associated gene 5 (MDA-5), which 
converge on the adaptor mitochondrial antiviral signaling protein (MAVS), and 
subsequently induces the production of inflammatory cytokines via NFκB or type I IFNs 
via Tank-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) and IRF7 
(176).  Cytosolic DNA is sensed by TBK1, and requires the adaptor stimulator of 
interferon genes (STING), for the downstream activation of IRF3 and production of type 
I IFNs.  dsDNA from certain viral infections can also activate gamma-interferon-
inducible-protein 16 (IFI16), which associates with STING for the production of pro-
inflammatory cytokines via NFκB or type I IFNs via IRF3 (176).  Thus, if indeed nucleic 
acid sensing pathways are revealed to have a critical role in the mechanisms of studied 
adjuvants, there are a multitude of innate immune signaling pathways worth evaluating.     
6. Research objectives 
 The observations from HIV-1 vaccine clinical trials have laid the groundwork for 
the future directions of vaccine design, and emphasize the importance of adjuvant 
selection.  Despite poorly understood correlates of protective immunity, the polyvalent 
prime-protein boost regimen has emerged as the most promising avenue towards an 
effective vaccine, with broad and robust induction of both humoral and cell-mediated 
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adaptive immune responses.  The original body of work described in the following 
chapters attempts to evaluate the unique profiles of several conventional and novel 
adjuvant systems in the context of a previously described HIV-1 Env DNA prime-boost 
vaccine strategy against HIV-1, DP6-001.   
In this dissertation, I aim to compare the ability of select adjuvants to contribute 
to the vaccine-specific adaptive immune responses induced by DP6-001.  In addition, I 
will utilize novel multiplex technology to characterize each adjuvant in the context of 
DP6-001 in terms of unique non-antigen specific serum cytokine and chemokine profiles.  
I expect that these profiles will indeed be unique to the DNA prime-protein boost vaccine 
strategy. 
  As a secondary objective, in the latter chapters of this dissertation, I will explore 
the impact of several innate immune pathways on the unique adaptive and inflammatory 
adjuvant profiles when formulated with DP6-002 vaccine.  These studies in particular 
focus on two novel adjuvant systems, MPLA and ISCOMATRIX™ adjuvant, with the 
goal of not only elucidating their incompletely defined mechanisms, but also to aid in the 
selection of an adjuvant for inclusion in future optimized HIV-1 Env DNA prime-protein 
boost vaccines.    
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CHAPTER II: 
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-
protein boost vaccination strategy 
Introduction 
Recently, the RV144 clinical trial using a viral vector prime-recombinant protein 
boost vaccine demonstrated a low level, but statistically significant, protection against 
HIV-1 infection in Thai volunteers (38, 125, 144, 150).  The RV144 trial employed a 
canarypox viral vector ALVAC, encoding HIV-1 antigens env, gag, and pro, as a prime, 
followed by a boost with bi-clade AIDSVAX B/E recombinant gp120 protein boost 
adsorbed onto the aluminum hydroxide gel adjuvant.  After extensive follow-up studies, 
new data are emerging to suggest that antibodies against certain critical areas of HIV-1 
envelope proteins are responsible for protection; however, the antibody responses in the 
RV144 trial were not long lasting, which may have led to reduced protection during the 
clinical trial observation period (125, 145, 187). 
Following the results of the RV144 trial, especially given the renewed interest of 
including recombinant Env proteins in the future HIV-1 vaccine development, the study 
of adjuvants is gaining more momentum as adjuvant is a critical component of most 
licensed recombinant protein-based human vaccines.  A more immunogenic adjuvant 
than aluminum hydroxide gel may provide enhanced and long lasting antibody responses, 
which may improve the level of protection compared to that observed in the RV144 trial 
(145, 187). 
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A key consideration in vaccine development is enhancing immunogenicity while 
mitigating associated adverse effects.  The inclusion of adjuvants in vaccine formulations 
has long been a method of improving vaccine efficacy, but these adjuvants are not 
without risk of eliciting local and systemic adverse effects.  HIV-1 recombinant Env 
protein-based vaccines are now primarily being used as a boost component in emerging 
HIV-1 vaccine strategies.  Thus, it is very important scientifically to examine how an 
adjuvant works when it is formulated with Env proteins, and in the context of hosts who 
have been primed by a gene-based vaccine (such as viral vector or DNA vaccine) 
encoding antigens similar to the boost. 
Our group has demonstrated the high immunogenicity of the pentavalent DNA 
prime-protein boost HIV-1 vaccine formulation, DP6-001, in preclinical and phase I 
clinical trials (7, 186).  The saponin adjuvant QS-21, derived from Quillaia saponaria, 
was included as part of the Env protein boost in the phase I clinical study of DP6-001 
formulation.  Previously published studies have also utilized QS-21 as part of 
recombinant Env protein alone vaccines in humans, demonstrating a potent 
immunogenicity allowing for reduced antigen dose, and characterized by improved 
binding and neutralizing antibody responses (50, 85).  However, in these studies QS-21 
has been associated with serious local reactions, including pain, induration, erythema, as 
well as systemic adverse effects such as hypertension, myalgia, headache, and vasovagal 
episodes which were rare and not proven to be caused by QS-21 directly (50, 85).  We 
also observed in clinical trials of DP6-001, local skin reactions as well as rare skin based 
vasculitis associated with QS-21 adjuvanted protein boosting (7).   
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In the current study, the serum cytokine profiles in mice in the context of the 
DP6-001 DNA prime-protein boost were analyzed, in the context of several protein-
adjuvant boost formulations.  MPLA and ISCOMATRIX™ adjuvant were examined in 
the context of the DP6-001 vaccine, along with QS-21 and aluminum hydroxide gel, 
herein referred to by its chemical formula Al(OH)3, which were tested in previous clinical 
studies of HIV-1 vaccines.  Similar to QS-21, ISCOMATRIX™ adjuvant consists of a 
Quillaia saponin fraction, which is mixed with cholesterol and phospholipid under 
controlled conditions to form a cage-like structure of approximately 40 nm in diameter.  
The ISCOMATRIX™ adjuvant can then be formulated with virtually any antigen to 
make a vaccine.  Complexing saponin with cholesterol and phospholipid appears to 
ameliorate the reactogenicity associated with using free saponin, as ISCOMATRIX™ 
adjuvant retains the immunogenic potency and antigen dose reduction potential of 
saponin but demonstrates improved tolerability (18, 120).  ISCOMATRIX™ adjuvant 
promotes a balanced Th1/Th2 response, as well as a uniquely strong cytotoxic T cell 
response and long-lasting antibody responses in both animal and human models (109, 
127, 141, 160).  This broad, robust activation of adaptive immunity has made 
ISCOMATRIX™ adjuvant particularly efficacious in clinical studies of anti-tumor 
vaccines (37, 110, 131), as well as trials of therapeutic and protective human papilloma 
virus (HPV) vaccines and influenza vaccines (4, 56).   Comprehensive clinical safety data 
has been compiled and reported for six clinical trials of ISCOMATRIX™ adjuvant with a 
variety of antigen formulations (120).   
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MPLA is low-toxicity, dephosphorylated derivative of lipopolysaccharide (LPS) 
(2).  MPLA, like LPS, acts via Toll-like receptor (TLR) 4, but results in significantly less 
inflammation compared to its parent molecule (2, 115).  As an adjuvant, MPLA improves 
vaccine-specific antibody responses, as well as induces potent Th1 responses in 
preclinical and clinical models, resulting in a complex inflammatory response consisting 
of neutrophils, antigen-presenting cells (APCs), and natural killer cells (NKs).  Despite 
its potency, MPLA has been well tolerated in clinical trials.  Currently, MPL® is a 
component of the licensed GlaxoSmithKline (GSK) human vaccines Fendrix® for 
hepatitis B in combination with aluminum phosphate and, in formulation with aluminum 
hydroxide in Adjuvant System AS04, in Cervarix ® for human papilloma virus (2, 115, 
175).  MPL® has also been clinically evaluated in GSK’s AS01 adjuvant system in 
combination with QS-21 as a component of a malaria vaccine (159).  Aluminum-based 
adjuvants are the most widely utilized in human vaccines due to their tolerability and 
consistent induction of humoral immunity.  Thus, aluminum hydroxide gel [Al(OH)3] has 
been included in the current study to provide a baseline control in the generation of an 
acceptable profile of tolerability (94, 119). 
The relative immunogenicity of our candidate adjuvants in combination with HIV 
Env proteins was assessed in both C57Bl/6 and Balb/c mice, based on a comprehensive 
profile of vaccine-specific antibody and T cell responses, as well as non-antigen specific 
serum cytokines detected shortly after protein immunization.   While results show that the 
candidate adjuvants demonstrated comparable vaccine-specific immunogenic potency by 
IgG ELISA and T cell ELISpot, the analysis of serum cytokines allowed us to distinguish 
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a profile of characteristic cytokines for each adjuvant.  With this information, we will be 
better informed in the future for the selection of an adjuvant as part of a prime-boost 
HIV-1 vaccine formulation such as the polyvalent DNA prime-Env protein boost shown 
in the current report.    
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Results 
Study Design and Immunization Schedule 
Wild type C57Bl/6 and Balb/c mice were immunized with DP6-001 gp120 vaccines 
formulated with different adjuvants based on a dose and schedule from previously 
completed clinical studies (Fig. 1).  Mice were primed i.m. three times with pentavalent 
gp120 DNA plasmids at weeks 0, 2, and 4 and boosted with two matched pentavalent 
gp120 protein boosts, formulated with either QS-21, Al(OH)3 , MPLA, or 
ISCOMATRIX™ adjuvant, at weeks 8 and 12.  For an initial study examining the impact 
of two different DNA plasmid preparation methods, controls groups were immunized 
with only three pentavalent gp120 DNA immunizations, and received saline 
immunization in lieu of protein boosts.   
Differences in serum cytokines following immunization with gp120-expressing DNA 
plasmids in different preparations   
In previous small animal studies of the DP6-001 DNA prime-protein boost formulation, 
gp120 DNA plasmid components were prepared using a regular plasmid kit as described 
above.  Prior to the analysis of serum cytokines in response to the DP6-001 and candidate 
adjuvants, we aimed to rule out the potential contribution of residual endotoxin content in 
DNA plasmid preparations to the cytokine profiles observed. DNA primes were prepared 
by either regular DNA plasmid kit or EndoFree DNA plasmid kit (referred to as EF DP6-
001), as described above in Materials and Methods.  Mice received either three DNA 
immunizations followed by two saline boosts, or the full course of the DP6-001 DNA 
prime-protein boost vaccine regimen.  The protein boosts were formulated with 21, as in 
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our previous studies of DP6-001 vaccine (7, 35, 137, 138, 186).  To characterize the 
systemic serum cytokines produced following adjuvanted protein immunization, in 
comparison to pre-immunized serum, we employed a multiplex cytokine array consisting 
of a panel of 12 cytokines including Th1 cytokines [Interleukin (IL)-2 and IFNγ], Th2 
cytokines [IL-4], and pro-inflammatory cytokines [IL-1β, IL-6, RANTES (CCL5)].  In 
addition, we included cytokines and chemokines associated with activation and 
chemoattraction of monocytes, macrophages, NK cells, and granulocytes [MCP-1 
(CCL2), MIP-1α (CCL3), MIP-1β (CCL4), G-CSF], neutrophils [KC (CXCL1)] and 
eosinophils [Eotaxin]. 
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  Serum Cytokines              
 
Figure 2.1.  Study design and immunization schedule.  Mice were immunized with 
three pentavalent DNA primes followed by two heterologous gp120 protein boost.  The 
pentavalent vaccine mixture of both DNA and protein components consisted of HIV-1 
Env from clades A (92UG037.8), B (92US715.6 and Bal), C (96ZM651), and E 
(93TH976.17).   DNA and protein doses indicated are for a total of five immunogens at 
each immunization.  Four adjuvants were tested individually as part of the protein boost.  
Time points of immunizations, and sample collections for different assays were indicated.  
(IMX = ISCOMATRIX™ adjuvant). 
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Overall, the different plasmid preparation methods employed did not substantially 
impact the levels of cytokine responses elicited at time points during the protein-adjuvant 
boost phase when the serum cytokine profiles will be measured.  Eotaxin and MIP-1α 
were the only two cytokines moderately elevated in serum in mice immunized with 
regular DNA prep following the first protein boost as compared to EF DP6-001 but the 
difference dropped after the 2nd protein boost (Fig. 2.2a).  Most cytokines detected in the 
serum clearly demonstrate the increased immune response associated with DNA prime-
protein boost as compared to immunization with DNA alone.  Regardless of the method 
of DNA vaccine preparation, the serum levels of IL-2, IL-6, MCP-1, G-CSF, and KC 
were significantly higher at 6 hours post-protein boost as compared to mice that received 
only DNA primes of either preparation (Fig. 2.2b).  During DNA priming, serum levels 
of IL-2 and MCP-1 were low overall, regardless of DNA plasmid preparation method.  A 
trend towards increased levels of IL-6, KC, and G-CSF during DNA priming in regular 
DNA preparations as compared to EF preparations, but this difference was not 
significant.  These results suggested that our future studies of adjuvanted protein-
associated serum cytokine profiles in the context of DNA prime-protein boost should 
focus on time points 6 hours after protein-adjuvant boosting.   
 Remaining cytokines were either not above the background levels during both 
after DNA and protein immunizations (IFNγ and IL-4) (Fig. 2.2c), or were at low 
concentration only after DNA priming phase but not after protein immunization (MIP-1β 
and RANTES) (Fig. 2.2d).   
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Figure 2.2.  Temporal serum cytokine levels in mice immunized with endotoxin-free 
(EF) DNA prime compared to regular DNA plasmid preparation.  Pentavalent gp120 
DNA priming components were produced with either a regular or an EF DNA plasmid 
preparation kit.  C57Bl/6 wildtype mice were immunized with either three gp120 DNA 
primes and two “mock” saline boosts (‘DNA’ or ‘EF DNA’), or with three gp120 DNA 
primes and two gp120 protein boosts adjuvanted by QS-21 (‘D+P-QS-21’ or ‘EF D+P-
QS-21’).  Serum cytokines were quantified with a 12-plex Luminex panel in sera 
collected pre-immunization, and at 6 hours after each DNA prime and protein boost 
immunization. (a) Sera cytokines associated with endotoxin content observed after 
protein boosting.  (b) Sera cytokines associated with the protein boost effect. (c) Sera 
cytokines at baseline levels.  (d) Sera cytokines associated with endotoxin content during 
DNA immunization, but ameliorated at time of protein boosts.   
Statistical analysis was performed with two-way ANOVA and Bonferroni post-test (*: p 
< 0.05, **: p < 0.01, ***: p < 0.001).   
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Effect of DNA prep in gp120-encoding DNA plasmid on DP6-001 vaccine-induced 
Env-specific IgG response 
In addition to examining nonspecific serum cytokine responses, we aimed to rule out the 
potential impact of gp120 DNA plasmid preparations on the Env-specific IgG antibody 
response observed in our adjuvant studies.  Sera collected from the immunized mice 7 
days following the final protein boost was used to determine the Env-specific IgG 
endpoint titer by ELISA (Fig. 2.3).   As expected, mice that received the full DP6-001 
with adjuvanted protein boost demonstrated significantly higher IgG titers than mice that 
received DNA priming only, regardless of the method of g120 DNA plasmid preparation.   
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Figure 2.3.  Endpoint gp120-specific IgG titer in mice immunized with endotoxin-
free DNA prime versus regular DNA plasmid preparation.  Total gp120-specific IgG 
was measured by ELISA in sera collected 7 days after the second protein boost, in week 
13.  Statistical analysis performed by one-way ANOVA and Tukey post-test (*: p<0.05).   
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Induction of Env-specific T cell responses by DP6-001 vaccine 
Once we established the regular DNA prep was qualified for use in the current 
studies, T cell responses following immunization with DP6-001 with various candidate 
adjuvants were characterized in C57Bl/6 mouse splenocytes.  ELISpot analysis was 
conducted to examine DP6-001 vaccine-induced production of Th1 and Th2 responses in 
the splenocytes of immunized mice, in response to a peptide pool (labeled ‘PP’) 
representing clade B Env consensus sequence (19).  Mice that received DP6-001 
formulated with QS-21 most strongly produced an Env-specific IFNγ response, with 
much lower levels observed in mice immunized with protein formulated with Al(OH)3, 
MPLA, and ISCOMATRIX™ adjuvant (Fig. 2.4a).  All mice receiving adjuvanted 
protein formulations demonstrated a positive IL-2 response to peptides (Fig. 2.4b) and 
minimal induction of IL-4 (Fig 2.4b) with no differences between groups.  Baseline 
levels of Th2 cytokines IL-4 and IL-6 were notably elevated (Fig. 2.4c, d).    Mice 
receiving protein formulated with QS-21 demonstrated a positive but not significant 
induction of IL-6 over background, while those receiving protein formulated with all 
other adjuvants showed minimal induction of IL-6 (Fig. 2.4d).   
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(a)      (b) 
 
(c)      (d) 
  
 
Figure 2.4.  Env-specific cellular immune responses in splenocytes from mice 
immunized with DP6-001 and candidate adjuvants.  Spleens were harvested at 
termination 7 days after the final protein boost.  Cells were cultured for 18 hours either 
receiving the stimulation of a truncated HIV-1 gp120 Clade B peptide pool (‘PP’) or 
media (‘mock’).   Cytokine spot-forming units (SFU) per million splenocytes were 
visualized with a CTL Imager and analyzed with Immunospot™ software.  Splenocyte 
production of gp120-specific Th1 cytokines (a) IFNγ and (b) IL-2, and gp120- specific 
Th2 cytokines (c) IL-4 and (d) IL-6 were measured.  Statistical analysis of peptide 
stimulation over mock stimulation was calculated by Student’s t-test.  Significant values 
(*: p < 0.05) are represented above error bars.  Statistical differences in peptide 
stimulation between adjuvant groups were calculated by a Two-way ANOVA and 
Bonferroni post-test (*: p < 0.05, **: p < 0.01, ***: p < 0.001). (IMX = 
ISCOMATRIX™ adjuvant) 
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Intracellular cytokine staining (ICS) was also conducted to evaluate the 
functionality of vaccine-specific T cells by the production of Th1 and Th2 cytokines 
(IFNγ, IL-2 and IL-6) in response to a pool of overlapping peptides representing the clade 
B consensus Env sequence.  No significant difference in CD4+ T cell cytokine induction 
was observed between adjuvanted protein groups.  Similar to ELISpot results, mice 
immunized with protein formulated with QS-21 showed significant induction of Env-
specific IFNγ (Fig. 2.5a) and IL-6 (Fig. 2.5c) by CD4+ T cells, and a marginally positive 
IL-2 response by CD4+ T cells (Fig. 2.5b).  While there was a trend of positive Env-
specific IFNγ responses by CD8+ T cells, responses were not significantly induced above 
background, nor were there any significant differences between the different adjuvants 
(Fig. 2.5d).  This result is not surprising as protein vaccines are not known for the 
induction of CD8+ T cell responses and DP6-001 vaccine was mainly designed for the 
induction of antibody responses. 
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(c)     (d) 
  
Figure 2.5  Magnitude of Env-specific CD4+ and CD8+ T cell responses induced by 
DP6-001 immunization and adjuvants.  Cytokines were analyzed in murine 
splenocytes 7 days after final protein boost.  Spleens were harvested at termination 7 days 
after the final protein boost.  Splenocytes were cultured for 5 hours either receiving the 
stimulation of a consensus HIV-1 gp120 Clade B peptide pool (‘Env-B’) or media 
(‘baseline’).  Env-specific cytokine production by T cells was quantified by intracellular 
cytokine staining and samples were run on an LSR II FACS machine.  Data was analyzed 
using FlowJo software.  Shown is the production of (a) IFNγ, (b) IL-2, and (c) IL-6 (c) by 
CD4+ T cells, and (d) IFNγ by CD8+ T cells in mice vaccinated with DP6-001 and 
candidate adjuvants. Statistical comparisons between adjuvant groups were performed 
with a one-way ANOVA and Tukey post-test.  Statistical significance of antigen-specific 
responses over background was performed with a Student’s t-test. 
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Eliciting Env-specific IgG antibody response using DP6-001 DNA prime and protein 
boost formulated with candidate adjuvants 
In immunogenicity studies of DP6-001 in small animals and clinical volunteers, we 
reported the robust induction of vaccine-specific antibody response following 
immunization with the polyvalent Env DNA prime-protein boost formulation DP6-001 
(7, 35, 137, 138, 186).  In our previous Phase I clinical study, DP6-001 protein boosts 
have been formulated with the saponin adjuvant, QS-21.  In order to investigate the 
immunogenicity of alternative candidate adjuvants, particularly in comparison to QS-21, 
we immunized two strains of wild type mice with the pentavalent gp120 DNA prime-
protein boost regimen employed in a phase I clinical trial (7, 186).  Balb/c and C57Bl/6 
mice were immunized with three DNA primes, followed by two protein boosts 
formulated with QS-21, Al(OH)3, MPLA, or ISCOMATRIX™ adjuvant according to the 
study design outlined in Figure 2.1.  Sera were collected every two weeks after DNA 
immunization, and six hours post-protein boosts.  Sera collected from mice seven days 
following the second protein boost were used to ascertain the endpoint titer of Env-
specific IgG responses.  For antibody responses, there is limited difference between 
Balb/c C57Bl/6 mice, and only data from C57Bl/6 wildtype mice are presented. 
 Immunization with DP6-001 produced comparably robust gp120-specific IgG 
responses following the final protein boost, independent of the adjuvant used.  Env-
specific IgG levels were detectable following the third DNA immunization, and were 
significantly boosted by the first protein immunization.  Levels of specific IgG dropped 
four weeks following the first protein boost, but were subsequently boosted by the second 
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protein immunization (Fig. 2.6a).  Endpoint titer analysis showed that gp120-specific IgG 
levels were comparable in mice receiving formulations containing QS-21 or MPLA.  IgG 
titers were significantly lower in mice immunized with formulations containing 
ISCOMATRIX™ adjuvant as compared to formulations containing MPLA and lower 
still in mice receiving formulations containing Al(OH)3 (Fig 2.6b).    
 In C57Bl/6 mice, sera collected 7 days after the final protein immunization was 
used to characterize the IgG isotype profiles of formulations with the candidate 
adjuvants.  HIV-1 gp120-specific IgG1 titers were comparable between mice that 
received formulations containing QS-21, Al(OH)3, or MPLA adjuvants (Fig. 2.6c).  In 
comparison, IgG1 titers were slightly, but not significantly lower, in mice that received 
formulations containing ISCOMATRIX™ adjuvant.  On the other hand, gp120-specific 
IgG2c titers were higher in mice immunized with formulations containing QS-21 and 
MPLA followed by formulations containing ISCOMATRIX™ adjuvant in comparison to 
mice that received formulations containing Al(OH)3 (Fig. 2.6d).  A ratio of the endpoint 
titers of Env-specific IgG2c, a correlate of Th1 responses, and IgG1, a correlate of Th2 
responses, were used to demonstrate the Th1 vs. Th2 responses associated with each 
adjuvant (Fig. 2.6d).  Mice immunized with formulations containing Al(OH)3 
demonstrated a low IgG2c/IgG1 ratio, and therefore predominantly Th2 response.  In 
contrast, mice immunized with formulations containing MPLA or QS-21, and to a greater 
extent, ISCOMATRIX™ adjuvant, demonstrated a higher IgG2c/IgG1 ratio, indicating 
strong Th1 responses. 
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(a)      (b) 
            
 
(c) 
  
(d) 
 
Figure 2.6.  HIV-1 gp120-specific IgG response in wildtype mice immunized with 
DP6-001 vaccine with different adjuvants. Total gp120-specific IgG was measured by 
ELISA in sera collected 7 days after final protein boost, in week 13.  Protein boosts were 
formulated with QS-21 (red), Al(OH)3 (green), MPLA (blue), or ISCOMATRIX™ 
adjuvant (IMX) (purple).  Naïve mice (black) received ‘mock’ saline injections in lieu of 
immunization.  (a) Temporal gp120-specific IgG response was determined by ELISA 
using pooled sera samples from each group collected at two-week intervals. (b) gp120-
specific endpoint IgG titer in was determined by ELISA using individual serum samples 
collected in week 13.  (c) Endpoint IgG isotype profiles were determined by ELISA using 
individual serum samples collected in week 13.  (d) Th1/Th2 ratio of IgG isotype 
responses was determined by comparing IgG2c/IgG1 ratio.  Statistical significance was 
determined by one-way ANOVA and Tukey post-test (*: p < .05, **: p < .01, ***: p < 
.001).   
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Induction of unique serum cytokine profiles following protein boost with candidate 
adjuvants 
Throughout the DP6-001 immunization regimen in the current study, sera were 
collected from immunized mice at time points 6 hours following the third DNA 
immunization, and following both protein boosts.  In order to characterize the serum 
cytokines produced following protein-adjuvant immunization, in comparison to pre-
immunized serum, we employed a 12-plex cytokine array described above.  By 
examining this panel of non-antigen specific, systemic cytokine responses in immunized 
mice 6 hours after each protein-adjuvant boost, our objective was to identify a unique 
profile of markers for each candidate adjuvant in the context of our prime-boost HIV 
vaccine.  In addition, we will also identify cytokines and chemokines that are broadly 
induced by formulations containing the candidate adjuvants.   
Animals immunized with DP6-001 including a boost of gp120 protein formulated 
with QS-21 demonstrated a unique serum cytokine profile, consisting of the Th1 cytokine 
IFNγ and the Th2 cytokine IL-4 (Fig. 2.7a).  Immunization with formulations containing 
QS21 was also associated with increased levels of the pro-inflammatory marker IL-1β, 
and the monocyte chemoattractant MIP-1β (Fig. 2.7a).  While levels of these four 
cytokines were relatively low in all adjuvant groups 6 hours after the first protein boost, 
they were clearly elevated in animals immunized with formulations containing QS21 
following the second protein boost.  Animals immunized with formulations containing 
QS-21 also demonstrated significantly higher IFNγ, IL-4, and IL-1β as compared to  
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Figure 2.7.  Serum cytokine concentration in mice vaccinated with DP6-001 and 
candidate adjuvants.  Mice were immunized with DP6-001 DNA prime-protein boost 
(‘D+P’), with each protein boost formulated with QS-21 (D+P-QS-21), Al(OH)3 (D+P-
Al(OH)3), MPLA (D+P-MPLA) or ISCOMATRIX™ adjuvant (D+P-IMX).  Naïve mice 
received saline injections in lieu of immunization.  Sera were collected pre-immunization 
and 6 hours following the first (P1) and second (P2) protein-adjuvant boosts. Cytokines 
were quantified in the serum of individual mice at a 1:4 dilution using a custom 12-plex 
Luminex panel.  (a) QS-21 cytokine profile.  (b) MPLA cytokine profile.  (c) 
ISCOMATRIX™ adjuvant (IMX) cytokine profile.  (d) Serum cytokines elevated 
following protein boost with formulations containing all candidate adjuvants.  
Significance over background is represented above error bars.  Bracketed lines represent 
differences between adjuvant groups.  Statistical significance was determined with a One-
way ANOVA and Tukey post-test (*: p < .05, **: p < .01, ***: p < .001).   
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animals immunized with formulations containing Al(OH)3 or MPLA.  Levels of MIP-1β, 
a chemoattractant for natural killer (NK) cells and monocytes, were significantly higher 
than in Al(OH)3-immunized animals.  While mice immunized with formulations 
containing QS-21 showed significantly higher levels of IL-4 after the second protein 
boost in comparison to mice immunized with formulations containing ISCOMATRIX™ 
adjuvant, no significant differences were observed in other signature cytokines at this 
time point (Fig. 2.7a). 
Mice immunized with DP6-001 formulated with MPLA demonstrated 
significantly higher levels of the multifunctional and broadly acting chemokine RANTES 
in serum 6 hours after the first protein boost, as compared to other protein-adjuvant 
formulations (Fig. 2.7b).  Following the second protein-adjuvant boost, serum levels of 
RANTES were reduced in all groups, though in mice immunized with formulations 
containing MPLA the levels remained elevated compared to other formulations.  In 
addition, levels of G-CSF were significantly increased in mice immunized with 
formulations containing MPLA following the first protein boost in comparison to mice 
immunized with formulations containing QS-21 or Al(OH)3 (Fig 2.7b).   
Similarly, G-CSF was significantly increased at this time point in mice 
immunized with formulations containing ISCOMATRIX™ adjuvant in comparison to 
mice immunized with formulations containing QS-21 or Al(OH)3 (Fig. 2.7b).  G-CSF, 
which induces proliferation and differentiation of granulocytes, was characteristic of 
formulations containing either MPLA or ISCOMATRIX™ adjuvant in the context of the 
DP6-001 vaccine.  In addition, animals receiving DP6-001 vaccine formulated with 
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ISCOMATRIX™ adjuvant exhibited a unique profile of pro-inflammatory markers.  The 
Th1 cytokine IL-2 was significantly increased following the first protein boost in mice 
immunized with formulations containing ISCOMATRIX™ adjuvant in comparison to 
formulations containing QS-21 or Al(OH)3.  In addition, chemoattractants for eosinophils 
(Eotaxin), or monocytes and DCs (MCP-1), were also characteristic of formulations 
containing ISCOMATRIX™ adjuvant (Fig. 2.7c).  After the first protein boost, serum 
levels of MCP-1 in mice immunized with formulations containing QS-21 or Al(OH)3 
were significantly lower compared to formulations containing ISCOMATRIX™ 
adjuvant, while levels in mice immunized with formulations containing MPLA were 
comparable.  However, serum levels of Eotaxin were significantly increased in mice 
immunized with formulations containing ISCOMATRIX™ adjuvant in comparison to 
mice immunized with all other adjuvanted formulations. 
Several serum cytokines and chemokines in our panel were shared among 
different candidate adjuvants in the context of HIV-1 gp120 DNA prime-protein boost 
vaccine. The neutrophil chemoattractant KC was strongly elevated in serum following 
protein boosts in mice immunized with DP6-001 formulated with QS-21, MPLA and 
ISCOMATRIX™ adjuvant, as compared to naïve and mice immunized with formulations 
containing Al(OH)3.  There was no significant difference between these three adjuvanted 
formulations, although mice immunized with formulations containing ISCOMATRIX™ 
adjuvant demonstrated significantly higher levels of KC after the second protein boost as 
compared to formulations containing Al(OH)3 (Fig. 2.7d).   
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IL-6, which may act as both a pro- and anti-inflammatory cytokine in response to 
a variety of stimuli, was strongly induced following protein boost in with formulations 
containing QS-21, MPLA, and ISCOMATRIX™ adjuvant, while levels in the mice 
immunized with formulations containing Al(OH)3 were very low.  After the first protein 
boost, levels of IL-6 in mice immunized with formulations containing QS-21 and 
ISCOMATRIX™ adjuvant were both elevated comparably.  Interestingly, in animals 
receiving protein boost formulated with MPLA, after one protein boost levels of IL-6 
were significantly lower than those induced by formulations containing 
ISCOMATRIX™ adjuvant.  By the second protein boost, however, levels of IL-6 
induced by the formulations containing MPLA had risen to be comparable to initial levels 
seen with formulations containing ISCOMATRIX™ adjuvant, while the levels of IL-6 in 
mice immunized with formulations containing ISCOMATRIX™ adjuvant had notably 
fallen (Fig. 2.7d).   
Table 1 summarizes the serum cytokine profiles associated with each candidate 
adjuvant in the context of DP6-001, by comparing the fold increase over background for 
each adjuvant. 
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Table 2.1. Temporal serum cytokine levels in mice immunized with endotoxin-free 
(EF) DNA prime compared to regular DNA plasmid preparation.   
 
  
D+P+QS-21 D+P+Al(OH)3 D+P+MPLA D+P+IMX 
P1 P2 P1 P2 P1 P2 P1 P2 
IFNγ + ++ + - + + + + 
IL-2 ++ ++ ++ + ++ + +++ ++ 
IL-4 - + - - - - - - 
IL-6 ++ + + - + ++ ++ + 
IL-1β - + - - - - - - 
Eotaxin + + + - ++ - +++ + 
KC + + + - + + + + 
G-CSF ++ + + + +++ ++ +++ ++ 
RANTES + - + - ++ + + - 
MCP-1 + + + - ++ ++ +++ +++ 
MIP-1α ++ + ++ + ++ + + + 
MIP-1β + + - - + + + + 
 
Profiles were determined by calculating the fold increase of individual mice in each 
group over their respective pre-immunization cytokine levels.  Data is representative of 
cytokine data shown in Figure 6.    <2-fold increase: -, clear box.  2-10-fold increase: +, 
clear box.  10-30-fold increase: ++, light yellow box.  >30-fold increase: +++, dark 
yellow box.  (IMX = ISCOMATRIX™ adjuvant) 
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Induction of serum cytokines by a protein-adjuvant vaccine in the absence of DNA 
prime 
In order to define the effect of DNA priming on the protein and adjuvant serum 
cytokine profiles, additional study was performed in C57Bl/6 wildtype mice that received 
only two DP6-001 protein boosts formulated with candidate adjuvants without DNA 
prime.  Mice were immunized at weeks 0 and 4, and sera were collected for cytokine 
analysis at 6 hours after each protein boost.  Serum cytokines were quantified in 
immunized mice in comparison to naïve mice using the 12-plex array described above.   
Generally, serum cytokine levels associated with a protein-only vaccine were 
reduced (Fig. 2.8) in comparison to those observed in mice immunized with the complete 
DP6-001 DNA prime-protein boost regimen (Fig. 2.7).  Protein-only vaccine formulated 
with QS-21 results in low to background levels of Th1 and Th2 cytokines, including the 
previously observed QS-21-associated signature cytokines, IFNγ and IL-4 (Fig. 2.8a).  
The inflammatory cytokine IL-1β and the chemokine MIP-1β, associated with QS-21 in 
the context of DP6-001 prime-boost vaccine, were substantially reduced after 
immunization with a protein-only vaccine.  Similarly, protein vaccine formulated with 
QS-21 demonstrated moderate reductions in the chemokines G-CSF, MCP-1, MIP-1α, 
and RANTES (Fig. 2.8a).  While DP6-001 prime-boost vaccine formulated with Al(OH)3 
produced overall low, unimpressive cytokine profiles, we observed that protein-only 
immunization with formulations containing Al(OH)3 also demonstrated even lower or 
negligible levels of Th1/Th2 cytokines, inflammatory cytokines, and chemokines (Fig. 
2.8b).   
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(a)      (b) 
  
Figure 2.8.  Compiled serum cytokine panels following the first protein boost in 
mice vaccinated with Env protein formulated with QS-21 or Al(OH)3.  Mice 
vaccinated with protein-only vaccine (‘P’) received immunizations at weeks 0 and 4 with 
the DP6-001 protein.  Cytokines were quantified in serum from individual mice collected 
6 hours following protein boost by a 12-plex Luminex array.  Shown are serum cytokine 
levels 6 hours after the first protein-adjuvant boost.  Mice were immunized with protein-
only vaccine formulated with  (a) QS-21 (red) or (b) Al(OH)3 (green).   
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Similar studies with protein alone vaccination were conducted with formulations 
containing MPLA and ISCOMATRIX™ adjuvant, but also included groups that received 
three empty DNA vector as the prime followed with protein boost (Fig. 2.9).  In the 
context of a prime-boost vaccine, formulations containing MPLA were primarily 
characterized by potent induction of G-CSF and RANTES (Fig. 2.9a).  Interestingly, 
while Th1/Th2 cytokines and other chemokines are notably reduced following a protein-
only vaccine formulated with MPLA, the MPLA formulation-associated signature 
chemokines G-CSF and RANTES, as well as MCP-1 and KC, are minimally changed in 
the absence of DNA priming (Fig. 2.9b).  Vector-primed mice immunized with protein-
MPLA demonstrated reduced cytokines and chemokines (Fig. 2.9c) in comparison to 
mice immunized with the complete DP6-001 regimen (Fig. 2.9a).  
 Of the signature cytokines associated with formulations containing 
ISCOMATRIX™ adjuvant in the context of the DP6-001 prime-boost vaccine, such as 
IL-2, Eotaxin, G-CSF and MCP-1 (Fig. 2.9d), we observed that IL-2, Eotaxin, and MCP-
1 were substantially reduced in mice immunized with protein-only vaccine containing 
ISCOMATRIX™ adjuvant (Fig. 2.9e).  Though still above pre-immunization levels, 
serum levels of G-CSF were reduced in the absence of a DNA prime (Fig. 2.9e).  Control 
mice immunized with three empty vector DNA primes followed by DP6-001 protein 
boosts formulated with ISCOMATRIX™ adjuvant, however, demonstrated low or 
negative levels of all of the serum cytokine and chemokines analyzed (Fig. 2.9f).   
 In summary, from our analysis of serum cytokines associated with candidate 
adjuvants formulated with the DP6-001 prime-boost vaccine, several markers, IL-6, KC, 
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and MIP-1β, were identified that were comparably induced following protein boosting 
with formulations containing either QS-21, MPLA, or ISCOMATRIX™ adjuvant.  
Consistent with the trend of reduced cytokines associated with the absence of DNA 
priming, both IL-6 and MIP-1β were reduced or negative in comparison to DNA primed 
animals.  A notable exception to this trend was the neutrophilic chemoattractant KC, 
which remained at comparable levels regardless of vaccine regimen (Fig. 2.8 and Fig. 
2.9).  The inclusion of protein-only vaccines and empty vector DNA prime controls 
allows us to confirm that the cytokine and chemokine profiles associated with our 
candidate adjuvants are unique to the context of a DNA prime-protein boost vaccine 
strategy, and confirmed the concept that the improved immunogenicity based on serum 
cytokines was due to the inclusion of DNA priming steps.   
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 (a)    (b)    (c) 
   
(d)    (e)    (f) 
   
 
Figure 2.9.  Compiled serum cytokine panels following the first protein boost in 
mice vaccinated with Env protein vaccine and candidate adjuvants, as compared to 
DNA primed-protein boosted animals.  As previously described, mice were immunized 
with the complete DP6-001 DNA prime followed by protein boosts (‘D+P’) containing 
(a) MPLA (blue) or (d) ISCOMATRIX™ adjuvant (IMX) (purple).  Mice vaccinated 
with protein-only vaccine (‘P’) received immunizations at weeks 0 and 4 with the DP6-
001 protein.  Protein alone vaccines were formulated with  (b) MPLA (blue), or (e) 
ISCOMATRIX™ adjuvant (IMX) (purple).  Control mice received empty vector DNA 
primes, followed by protein boosts (‘V+P’) formulated with (c) MPLA (brown) or  (f) 
ISCOMATRIX™ adjuvant (IMX) (grey).  
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Discussion 
In recent years, the heterologous prime-boost vaccination strategy has 
demonstrated considerable advantages over the classical vaccine strategies based on 
homologous prime-boost strategies.  Results from RV144 clinical trial of viral vector 
prime and recombinant gp120 protein boost demonstrated unprecedented partial 
protection against the transmission of HIV-1 (38, 125, 144, 150).  Similarly, we have 
previously reported that the DP6-001 vaccine formulation, consisting of a DNA prime 
and protein boost, was highly immunogenic in both preclinical and clinical studies (7, 35, 
137, 138, 186).  A Phase I clinical trial of DP6-001 vaccine showed the generation of 
balanced Env-specific T cell and high titer Env-specific antibody responses including 
broadly neutralizing antibodies in study vaccinees (186).  
In both of the above studies, the Env protein boost is now recognized as a critical 
component.  However, the roles of adjuvant in such a protein boost immunization 
remains unclear.  Protein vaccines are formulated with adjuvants with the goal of 
promoting and harnessing the innate non-antigen specific, pro-inflammatory response, 
and ultimately enhancing the antigen-specific adaptive immune response.  However, this 
strategy is not without the risk of adverse effects.  Out of candidate adjuvants in the 
current study, only Al(OH)3 and MPLA are components in licensed vaccines in the 
United States.  Even well established and tolerable vaccine adjuvants such as Al(OH)3 
must be thoroughly evaluated for both efficacy and safety in the context of new vaccine 
formulations before being approved for clinical use.  Vaccine antigen, dosing, route of 
administration, and schedule may all impact the immunogenic profile as well as the 
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reactogenicity of a given adjuvant.  In addition, adjuvants must be selected with the 
pathogen-specific requirements of protection in mind.  Sterilizing immunity against HIV-
1 infection requires not only a strong humoral response including neutralizing antibodies, 
but also CD8+ cytotoxic T cell responses, and CD4+ T cells facilitating both the humoral 
and cell-mediated immunity.   
In the current study, three well-studied adjuvants, QS-21, MPLA, and 
ISCOMATRIX™ adjuvant, in addition to the widely used Al(OH)3 adjuvant as a control, 
all demonstrated comparable immunogenicity in the context of the DP6-001 DNA prime-
protein boost in a mouse model.  With the exception of Al(OH)3, the other three potent 
adjuvants each strongly induced a vaccine-specific antibody response.  While the QS-21 
adjuvant was associated with the strongest induction of Env-specific CD4+ T cell 
responses by intracellular cytokine staining and ELISpot assay, there were no significant 
differences in Env-specific Th1 and Th2 responses between the adjuvants evaluated as 
determined by ICS.  Env-specific T cell ELISpot results showed that formulations 
containing QS-21 induced significantly greater Th1 responses as compared to other 
adjuvants, while formulations containing MPLA and ISCOMATRIX™ adjuvant induced 
relatively low positive Th1 responses.  In contrast, all adjuvant formulations could elicit 
comparably weak Env-specific Th2 responses.   
While antigen specific responses were similar for formulations containing each of 
the adjuvants included in the current study, the serum cytokine profiles were quite 
different.  Multiplex arrays for nonspecific serum cytokines proved an invaluable tool in 
detecting differences in the non-Env specific innate responses to the DP6-001 vaccine 
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and candidate adjuvants.  In the context of the DP6-001 prime-boost vaccine, the 
candidate adjuvants were easily distinguished by these cytokine profiles and 
chemoattractants indicative of differential immune cell recruitment.  The local and 
systemic inflammatory environment induced by an adjuvant formulated with vaccine 
requires a delicate balancing act.  Early resident and recruited innate immune cells release 
of a complex milieu of cytokines and chemoattractants that together influence subsequent 
waves of immune cell infiltrates, and thus enhance antigen uptake and presentation (66).  
Ultimately, this microenvironment shapes the antigen-specific adaptive immune 
response, directing a Th1 or Th2 CD4+ T cell bias and enhancing B cell function and 
antibody production.  However, overstimulation of a pro-inflammatory response may 
result in undesirable local and systemic symptoms, including hypersensitivity reactions, 
fever and myalgia. 
The multifunctional cytokine IL-6 is a central player in inflammation. Along with 
IL-1β, IL-6 promotes the acute phase response and fever (106).  IL-6 also mediates 
neutrophilic inflammation and the shift from innate acute inflammation to chronic 
inflammation and adaptive immunity (79, 81, 82, 135).   In the current study, 6 hours 
following protein boost, we observed that IL-6 was universally induced to comparable 
levels by formulations containing each candidate adjuvant.  This pattern was also 
observed for the neutrophil chemoattractant, KC.  These serum cytokine levels associated 
with formulations containing the control adjuvant, Al(OH)3, were typically low compared 
to all other groups.  MIP-1α, which, like MIP-1β, is produced by macrophages to 
promote neutrophilic inflammation and immune cell recruitment (163), was produced 
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comparably by all adjuvanted formulations including those with Al(OH)3, but at levels 
not significantly elevated above background.  These cytokines characteristic of DP6-001 
DNA prime-protein boost with all adjuvants reflects an early, acute inflammatory 
response to immunization, likely predominated by neutrophils.   
In the current study, formulations containing QS-21 were associated with the Th1 
cytokine IFNγ and the Th2 cytokine IL-4, supporting our findings of mixed Env-specific 
Th1/Th2 T cell responses and IgG isotyping, as well as previous reports of Quillaia 
saponin fractions (172).  Elevated serum MIP-1β was characteristic of only formulations 
containing QS-21.  IL-1β, which plays a major role in the acute phase response and fever 
(106), as well as neutrophilic inflammation (27, 163), was also strongly associated with 
formulations containing QS-21.  It may be a point of interest that these characteristic 
cytokines were most strongly observed following the second protein boost, rather than 
following the first protein boost, as was the pattern for other adjuvants.  This may be 
suggestive of a progressive inflammatory response with subsequent immunizations. 
By comparison, the more clinically tolerable saponin formulation 
ISCOMATRIX™ adjuvant was characterized by strong IL-2, supportive of an expected 
Th1 and CD8+ T cell response.  Elevated systemic IL-6 as well as Eotaxin, a 
chemoattractant for eosinophils, are indicative of a Th2 response, supporting the reported 
mixed Th1/Th2 profile of ISCOMATRIX™ vaccines (37, 41, 109, 127, 141, 171).  
Granulocyte factor G-CSF and MCP-1, which recruits monocytes and macrophages 
subsequent to early neutrophil infiltration (195), were also associated with the protein 
boost containing ISCOMATRIX™ adjuvant. The distinct cytokine and chemokine 
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pattern observed here with DP6-001/ISCOMATRIX™ adjuvant consists of Th1 and Th2 
cytokines as well as chemoattractants indicative of the recruitment of monocytes, 
macrophages, NK cells, and granulocytes.  This profile supports a serum cytokine profile 
recently reported by Wilson et al. 6 hours following subcutaneous administration of 
ISCOMATRIX™ adjuvant without antigen (191).  Our profile of DP6-
001/ISCOMATRIX™ adjuvant is consistent with a profile of serum cytokines and 
immune cell infiltration at draining lymph nodes described by Duewell et al., consisting 
of B and T cells, DCs, NK cells, and granulocytes, in mice subcutaneously immunized 
with OVA antigen and ISCOMATRIX™ adjuvant (42).  
DP6-001 formulated with MPLA demonstrated high serum levels of granulocyte 
factor G-CSF, in addition to elevated serum RANTES, a T cell-produced chemoattractant 
for eosinophils, T cells, and NK cells. The serum cytokine profile of MPLA observed in 
the context of the DP6-001 Env DNA prime-protein boost may support previous 
evaluations of MPLA formulations in a mouse model.  Mata-Haro et al. previously 
reported that in the hours following injection, MPLA formulated with OVA antigen was 
correlated with serum G-CSF and MCP-1, and low but positive RANTES, as compared 
to LPS.  MyD88-associated IL-6 and MIP-1α were weakly positive, while IFNγ and IL-
1β were minimal (115).   
 We have described here a complex picture of the differential immune responses 
elicited by each candidate adjuvant in the context of a novel heterologous prime-boost 
vaccine, with the goal of identifying correlates of immunogenicity and markers of 
reactogenicity that may aid in the selection of an adjuvant for future optimized vaccine 
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formulations.  While the immunogenicity of the formulation containing our previously 
employed adjuvant QS-21 was comparable to formulations with our other candidate 
adjuvants, we may be able to correlate a unique systemic inflammatory response 
associated with QS-21.  Formulations with all three potent adjuvants, with the exception 
of Al(OH)3, demonstrated comparable serum levels of IL-6 and KC, and low but positive 
levels of MIP-1α.  Beyond this, the additional pro-inflammatory environment of serum 
IL-1β and MIP-1β associated specifically with QS-21 may contribute to reported adverse 
events.  The predominance of markers for acute inflammation and fever, as well as 
products and mediators of neutrophilic inflammation, is of particular interest given the 
nature of a previously reported vasculitis associated with DP6-001 and QS-21 (7).  
Leukocytoclastic vasculitis is due to the toxic effect of neutrophilic degranulation 
products on the endothelial cells of small vasculature (174).   
 In contrast to QS-21, formulations containing MPLA and ISCOMATRIX™ 
adjuvant likely demonstrate potentially milder reactogenic profiles.  Both MPLA and 
ISCOMATRIX™ adjuvant are largely characterized by broadly acting chemoattractants 
recruiting a varied population of immune cells, including granulocytes, NK cells, 
monocytes, DCs, and macrophages.  However, formulations containing either of these 
adjuvants demonstrate notably lower levels of additional inflammatory cytokines and 
chemokines such as IL-1β and MIP-1β in comparison to QS-21.  
 In the process of evaluating different adjuvants with the DP6-001 formulation, we 
observed that serum cytokine responses demonstrate unique kinetics in a prime-boost 
vaccine regimen.  The optimal time to detect high level cytokine responses was at 6 hours 
 72 
after the protein boost, while early studies demonstrated low to negative responses at the 
end of DNA priming immunization.  Repeated boost with protein-adjuvant vaccines 
actually led to a reduced cytokine response following subsequent protein boosts, except 
with the use of QS-21. 
 In the current study, we performed several control immunizations to confirm the 
correlation of our unique adjuvant serum cytokine profiles to their use in the context of a 
unique DNA prime-protein boost vaccine strategy.  In animals immunized with a protein-
only vaccine formulated with QS-21, Al(OH)3, MPLA, or ISCOMATRIX™ adjuvant, 
serum cytokine and chemokine panels were largely reduced in comparison to those in 
DNA-primed animals.  A similar trend was observed in animals that received an empty 
vector DNA prime and protein boost formulated with our candidate adjuvants.  These 
serum cytokine profiles from protein-only or empty vector primed vaccine formulations 
suggest that the serum cytokine and chemokine profiles we have defined for QS-21, 
MPLA, and ISCOMATRIX™ adjuvant are unique to the context of a DNA prime-protein 
boost vaccine strategy. 
A few notable exceptions to this trend were observed.  In mice immunized with 
protein formulated with MPLA, the markers G-CSF and RANTES, associated with 
MPLA in the context of the full DP6-001 regimen, were apparently uncompromised in 
the absence of DNA priming.  In addition, the neutrophil chemoattractant KC remained at 
relatively unchanged levels in the context of formulations containing QS-21, MPLA, or 
ISCOMATRIX™ adjuvant, regardless of vaccination strategy.  This observation suggests 
that an early immune response to vaccination characterized by strong neutrophilia was 
 73 
common to all tested vaccine strategies and adjuvants, and was minimally impacted by 
the presence or absence of DNA priming.   
The current study also suggested that while trace amount of endotoxin 
contaminants will lead to elevated levels of only a few cytokines, this has a minimal 
effect on the overall levels of Env-specific antibody responses.  These findings ruled out 
the potential contribution of endotoxin contamination to vaccine-induced 
immunogenicity and the observed profiles of non-antigen specific serum cytokines.  This 
analysis confirmed that the adjuvant effects we observed with our various DP6-001 
formulations were related to the adjuvant used, and not potentiated by method of DNA 
preparation.   
In summary, we have reported that two potent candidate adjuvants MPLA and 
ISCOMATRIX™ adjuvant demonstrate comparable immunogenicity to our previously 
employed adjuvant QS-21, in the context of a heterologous, multiclade HIV-1 Env DNA 
prime-protein boost regimen.  However, these adjuvants differ considerably in terms of 
induction of pro-inflammatory cytokines and chemokines responsible for local and 
systemic immune cell recruitment.  This study provides critical insight about these 
adjuvants in formulation with Env antigen, as well as in the context of a DNA-primed 
immune system.  In addition, the distinct cytokine and chemokine profiles defined for 
each adjuvant shed light on useful correlates of vaccine immunogenicity as well as pro-
inflammatory markers of reactogenicity for guidance in adjuvant selection for optimized 
Env prime-boost formulations.   
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CHAPTER III: 
Impact of innate signaling pathways on the adaptive and innate profiles of 
Monophosphoryl Lipid A and other adjuvants in the context of a DNA prime-
protein boost vaccine 
Introduction 
 
 Many vaccines are formulated with an adjuvant component that is capable of 
eliciting an immunomodulatory or immunostimulatory effect with the purpose of 
enhancing the adaptive immune response to the vaccine antigen, and thus improved 
efficacy.  Classically, compounds such as aluminum salts have been utilized in licensed 
human vaccines, including vaccines against diphtheria/tetanus/pertussis (DTaP) and 
hepatitis B virus (HBV), which deliver protein antigen to the immune system in order to 
raise protective immunity.  Aluminum salts have been used in humans for the last 70 
years in part due to their ability to raise a vaccine-specific antibody response, and also 
because of their clinical tolerability (66, 119).  More recently, novel adjuvant systems 
that specifically activate innate immune signaling pathways to ultimately enhance 
adaptive immunity have emerged as candidates for inclusion in human vaccines.  
Interactions with receptors for a variety of innate immune pathways impact vaccine-
specific immune responses, but also induce the secretion of pro-inflammatory cytokines 
and chemokines, and recruitment of a diverse population of immune cells that shape and 
direct the humoral and cell-mediated immune response.  Work to clearly understand the 
mechanism of adjuvants described herein is still underway. 
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Every vaccine and its respective adjuvant must be evaluated for efficacy and 
safety in terms of specific antigen, dosage, and delivery method.  In this study, we report 
on the evaluation of a previously described pentavalent HIV-1 Env DNA prime-protein 
boost vaccine DP6-001 (7, 137, 138, 186) in the context of three candidate adjuvants, 
with the goal of better understanding the innate pathways uniquely harnessed by each 
adjuvant.  Protein components of the DP6-001 vaccine were formulated with QS-21 as 
previously evaluated in preclinical and clinical studies or with the well-established 
aluminum salt-based adjuvant, aluminum hydroxide gel, referred to by its chemical 
formula Al(OH)3, as a control.  Alternatively, DP6-001 was formulated with MPLA, an 
adjuvant that has recently been approved for use in licensed human vaccines.  MPLA 
may be a clinically advantageous approach particularly in vaccines against HIV-1, as it is 
capable of inducing a strong antibody response as well as Th1-biased CD4+ T cells (2, 
115, 162, 175, 181, 182, 189).  MPL® is currently approved in formulation with 
aluminum hydroxide in the adjuvant system AS04 produced by GlaxoSmithKline (GSK) 
for the Fendrix® vaccine against HBV and the Cervarix® vaccine for human 
papillomavirus (HPV).  Additionally, AS01 and AS02, formulations of MPL® with QS-
21, are currently undergoing clinical trials for anti-malarial vaccines (159, 180). 
 MPLA is a derivative of LPS from Gram negative bacteria that is characterized by 
reduced toxicity in comparison to its parent molecule while still serving as an 
immunomodulatory compound (2).  LPS is highly toxic and produces a systemic 
inflammatory response via signaling through the pattern recognition receptor (PRR) Toll-
like receptor 4 (TLR4).  Through the process of acid-base hydrolysis, LPS is 
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dephosphorylated and a hydroxytetradecanoyl group is removed, resulting in the less 
toxic MPLA derivative (2, 151, 152).  Like LPS, MPLA is an agonist of TLR4 and 
requires signaling via TLR4 to mount an adaptive immune response.  However, the 
dependency of MPLA’s adjuvanticity on the activation of downstream signaling 
pathways remains less clear.  In particular, controversy remains regarding the relative 
bias of signaling via MyD88 or TRIF downstream of TLR4 activation.   
In a report by Mata-Haro et al. comparing the innate and adaptive responses to 
OVA protein antigen formulated with LPS or MPLA, it was suggested that TRIF-biased 
signaling with a concurrent reduction of activity via MyD88 adaptor and MyD88-
dependent inflammatory responses, was responsible for the reduced toxicity observed 
clinically with MPLA (115).  More recent studies have investigated whether this bias 
may be due to either a passive signaling bias or active inhibition of MyD88-dependent 
responses (29).  Our immunization studies of DP6-001 and adjuvants included genetically 
modified mice that are deficient in the required MPLA receptor, TLR4, or the adaptor 
molecule MyD88.  This allowed us to evaluate the contribution of MPLA activation of 
TLR4 signaling to the adaptive immune response in the context of the DP6-001 vaccine, 
and also determine the dependence of vaccine-induced humoral and CMI on downstream 
signaling via MyD88.  In addition, we observed the dependence of the non-antigen 
specific serum pro-inflammatory cytokine and chemokine profiles established in Chapter 
II to be associated with DP6-001/MPLA immunization on intact signaling via either 
TLR4 or MyD88.   
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 Unlike MPLA, the mechanisms of both alum adjuvants and QS-21 via innate 
immune signaling pathways remain largely unknown, and neither appear to activate any 
of the known TLRs.  Evidence indicates that aluminum salts interact directly with DC 
membranes in order to facilitate and maintain processing and presentation of antigen, and 
also inhibits release of IL-12, consistent with its Th2-biased response (51).  Aluminum 
salts have been extensively evaluated in vitro and in vivo for activation of the NLRP3 
inflammasome complex in DCs and other APCs, which results in the production of pro-
inflammatory cytokines IL-1β and IL-18.  As described in Chapter I, aluminum salts, 
along with other particulates such as asbestos or silica, may act directly on the NLRP3 
inflammasome, inducing assembly of inflammasome components and secretion of 
cytokines.  Conversely, administration of aluminum salts may cause tissue damage and 
cell death resulting in the release of ‘danger signals,’ including host DNA, which 
themselves induce the NLRP3 or other inflammasome complexes (22, 45, 53, 92, 97, 
119, 149).  Maturation and secretion of pro-inflammatory cytokines via the NLRP3 
inflammasome requires a first signal via MyD88 for the transcription of pro-cytokines 
(10).  Thus, while it is unlikely that the adjuvant effect of aluminum-based adjuvants, like 
Al(OH)3, is impacted by deficient TLR4 signaling, the MyD88 adaptor molecule is an 
important checkpoint for a variety of innate pathways that may be involved in the 
adjuvant effect of aluminum salts.  By similar logic, the saponin adjuvant QS-21, which 
is a known hemolytic agent associated with inflammation and reactogenicity, may well 
activate innate signaling pathways by producing cell damage and release of danger 
signals at the injection site. 
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The exact nature of the linkage between this innate inflammatory response and the 
generation of adaptive immunity to adjuvanted vaccine remains unclear.  The studies 
discussed in this chapter aim to determine the dependence of the antigen-specific 
responses (defined by antibody and T cell response) and non-antigen specific serum 
cytokine profiles associated with DP6-001 DNA prime-protein boost vaccine and 
candidate adjuvants, on intact signaling via TLR4 or MyD88, with a particular focus on 
the novel adjuvant system MPLA.    
Results 
 
Study Design and Immunization Schedule 
 
For these studies, C57Bl/6 wildtype mice or mice deficient in TLR4 or in MyD88 were 
immunized with the DP6-001 vaccine as previously described in Chapter II.  Knockout 
mice were generated as previously described (1).  Mice were immunized i.m. with the 
pentavalent DNA prime-protein regimen weeks 0, 2, and 4 and then boosted with DP6-
001 pentavalent protein and one of three adjuvants (QS-21, Al(OH)3, or MPLA) in weeks 
8 and 12 according the schedule in Figure 3.1.  As a control, some mice were primed with 
an empty vector DNA plasmid pSW3891, and then boosted with DP6-001 protein and 
MPLA.  Throughout the immunization schedule, sera were collected from each mouse 
biweekly, and 6 hours following the final DNA prime and each protein-adjuvant boost.  
At termination 7 days after the final protein boost, sera and spleens were harvested from 
immunized mice for downstream application.     
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        DNA Prime     Protein Boost 
          
 
     Week       0 2 4 6 8 10 12 13 
     Bleed I II III* IV V* VI VII* VIII 
 
Figure 3.1. Study design and immunization schedule. Mice were immunized i.m. with 
three DNA primes containing either DP6-001 or pSW3891 DNA two weeks apart.  Mice 
were immunized i.m. twice with DP6-001 protein formulated with either QS-21, Al(OH)3 
or MPLA.  Blood was harvested every two weeks. (* Mice bled 6 hours after 
immunization) 
  
    Prime (120 µg)  Boost (35 µg) 
 
DP6-001 DNA             DP6-001 Protein 
         QS-21, Al(OH)3, MPLA 
     
pSW3891             DP6-001 Protein 
         QS-21, Al(OH)3, MPLA 
 
 
 
DP6-001 gp120s 92UG037, 92US715, 
   Ba-L, 96ZM651, 93TH976 
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TLR4 is required for antibody responses in DP6-001/MPLA immunized mice 
 
In sera collected from immunized mice at termination, 7 days after the final 
protein-adjuvant boost, total Env-specific IgG antibody in serum was measured by 
ELISA.  All immunized mice produced a positive, vaccine antigen-specific IgG antibody 
in comparison to naïve mice (Fig. 3.2a).  As observed in previous studies of wildtype 
mice, there was minimal difference between Env-specific endpoint titers in response to 
DP6-001 when formulated with different adjuvants.  While not significant, animals 
immunized with an empty vector prime followed by boosting with DP6-001 protein and 
MPLA produced more modest Env-specific IgG endpoint titers compared to DP6-001 
DNA primed animals (Fig. 3.2a).  Notably, animals deficient in TLR4 demonstrated 
positive but significantly reduced endpoint IgG titers in comparison to wildtype mice, 
following immunization with DP6-001/MPLA (Fig. 3.2a).  This dependency on TLR4 
was not observed in mice immunized with DP6-001 and either QS-21 or Al(OH)3.   
 Temporal production of Env-specific IgG was quantified in sera collected 
biweekly throughout the immunization schedule by ELISA.  While animals immunized 
with vector prime did not demonstrate a detectable vaccine-specific IgG response in 
serum until after protein-MPLA boosting, there was no significant difference in the 
endpoint IgG titers between DP6-001 or vector primed wildtype animals (Fig. 3.2b).  A 
slight reduction was observed in the temporal induction of IgG during protein-MPLA 
boost time points in TLR deficient mice immunized with either DP6-001 or vector prime 
and MPLA, as compared to wildtype mice (Fig. 3.2b). 
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    (a)        
 
 
    (b) 
  
 
Figure 3.2. Optimal Env-specific IgG antibody responses in mice immunized with 
MPLA/DP6-001 are dependent upon TLR4.    (a) Env-specific endpoint IgG titer in 
wildtype and TLR4-deficient mice immunized with DP6-001 or pSW3891 vector prime 
followed by DP6-001 protein adjuvanted with QS-21, Al(OH)3 or MPLA.  (b) Temporal 
gp120-specific IgG response was determined by ELISA using pooled sera samples from 
each group collected at two-week intervals.  Statistical significance was determined by 
Student’s t test (* p < 0.05). 
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Characterization of IgG isotypes indicative of a Th1- or Th2-biased response were 
quantified in serum collected at termination by ELISA (Fig. 3.3).  Production of the Th2-
associated isotype IgG1 was significantly greater in wild type mice immunized with DP6-
001/MPLA compared to mice primed with empty vector (Fig. 3.3a).  Furthermore, a 
moderate but significant reduction in Env-specific IgG1 was observed in TLR4 deficient 
mice compared to wild type (Fig. 3.3a).  In contrast, Th1-associated isotypes IgG2b and 
IgG2c were comparable between wild type mice immunized with either DP6-001 or 
vector prime and protein-MPLA boost (Fig. 3.3b,c).  However, endpoint titers of both 
IgG2b and IgG2c were significantly reduced nearly to background levels in both groups 
of immunized TLR4 deficient mice, indicating a dependency of the Th1 response to DP6-
001/MPLA on intact TLR4 signaling (Fig. 3.3b,c). 
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(a) 
 
(b) 
 
(c) 
 
 
Figure 3.3. Optimal Env-specific IgG isotype responses in MPLA/DP6-001 
immunized mice are dependent upon TLR4.  Endpoint IgG isotype titers were 
determined in terminal sera from wildtype and TLR4-deficient mice by ELISA.  (a) 
IgG1, (b) IgG2b, and (c) IgG2c.  Statistical significance was determined by Student’s t 
test (* p < 0.05). 
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TLR4 is required for T-cell mediated IFNγ  responses in DP6-001/MPLA immunized 
mice 
Upon termination of study, 7 days following final protein boost, splenocytes were 
harvested from immunized mice in order to quantify the vaccine-induced antigen-specific 
T cell responses.  Splenocytes were incubated with abbreviated peptide pools of 
overlapping 15mers representing a small region from a clade B consensus sequence 
covering the length of gp120.  Peptide pools stimulated production of Th1 (IFNγ, IL-2) 
and Th2 (IL-4, IL-6) cytokines by vaccine-specific T cells as measured by ELISpot.  As 
negative and positive controls, splenocytes were alternatively incubated with either RPMI 
media or PMA and ionomycin, respectively.  With a particular focus on the T cell 
responses associated with MPL, we observed that Env-specific production of IFNγ was 
greater in DP6-001 prime-boost immunized mice compared to vector primed mice (Fig. 
3.4).  In both immunization groups adjuvanted by MPLA, deficiency in TLR4 signaling 
resulted in significantly reduced Env-specific IFNγ by ELISpot (Fig. 3.4).  These results 
indicate that the T cell response induced by the DP6-001 vaccine is enhanced by Env-
encoding DNA plasmid priming, and that the adjuvant effect of MPLA required intact 
TLR4 signaling. 
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Figure 3.4.  Env-specific T-cell mediated IFNγ  response in DP6-001/MPLA or 
pSW3891/MPLA-immunized mice are dependent upon TLR4.  After immunization 
with DP6-001/MPLA or pSW3891 vector prime and DP6-001 protein boost with MPL, 
spleens were harvested at termination 7 days after the final protein boost.  Single cell 
suspensions of splenocytes were seeded into 96-well multiscreen filter plates and 
stimulated for 18 hours with Env-specific peptides (“G pool”) or media alone (“mock”).   
IFNγ release was measured by ELISpot assay and spots quantified using CTL software.  
Statistical analysis of peptide stimulation over mock stimulation was calculated by 
Student’s t-test (*: p < 0.05). 
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TLR4 is required for pro-inflammatory responses in DP6-001/MPLA immunized 
mice following protein boosting 
 Initial screening of a large panel of non-antigen specific inflammatory cytokines 
and chemokines in immunized wildtype mice identified a panel of analytes that were 
significantly induced above background by immunization with DP6-001 and candidate 
adjuvants.  Levels of cytokines and chemokines in the sera of immunized mice were 
highly elevated at time points 6 hours after each protein-adjuvant boost.  We have 
previously identified non-antigen specific serum cytokines and chemokines characteristic 
of the DP6-001 vaccine and candidate adjuvants at time points 6 hours after protein-
adjuvant boosting (Buglione-Corbett, et al., unpublished data).  In wildtype mice 
immunized with DP6-001 DNA prime and protein boost, we have observed that 
formulation of protein boost with MPLA resulted in a unique profile of elevated serum 
RANTES and G-CSF.  We also noted several analytes that were commonly induced 
following protein boosts formulated with all candidate adjuvants, including IL-6.  
Overall, of the 12-plex panel of serum cytokines and chemokines assessed in immunized 
mice, minimal differences were observed between wildtype mice immunized with DP6-
001 and either QS-21 or Al(OH)3.   However, serum levels of MPLA-associated G-CSF 
and RANTES, as well as IL-6, were significantly reduced in TLR4 deficient mice 
immunized with DP6-001/MPLA compared to wildtype mice (Fig. 3.5).  These results 
suggest that the pro-inflammatory environment uniquely induced by MPLA in 
association with DP6-001 vaccine is dependent on its action via TLR4. 
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(a)     (b) 
 
(c) 
 
 
Figure 3.5.  Optimal induction of pro-inflammatory cytokines requires TLR4 in 
DP6/MPL-immunized mice.  Sera were collected pre-immunization and 6 hours 
following protein-adjuvant boosts.  Cytokines were quantified in the serum of individual 
mice at a 1:4 dilution using a custom 12-plex Luminex panel.  Shown are significant 
decreases in chemoattractants and proliferative factors after protein boosting in TLR4 
deficient mice immunized with DP6-001 adjuvanted with MPLA or other adjuvants: (a) 
RANTES, (b) G-CSF, and (c) IL-6.  Statistical significance was determined by Student’s 
t test (* p < 0.05). 
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MyD88 is required for antibody responses in DP6-001/MPLA immunized mice 
Endpoint titers of Env-specific IgG was determined by ELISA in sera collected 
upon termination 7 days after the final protein-adjuvant boost.  While MyD88 deficiency 
did not substantially impact the antibody response induced by DP6-001 formulated with 
either QS-21 or Al(OH)3, MyD88 deficiency had a partial but significant negative impact 
on the Env-specific IgG response to DP6-001/MPLA (Fig. 3.6a,b).  The vaccine-induced 
antibody responses were further characterized by IgG isotyping as previously described.  
As was observed in TLR4 mice immunized with DP6-001 and MPLA adjuvant, there was 
a moderate but significant reduction in the induction of Th2-associated IgG1 endpoint 
titers in MyD88 deficient mice as compared to wild type mice (Fig. 3.7a).  Furthermore, a 
more substantial impact on Th1-associated isotypes IgG2b and IgG2c was observed in 
MyD88 deficient mice immunized with either DP6-001 DNA primed mice or vector 
primed mice and MPLA (Fig. 3.7b,c).  Therefore, as observed in immunization studies 
with TLR4 deficient mice, it appears that a vaccine-induced Th1-biased adaptive immune 
response requires intact MyD88 signaling downstream of TLR4 signaling.   
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Figure 3.6.  Optimal Env-specific IgG antibody responses in MPLA/DP6-001 
immunized mice are dependent upon MyD88. Env-specific endpoint IgG titer in wild 
type (WT) and MyD88-deficient mice immunized with DP6-001 or vector pSW3891  
prime followed by DP6-001 protein adjuvanted with QS-21, Al(OH)3 or MPLA.  
Statistical analysis of peptide stimulation over mock stimulation was calculated by 
Student’s t-test (*: p < 0.05).   
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Figure 3.7. Optimal Env-specific IgG isotype responses in MPL/DP6-001 immunized 
mice are dependent upon MyD88.  Endpoint IgG isotype titers were determined in 
terminal sera from wildtype and MyD88-deficient mice by ELISA.  (a) IgG1, (b) IgG2b, 
and (c) IgG2c.  Statistical significance was determined by Student’s t test (* p < 0.05). 
 
 
IgG1
102
103
104
105
106
R
ec
ip
ro
ca
l E
nd
po
in
t T
ite
r
*
*
WT
DP6-001 Protein
                           
 
        DP6-001 DNA          Vector DNA 
                                
      
MyD88 KO
IgG2b
102
103
104
105
106
R
ec
ip
ro
ca
l E
nd
po
in
t T
ite
r
*
WT
MyD88 KO
p=0.06
DP6-001 Protein
                           
 
        DP6-001 DNA          Vector DNA 
                                
      
IgG2c
102
103
104
105
106
R
ec
ip
ro
ca
l E
nd
po
in
t T
ite
r
* *
WT
MyD88 KO
DP6-001 Protein
                           
 
        DP6-001 DNA          Vector DNA 
                                
      
 92 
MyD88 is required for T-cell mediated IFNγ  responses in DP6-001/MPLA 
immunized mice 
As previously described, splenocytes harvested from immunized mice 7 days after 
the final protein boost were assessed for their ability to generate vaccine-specific T cell 
responses by ELISpot.  Generally, mice immunized with DP6-001 and candidate 
adjuvants demonstrated modest but positive induction of Env-specific Th1 (IFNγ, IL-2) 
and Th2 (IL-4, IL-6) cytokines in response to stimulation with overlapping peptide pools 
representative of gp120.  In MyD88 deficient mice, a significant reduction in the Env-
specific IFNγ response was observed after immunization with DP6-001 formulated with 
or MPLA (Fig. 3.8).  Control mice designed to focus on MPLA were immunized with 
empty vector prime and DP6-001 protein-MPLA boosts.  The specific induction of IFNγ 
was much more modest in wild type mice in comparison to DP6-001 DNA primed mice 
(Fig. 3.8).  Furthermore, while it was previously observed that the IFNγ was significantly 
reduced in TLR4 deficient control mice, there was no change in IFNγ response between 
MyD88 deficient mice immunized with vector control compared to wild type (Fig. 3.8).   
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Figure 3.8. T-cell mediated IFNγ response in DP6-001/MPLA immunized mice are 
dependent upon MyD88.  After immunization with DP6-001/MPLA or pSW3891 vector 
prime and DP6-001 protein boost with MPLA, spleens were harvested at termination 7 
days after the final protein boost.  Single cell suspensions of splenocytes were seeded into 
96-well multiscreen filter plates and stimulated for 18 hours with Env-specific peptides 
(“G pool”) or media alone (“mock”).   IFNγ release was measured by ELISpot assay and 
spots quantified using CTL software.  Statistical analysis of peptide stimulation over 
mock stimulation was calculated by Student’s t-test (*: p < 0.05). 
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MyD88 is required for pro-inflammatory responses in DP6-001/MPLA immunized 
mice following protein boosting 
Serum cytokines and chemokines were quantified by multiplex in sera collected 
from immunized mice 6 hours after each protein-adjuvant group, with a particular focus 
on analytes associated uniquely with DP6-001/MPLA.  As was observed in TLR 
deficient mice, the characteristic induction of G-CSF by DP6-001/MPLA was reduced 
after protein-MPLA boosting in immunized MyD88 deficient mice, and this reduction 
was significant after the second protein boost (Fig. 3.9b).  Additionally, serum levels of 
the inflammatory cytokine IL-6, which was associated with protein boosting in all 
adjuvant groups, was reduced by MyD88 deficiency (Fig. 3.9c).  While a mild reduction 
was observed in DP6-001 groups adjuvanted by QS-21, this reduction was significant in 
mice immunized with DP6-001 protein boosts formulated with MPLA.  
 In contrast to these observations, the chemokine RANTES, which has previously 
been shown to be associated with DP6-001/MPLA vaccination and to also require intact 
TLR4 signaling for robust serum levels, was unchanged in MyD88 deficient mice in 
comparison to wild type mice (Fig. 3.9a).  Similarly, while TLR4 deficiency had a 
significant negative impact on the pro-inflammatory chemokines MIP-1α, MIP-1β, and 
MCP-1 associated with DP6-001/MPLA immunization, the macrophage inflammatory 
proteins MIP-1α and MIP-1β were unchanged in MyD88 deficient mice compared to 
wild type (data not shown).  With a focus on the DP6-001/MPLA, specifically, we 
identified a dependency of the adjuvant profile on TLR4, but only a partial dependency 
on intact signaling downstream of TLR4 via MyD88.  
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(a)      (b) 
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Figure 3.9.  Optimal induction of pro-inflammatory cytokines requires MyD88 in 
DP6/MPLA-immunized mice.  Sera were collected pre-immunization and 6 hours 
following protein-adjuvant boosts.  Cytokines were quantified in the serum of individual 
mice at a 1:4 dilution using a custom 12-plex Luminex panel.  Shown are significant 
decreases in chemoattractants and proliferative factors after protein boosting in MyD88 
deficient mice immunized with DP6-001 adjuvanted with MPLA: (a) RANTES, (b) G-
CSF, and (c) IL-6.  Statistical significance was determined by Student’s t test (* p < 
0.05). 
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Discussion 
In the current chapter, we describe the dependence of adaptive and innate immune 
responses to vaccination with DP6-001 and candidate adjuvants on intact signaling via 
TLR4 or the adaptor MyD88.  Specifically, we focused on the recently approved MPLA 
adjuvant, in the unique context of DP6-001 prime-boost vaccine.  It is well established 
that MPLA depends on TLR4 signaling for its adjuvanticity, like its parent molecule 
LPS.  However, it remains unclear the dependency of both induction of pro-inflammatory 
serum cytokines as well as adaptive immune responses on multiple signaling pathways 
downstream of TLR4 activation.   Furthermore, DNA priming provides a unique 
environment for subsequent immunizations with antigen and adjuvant.  The studies 
described herein aim to highlight the impact of DNA priming on the innate signaling 
pathways utilized by MPLA and its immunogenicity in the context of DP6-001.   
As previously described, while MPLA and LPS both signal via TLR4 and both 
potently induce immune responses, MPLA is less inflammatory and demonstrates 
reduced pro-inflammatory cytokines in comparison to LPS (28, 29, 115, 123, 136, 175).  
Reports based on a model of OVA protein vaccine formulated with MPLA attribute the 
reduced inflammatory response of MPLA to biased signaling downstream of TLR4.  
Mata-Haro et al. indicate that MPLA activates TRIF-biased signaling, resulting in the 
production of TRIF-associated serum cytokines after immunization, including G-CSF, 
RANTES and MCP-1.  Conversely, immunization with LPS results in increased 
production of MyD88-associated IFNγ, IL-1β, IL-6, and MIP-1α (115).  Making a 
clinically relevant link between innate and adaptive immune responses to vaccination, 
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they utilized transgenic OVA-specific mice in order to demonstrate that OVA-specific T 
cell priming required intact TRIF signaling but not MyD88.  These reports suggest that 
MPLA only weakly activates MyD88-dependent pathways downstream of TLR4 (115).  
This would appear to be supported by reports that MPLA results in decreased production 
of pro-inflammatory cytokines indicative of MyD88 signaling, such as IL-1β (29, 123, 
136).  It was also demonstrated that while MPLA and LPS comparably induce the 
transcription of pro-IL-1β and pro-IL-18, MPLA fails to induce sufficient MyD88 
signaling for expression and assembly of the NLRP3 inflammasome and therefore, 
secretion of mature pro-inflammatory cytokines (123).  Some reports have suggested that 
this less inflammatory bias of MPLA signaling via TLR4 is due to active inhibition of 
MyD88 rather than a passive bias of “weak” MyD88 activation (29).  Though the 
mechanism is unclear, the ability of MPLA to harness TLR4 signaling and 
immunostimulation without the toxic inflammation that characterizes LPS makes it 
clinically appealing. 
In Chapter II, we defined a profile of adaptive and innate immune responses to 
MPLA formulated with DP6-001 prime-boost vaccine, in terms of antigen-specific 
antibody and T cell responses as well as non-antigen specific serum cytokines and 
chemokines induced by protein-MPLA boosting.  In the current chapter, we further 
explored how signaling via TLR4 and the MyD88 adaptor impacts these immune 
responses to DP6-001 and select adjuvants, with a particular focus on MPLA.  We also 
confirmed that while QS-21 and Al(OH)3 do not appear to activate TLR4, they might to 
some extent activate MyD88-dependent pathways.   
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As we expected, total Env-specific IgG antibody responses to either DP6-001 or 
empty vector primed immunization formulated with MPLA were significantly decreased 
in TLR4 deficient animals; however, this reduction was only partial.  More specifically, 
analysis of IgG isotypes induced by vaccination with MPLA showed that Th1-associated 
responses were completely abrogated by TLR4 deficiency, while Th2-associated 
responses were only partially reduced.  Perhaps surprisingly, MyD88 deficiency had a 
similar impact on Env-specific antibody responses.  These results indicate that while 
intact TLR4 signaling is required for an improved humoral response to DP6-001/MPLA, 
MyD88 signaling also contributes to the adjuvant effect of MPLA.  The overall reduced 
antibody response observed in the vector prime control with MPLA demonstrates the 
contribution of both DNA priming and MPLA adjuvant to improved humoral immunity.  
In contrast to MPLA, we did not observe any impact of either TLR4 or MyD88 
deficiency on the humoral response associated with DP6-001 and QS-21 or Al(OH)3. 
In parallel with these results, we also noticed a significant contribution of both 
TLR4 and MyD88 signaling to Env-specific Th1 responses to DP6-001/MPLA as 
measured by IFNγ ELISpot.  In addition, Env-specific IFNγ in splenocytes from mice 
immunized with DP6-001/QS-21 was significantly reduced in MyD88 deficient mice, 
suggesting a possible role for MyD88 adaptor in an undefined mechanism of QS-21.  
Meanwhile, Th2 responses as measured by IL-4 or IL-6 ELISpot were similar between all 
adjuvant groups, and were not impacted by TLR4 or MyD88 deficiency. 
In Chapter II, we established that there were unique profiles of serum cytokine 
and chemokines induced by each adjuvant and the DP6-001 vaccine.  In our studies, 
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MPLA was characterized by potent induction of G-CSF and RANTES at time points 6 
hours after protein-adjuvant boosting.  This profile is supported by reports profiling 
MPLA formulated with OVA antigen (115, 182).  We also identified that serum IL-6 was 
induced following protein immunization with all of our candidate adjuvants, including 
MPLA.  These serum cytokines were more strongly induced by DP6-001/MPLA in 
comparison to mice primed with empty vector; however, in both cases, serum levels of 
G-CSF and RANTES were significantly reduced by TLR4 deficiency.  Serum levels of 
IL-6 were also reduced by TLR4 deficiency.  In contrast, MyD88 had a less obvious 
impact on serum cytokine profiles.  In mice immunized with DP6-001/MPLA, both G-
CSF and IL-6 were significantly reduced in the absence of MyD88; however, RANTES 
was unchanged between wild type and MyD88 deficient mice.  Notably, MyD88 
deficiency did not have a significant impact on the sera cytokine profiles of DP6-001 
vaccine formulated with either QS-21 or Al(OH)3.   
Altogether, our results are supportive of the dependence of MPLA adjuvanticity 
on intact TLR4 signaling.  Furthermore, these results demonstrate that both the vaccine-
specific adaptive immunity and early pro-inflammatory cytokine profiles associated with 
MPLA are not independent of MyD88 signaling.  Finally, induction of chemokines G-
CSF and RANTES, and the pro-inflammatory cytokine IL-6, by MPLA were enhanced 
by a DNA primed vaccine strategy.  G-CSF is involved in the production of granulocytes, 
as well as the survival, proliferation, and function of neutrophils.  RANTES serves as a 
chemoattractant recruiting leukocytes, eosinophils and basophils to sites of inflammation 
and also contributing to NK cell activation.  The induction of these two broadly acting 
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chemokines shortly after protein-MPLA boosting suggests an inflammatory response 
characterized by recruitment of a diverse population of immune cells.  Evaluation of 
cellular infiltrates by histology and flow cytometry associated with subcutaneous 
immunization with MPLA indicated a rapid infiltration of neutrophils within 12 hours 
(182).   In addition, initial reduction in circulating lymphocytes and subsequent 
recruitment to draining lymph nodes were also observed after MPLA administration 
(182).  Gene expression studies indicate that MPLA, given intraperitoneally, supports a 
diverse microenvironment characterized by Th1 and pro-inflammatory cytokines, as well 
as chemoattractants for granulocytes and monocytes, and immune cell infiltrate 
predominated by APCs, neutrophils, and NK cells (93).   The consistent trend of the 
induction of G-CSF, RANTES, and IL-6 shortly after MPLA administration formulated 
with a variety of antigens is supportive of the rapid and diverse recruitment of immune 
cells, which serve to support and enhance adaptive immune responses (115, 182).  
The activation of pattern-recognition receptors such as TLR4 on DCs and other 
APCs at the injection site contributes to the adjuvant effect of MPLA, by increasing local 
inflammation.  This response influences the recruitment of lymphocytes and other 
inflammatory cells that are responsible for the uptake and presentation of antigen for the 
generation of adaptive immunity.  In this chapter, we have demonstrated the induction of 
broadly acting cytokines and chemokines (IL-6, RANTES, and G-CSF) associated with 
DP6-001/MPLA, consistent with other reports.  The induction of this non-antigen 
specific inflammatory response is enhanced in subsequent immunizations by a DNA 
primed environment.  This inflammatory response to MPLA is dependent on intact 
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signaling via TLR4 as well as the adaptor MyD88.  Therefore, not only the adaptive T 
cell and antibody responses, but also the innate inflammation induced by MPLA 
adjuvant, involves TLR4 and MyD88 signaling.   
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CHAPTER IV: 
Potent adjuvant effects of ISCOMATRIX™ adjuvant as part of a DNA prime-
protein boost HIV-1 vaccine formulation 
Introduction 
Effective prophylactic vaccination against Human Immunodeficiency Virus 
(HIV-1) requires induction of a diverse and specific immune response, consisting of 
neutralizing antibodies specific to viral epitopes, as well as effector CD4+ and CD8+ T 
cells.  Development of a vaccine with the ability to stimulate both the humoral and 
cellular arms of the adaptive immune system to produce sterilizing immunity remains 
elusive.  In approaching the complex problem of HIV-1 vaccination, the choice of an 
adjuvant capable of stimulating both humoral and cellular immune responses is a critical 
component of a protective vaccine.   
‘Immunostimulatory complexes’ (ISCOMs) were first described as an adjuvant 
and antigen delivery system by Morein et al. in 1984 (126).  The ISCOMATRIX™ 
adjuvant formulation is a particulate adjuvant that consists of cholesterol and dipalmitoyl-
sn-phosphatidylcholine (DPCC) in a cage-like matrix, and purified ISCOPREP™ saponin 
Fraction C derived from Quillaja saponaria, with which protein antigen can be 
formulated.  ISCOMATRIX™ adjuvant is easily formulated with a range of antigens by 
simple mixing.  ISCOMATRIX™ adjuvant demonstrates a promising alternative to other 
saponin adjuvants such as QS-21, which, while potently immunogenic, are associated 
with hemolytic activity and a range of adverse effects in preclinical and clinical models 
(85, 99, 129, 130, 183).  The formulation of the saponin fraction within this cholesterol-
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phospholipid matrix results offers the potential of improved tolerability without 
sacrificing potency (170, 171).  In addition, ISCOMATRIX™ adjuvant is both an 
effective delivery vehicle for antigen, as well as a strong inducer of an 
immunomodulatory response.  As a vaccine component, ISCOMATRIX™ adjuvant is 
not only formulated with antigen by simple mixing, but is also stable for several years 
when stored at 2-8oC, an advantage for use in large scale production and wide 
distribution of vaccines (141).   
The precise mechanisms of many saponin-based adjuvants remain to be 
elucidated.  ISCOMATRIX™ adjuvant effectively facilitates antigen-adjuvant complex 
uptake by and activation of dendritic cells (DCs) locally and in draining lymph nodes, 
resulting in cross-presentation to CD8+ T cells via MHC I, as well as presentation to 
CD4+ T cells, indirectly contributing to specific B cell function, via MHC II (157, 166, 
167).  ISCOMATRIX™ adjuvant also stimulates local and systemic induction of pro-
inflammatory cytokines and chemokines that play an important role in the recruitment 
and activation of immune cells such as DCs, B cells, T cells, and NK cells in the DLN 
(42, 191).  Lymphatic cannulation studies have demonstrated that ISCOMATRIX™ 
adjuvant also aids in the trafficking of antigen-adjuvant complexes to DLNs, temporarily 
reducing LN cellular output, effectively prolonging presentation of antigen to immune 
cells (192, 193).  ISCOMATRIX™ adjuvant is particularly effective in facilitating the 
cross-presentation of antigen via MHC I, thus promoting a potent CTL response, a 
desired quality in the vaccine design against a number of pathogens as well as anti-tumor 
vaccines.  Wilson et al. demonstrated that the action of ISCOMATRIX™ adjuvant on 
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DCs and cross-presentation to CD8+ T cells, as well as vaccine-specific adaptive immune 
responses, are to some extent dependent on the adaptor protein MyD88 (191).  
The integrated delivery and immunomodulatory functions of ISCOMATRIX™ 
adjuvant result in strong adaptive immune responses.  In guinea pigs, using an HIV-1 
gp120 antigen, ISCOMATRIX™ adjuvant was demonstrated to allow for protein antigen 
dose reduction up to 100-fold while enhancing neutralizing antibody responses in 
comparison to an aluminum-based adjuvant (18).  Formulation of protein antigens 
including HPV16 E6 and E7, and H5N1 influenza hemaglutinin (HA), with 
ISCOMATRIX™ adjuvant have also demonstrated in small animal models durable 
specific antibody responses with reduced antigen dose, as compared to formulations with 
aluminum-based adjuvants (18, 122, 173).  The induced antibody response is long lasting, 
as demonstrated in nonhuman primates receiving hepatitis C virus core protein with 
ISCOMATRIX™ adjuvant (146).   
The broad, multifunctional induction of vaccine-specific immunity associated 
with ISCOMATRIX™ adjuvant makes it an ideal adjuvant for applications ranging from 
prophylactic vaccines against viral and intracellular pathogens, to therapeutic vaccines 
against cancer.  Clinically, up to 1600 individuals participating in 16 Phase I clinical 
trials have received doses of ISCOMATRIX™ adjuvant ranging from 22.5-90 ISCO™ 
Units, including vaccines for hepatitis C virus (HCV), human papilloma virus (HPV), and 
influenza, as well as therapeutic cancer vaccines.  Rimmelzwaan et al. demonstrated the 
ISCOMATRIX™ adjuvant formulated vaccines produced more rapid immunity to 
influenza as compared to traditional vaccines (154).  A substantial body of work has 
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utilized the highly immunogenic NY-ESO-1 cancer testis tumor antigen with 
ISCOMATRIX™ adjuvant in humans, resulting in the induction of broad tumor-specific 
antibodies, as well as CD4+ and CD8+ T cell responses, which could be correlated to 
improved clinical outcome (37) and long-term persistent immunity (131).  
ISCOMATRIX™ adjuvant has also demonstrated therapeutic applications in vaccines for 
HPV16 in HIV-infected individuals (4), in HPV-associated cervical neoplasia (56), and 
in individuals chronically infected with HCV (41).  ISCOMATRIX™ adjuvant has been 
well-tolerated in clinical trials, with adverse effects being mild and typically self-limited 
local reactions (120).   
In clinical trials, ISCOMATRIX™ adjuvant has typically been formulated with 
recombinant protein.  The current study focuses on the adjuvant effect of 
ISCOMATRIX™ adjuvant in the unique context of a previously described polyvalent 
HIV-1 gp120 DNA prime-protein boost construct, DP6-001.  We have previously 
demonstrated the immunogenicity of DP6-001 in human volunteers, with the induction of 
Env-specific antibody responses with neutralizing ability, as well as induction of vaccine-
specific T cell responses (7, 186).  The protein boost component of DP6-001 was 
formulated with the saponin adjuvant QS-21 in preclinical and clinical evaluations.  As a 
saponin-based complex with reduced reactogenicity but uncompromised potency, 
ISCOMATRIX™ adjuvant is a promising alternative to QS-21.  In addition, protective 
immunity against HIV-1 infection requires the action of both the humoral and cellular 
arms of the adaptive immune response, and so a broadly acting integrated adjuvant 
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system like ISCOMATRIX™ adjuvant is an obvious choice for inclusion in future Env 
DNA prime-protein boost vaccine formulations.   
In the current study, we have demonstrated the efficacy of a the DP6-001 gp120 
DNA prime-protein boost formulated with ISCOMATRIX™ adjuvant in generating a 
robust antibody response in both Balb/c and C57Bl/6 mice, and New Zealand White 
rabbits, in comparison to DP6-001 formulated with aluminum hydroxide gel adjuvant, 
Al(OH)3.  Improved strength and breadth of neutralizing antibodies was demonstrated in 
rabbits receiving ISCOMATRIX™ adjuvant.  Serum cytokines following each protein-
adjuvant immunization were quantified in mice, demonstrating potent induction of Th1 
and Th2 cytokines by DP6-001 formulated with ISCOMATRIX™ adjuvant.  
Immunization of MyD88 deficient mice with DP6-001 DNA prime and protein-
ISCOMATRIX™ adjuvant boost demonstrated a partial albeit incomplete reduction in 
humoral and serum cytokine responses, consistent with a role for MyD88 in the adjuvant 
activity of ISCOMATRIX™ adjuvant.   Our data also suggests that DNA priming itself 
may impact the dependence of an ISCOMATRIX™ adjuvant-based vaccine on MyD88 
signaling.  To our knowledge, this is the first study of the adjuvanticity of 
ISCOMATRIX™ adjuvant in the context of a DNA prime-protein boost vaccine 
construct utilizing an HIV-1 Env gp120 antigen.   
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Results 
Vaccine-induced temporal serum cytokine profiles following protein-adjuvant boost 
in Balb/c wildtype mice 
Wildtype Balb/c mice received three DP6-001 DNA followed by DP6-001 protein boosts 
adjuvanted by either ISCOMATRIX™ adjuvant or our control adjuvant Al(OH)3.  
Control animals received an empty vector DNA prime followed by a protein boost with 
ISCOMATRIX™ adjuvant.  Naïve animals received a saline injection.  Sera were 
collected at two-week intervals and following each immunization, as well as one week 
following final protein boost, according to Figure 4.1.  Serum cytokines were quantified 
by Cytometric Bead Array (CBA) in samples collected pre-immunization, at 6 hours 
following each protein boost, and upon termination at 7 days after the final protein boost.  
All immunized and naïve animals demonstrated background levels of the measured 
serum cytokines prior to immunization and upon termination at week 13, with the 
strongest levels of serum cytokine production measured following each protein boost.   
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        DNA Prime     Protein Boost 
          
 
     Week       0 2 4 6 8 10 12 13 
     Bleed              
     T cell         
Antibody              
  Serum Cytokines               
 
Figure 4.1.  Study design and immunization schedule.  Mice were immunized with 
three pentavalent DNA primes followed by two heterologous gp120 protein boosts.  The 
pentavalent vaccine mixture of both DNA and protein components consisted of HIV-1 
Env from clades A (92UG037.8), B (92US715.6 and Bal), C (96ZM651), and E 
(93TH976.17).   As a control, mice were immunized with empty pSW3891 vector primes 
followed by DP6-001 protein and adjuvant boosts.  DNA and protein doses indicated are 
for a total of five immunogens at each immunization.  Two adjuvants, Al(OH)3 or 
ISCOMATRIX™ adjuvant were tested individually as part of the protein boost.  Time 
points of immunizations, and sample collections for different assays were indicated.  
(IMX = ISCOMATRIX™ adjuvant)  
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Mice immunized with DP6-001/ISCOMATRIX™ adjuvant produced a more 
diverse and Th1/Th2 balanced serum cytokine profile following each protein boosting as 
compared to animals immunized with D6-001/Al(OH)3, or with vector prime and DP6-
001 protein boost formulated with ISCOMATRIX™ adjuvant (Fig. 4.2).  Immunization 
with DP6-001/ISCOMATRIX™ adjuvant induced significantly elevated serum levels of 
Th1 cytokines IFNγ (Fig. 4.2a) and IL-2 (Fig. 4.2b), as well as the Th2-associated 
cytokine IL-6 (Fig. 4.2c).   Notably, all three serum cytokines were more prominent at 6 
hours following the first protein boost versus the second boost.  Conversely, DP6-
001/Al(OH)3 resulted in low positive serum cytokine responses.  Priming with empty 
vector as opposed to DP6-001 DNA resulted in background levels of Th1 serum 
cytokines.  Serum levels of IL-6 were also reduced in vector-primed animals boosted 
with DP6-001 protein formulated with ISCOMATRIX™ adjuvant, but remained 
moderately positive compared to background (Fig. 4.2c).     
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(a)      (b) 
 
(c) 
 
 
Figure 4.2.  Temporal induction of Th1 and Th2 serum cytokines in wildtype Balb/c 
mice.  Wildtype Balb/c mice were immunized with DP6-001 and Al(OH)3 (D+P-
Al(OH)3) or ISCOMATRIX™ adjuvant (D+P-IMX), or with an empty vector DNA 
prime followed by protein boost formulated with ISCOMATRIX™ adjuvant (V+P-IMX).  
Naïve mice received saline injections.  Sera were collected pre-immunization (Bleed I), 6 
hours following the first (Bleed V ‘P1’) and second (Bleed VII ‘P2’) protein-adjuvant 
boost, and at termination 7 days after the final protein boost (Bleed VIII ‘T’).  Levels of 
serum cytokines in individual mice were measured by CBA.  Sera were evaluated for 
levels of Th1 cytokines (a) IFNγ, (b) IL-2, or (c) the Th2-associated cytokine IL-6.  (IMX 
= ISCOMATRIX™ adjuvant)  
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Induction of Env-specific IgG antibody responses in Balb/c wildtype mice 
We have previously reported robust antibody responses to immunization with DP6-001 
formulated with QS-21 in small animals, non-human primates, and clinical settings (139, 
186).  In wildtype Balb/c mice, we did not observe a significant difference in the end-
point titer of Env-specific IgG responses at one week following the final protein boost in 
mice immunized with DP6-001 and either Al(OH)3 or ISCOMATRIX™ adjuvant (Fig. 
4.3b).   In addition, the temporal course of antibody induction was similar in immunized 
mice regardless of adjuvant (Fig. 4.3a).  Mice immunized with empty vector prime and 
protein-ISCOMATRIX™ adjuvant boost also demonstrated comparable Env-specific 
endpoint IgG to mice receiving the full DNA prime.  While Env-specific IgG levels in 
vector-primed mice remained low compared to DP6-001 DNA-primed mice during initial 
immunizations, antibody levels rose sharply following the first and second protein boosts 
to reach levels comparable to those seen in animals immunized with the complete DP6-
001 prime-boost vaccine. 
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(a)        
 
(b) 
 
 
Figure 4.3.  Env-specific IgG response in wildtype Balb/c mice immunized with DP6-
001 vaccine with different adjuvants. Total gp120-specific IgG was measured by 
ELISA in sera collected from immunized Balb/c mice 7 days after final protein boost, in 
week 13.  Protein boosts were adjuvanted by Al(OH)3 (green), or ISCOMATRIX™ 
adjuvant (purple).  Control mice were immunized with empty vector prime followed by 
DP6-001 protein boost formulated with ISCOMATRIX™ adjuvant (brown).  Naïve mice 
(black) received “mock” saline injections in lieu of immunization.  (a) Temporal gp120-
specific IgG response was determined by ELISA using pooled sera samples from each 
group collected at two-week intervals. (b) Env-specific endpoint IgG titer in was 
determined by ELISA using individual serum samples collected in week 13.   
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Vaccine-induced serum cytokines following protein-adjuvant boost in C57Bl/6 
wildtype mice 
C57Bl/6 wildtype mice were immunized according to Figure 1, and sera was collected 
prior to immunization, 6 hours after each protein boost, and 7 days after final protein 
boost at termination.  Serum cytokine levels were quantified by CBA.  As observed in 
Balb/c wildtype mice, the highest cytokine levels were measured at 6 hours following the 
first protein boost, with reduced levels following the second protein boost (Fig. 4.4).  At 
termination, serum cytokine levels were at background levels.  Animals immunized with 
DP6-001 and either Al(OH)3 or ISCOMATRIX™ adjuvant demonstrated comparable 
levels of Th1 cytokines IFNγ (Fig. 4.4a) and IL-2 (Fig. 4.4b) following the first protein 
boost.  IFNγ levels dropped in both groups to background levels by the second protein 
boost.  Animals immunized with DP6-001/ISCOMATRIX™ adjuvant demonstrated a 
more durable IL-2 response through the second protein boost as compared to animals 
receiving DP6-001/Al(OH)3.  Serum IL-6 was more prominently induced following each 
protein boost in animals immunized with DP6-001/ISCOMATRIX™ adjuvant as 
compared to the low positive response observed in mice receiving DP6-001/Al(OH)3 
(Fig. 4.4c).  Generally, serum cytokine responses in mice immunized with vector prime 
and protein-ISCOMATRIX™ adjuvant boost were low or at background levels compared 
to animals immunized with the complete prime-boost regimen.  Serum IL-6 was 
moderately elevated in vector-primed animals only after the second protein boost before 
falling again to baseline levels (Fig. 4.4c).  
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(a)      (b) 
 
(c) 
 
Figure 4.4.  Temporal induction of Th1 and Th2 serum cytokines in wildtype 
C57Bl/6 mice.  Wildtype C57Bl/6 mice were immunized with DP6-001 and Al(OH)3 
(D+P-Al(OH)3) or ISCOMATRIX™ adjuvant (D+P-IMX), or with an empty vector 
DNA prime followed by protein boost formulated with ISCOMATRIX™ adjuvant (V+P-
IMX).  Naïve mice received saline injections.  Sera were collected pre-immunization 
(Bleed I), 6 hours following the first (Bleed V ‘P1’) and second (Bleed VII ‘P2’) protein-
adjuvant boost, and at termination 7 days after the final protein boost (Bleed VIII ‘T’).  
Levels of serum cytokines in individual mice were measured by CBA.  Sera were 
evaluated for levels of Th1 cytokines (a) IFNγ, (b) IL-2, or (c) the Th2-associated 
cytokine IL-6.  (IMX = ISCOMATRIX™ adjuvant)  
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Induction of Env-specific IgG antibody responses in C57Bl/6 wildtype and MyD88 
deficient mice 
As we observed in Balb/c mice, there was no significant difference between 
immunization groups in the Env-specific IgG endpoint titers (Fig. 4.5b).  In addition, the 
temporal course of specific IgG induction was relatively similar between mice 
immunized with DP6-001 and either Al(OH)3 or ISCOMATRIX™ adjuvant (Fig. 4.5a).  
In mice immunized with vector prime and protein-ISCOMATRIX™ adjuvant boost, 
Env-specific IgG titers were low during priming immunizations, and following protein 
boosts rose to levels comparable to mice immunized with the full DP6-001 vaccine 
regimen (Fig. 4.5a).  In MyD88 deficient mice immunized with DP6-001/Al(OH)3, the 
final titer of Env-specific IgG was significantly decreased as compared to wildtype (Fig. 
4.5d).  While slight reductions in IgG titers were observed in MyD88 deficient mice 
immunized with either DP6-001/ISCOMATRIX™ adjuvant or vector prime and protein-
ISCOMATRIX™ adjuvant boost, this difference was not significant.   
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(a)      (c) 
  
(b)      (d) 
  
 
Figure 4.5.  Env-specific IgG response in wildtype C57Bl/6 mice immunized with 
DP6-001 vaccine with different adjuvants. Total Env-specific IgG was measured by 
ELISA in sera collected from immunized C57Bl/6 mice 7 days after final protein boost, 
in week 13.  Protein boosts were adjuvanted by Al(OH)3 (green), or ISCOMATRIX™ 
adjuvant (purple).  Control mice were immunized with empty vector prime followed by 
DP6-001 protein boost formulated with ISCOMATRIX™ adjuvant (brown).  Naïve mice 
(black) received “mock” saline injections in lieu of immunization.  Temporal Env-
specific IgG response was determined by ELISA using pooled sera samples from each 
group collected at two-week intervals from immunized (a) wildtype or (b) MyD88 
deficient mice.  Env-specific endpoint IgG titer was determined by ELISA using 
individual serum samples collected in week 13 from immunized (c) wildtype or (d) 
MyD88 deficient mice.  (IMX = ISCOMATRIX™ adjuvant)   
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Serum cytokine profiles of DP6-001 and adjuvants in C57Bl/6 wildtype and MyD88 
deficient mice by CBA 
Pro-inflammatory serum cytokines were quantified by CBA in wildtype C57Bl/6 
and MyD88 deficient mice at 6 hours following the first protein boost (Fig. 4.6).  The 
first protein boost time point was identified in earlier assays to demonstrate the highest 
levels of serum cytokines.  Animals immunized with DP6-001/ISCOMATRIX™ 
adjuvant demonstrated significantly elevated IFNγ (Fig. 4.6a), TNFα (Fig. 4.6c), and IL-
6 (Fig. 4.6d) as compared to animals immunized with DP6-001/Al(OH)3 or vector prime 
and protein-ISCOMATRIX™ adjuvant boost.  Notably, in MyD88 deficient mice 
immunized with DP6-001/ISCOMATRIX™ adjuvant, serum IFNγ (Fig. 4.6a) and IL-6 
(Fig. 4.6d) are significantly reduced as compared to wildtype.  In MyD88 deficient mice 
immunized with DP6-001/Al(OH)3, serum levels of IFNγ (Fig. 4.6a), TNFα (Fig. 4.6c), 
and IL-6 (Fig. 4.6d) are significantly reduced compared to wildtype.  Serum cytokines 
induced in mice immunized with vector prime and protein-ISCOMATRIX™ adjuvant 
boost were typically low or at background levels in comparison to DP6-
001/ISCOMATRIX™ adjuvant.  However, serum TNFα associated with vector prime 
and protein-ISCOMATRIX™ adjuvant boost was significantly elevated above 
background, though at significantly lower levels than those observed in DP6-
001/ISCOMATRIX™ adjuvant groups (Fig. 4.6c).  In vector primed mice receiving a 
protein-ISCOMATRIX™ adjuvant boost, serum TNFα was significantly reduced in 
MyD88 deficient mice (Fig. 4.6c). 
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 The Th1-associated cytokine IL-2 was comparably elevated in mice immunized 
with DP6-001/Al(OH)3 or DP6-001/ISCOMATRIX™ adjuvant, but not in mice 
immunized with vector prime and protein-ISCOMATRIX™ adjuvant boost (Fig. 4.6b).  
Interestingly, serum IL-2 was significantly greater in MyD88 deficient mice immunized 
with DP6-001 and either Al(OH)3 or ISCOMATRIX™ adjuvant (Fig. 4.6b).  Similar 
results were observed for the anti-inflammatory cytokine IL-10, which was strongly 
elevated in MyD88 deficient mice immunized with DP6-001 and either Al(OH)3 or 
ISCOMATRIX™ adjuvant, as compared to the baseline levels observed in all wildtype 
mice (Fig. 4.6e).  This phenomenon was not observed to such a great extent in mice 
immunized with a vector prime and DP6-001 protein boost formulated with 
ISCOMATRIX™ adjuvant.   
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Figure 4.6.  Differential induction of Th1 and Th2 serum cytokines in C57Bl/6 
wildtype and MyD88 deficient mice after first protein-adjuvant boost.  Wildtype 
C57Bl/6 mice were immunized with DP6-001 and Al(OH)3 (green) or ISCOMATRIX™ 
adjuvant (purple), or with an empty vector DNA prime followed by protein boost 
formulated with ISCOMATRIX™ adjuvant (brown).  Naïve mice received saline 
injections (white).  Sera were collected pre-immunization, 6 hours following each 
protein-adjuvant group, and at termination 7 days after the final protein boost.  Shown are 
levels of serum cytokines in individual mice measured by CBA after first protein-
adjuvant boost in wildtype (solid) or MyD88 deficient (checkered) mice.  Sera were 
evaluated for (a) IFNγ, (b) IL-2,  (c) TNF, (d) IL-6, or (e) IL-10.  Statistical significance 
was determined by a one-way ANOVA and a Tukey post-test (*: p < 0.05, **: p < 0.01, 
***: p < 0.001).  (IMX = ISCOMATRIX™ adjuvant) 
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Impact of DNA priming on antibody and sera cytokine responses in MyD88 
deficient mice 
In a subsequent study, mice were immunized with two DP6-001 protein boosts 
and ISCOMATRIX™ adjuvant in the absence of DNA priming.  As previously shown in 
Figure 4.6, we did not observe a significant impact of MyD88 deficient on the Env-
specific IgG responses produced in mice immunized with DP6-001/ISCOMATRIX™ 
adjuvant (Fig. 4.7a, c).  These results suggest that MyD88 is minimally involved in the 
specific humoral response induced by ISCOMATRIX™ adjuvant in the context of a 
DNA prime-protein boost vaccine. In the context of immunization with DP6-001 protein 
formulated with ISCOMATRIX™ adjuvant in the absence of DNA priming, a significant 
decrease in Env-specific IgG titers was observed in MyD88 deficient mice as compared 
with wildtype (Fig. 4.7b, d).  This suggests either the impact of the extended (five) 
immunizations included in the full DP6-001 regimen, or the impact of DNA priming on 
the utilization of and dependence on the MyD88 adaptor molecule, and subsequent 
generation of humoral immunity.   
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(a)      (b) 
  
(c)      (d) 
  
Figure 4.7. DNA priming improves Env-specific IgG response to DP6-001 and 
ISCOMATRIX™ adjuvant and alters dependency on MyD88.  Total Env-specific 
IgG was measured by ELISA in sera collected from immunized C57Bl/6 mice 7 days 
after final protein boost, in week 13.  DNA-primed wildtype (solid, ‘WT’) and MyD88 
deficient (checkered, ‘KO’) mice were immunized with DP6-001 DNA prime-protein 
boost and ISCOMATRIX™ adjuvant (a-b).  In the absence of DNA priming, wildtype 
and MyD88 deficient mice were immunized with two DP6-001 protein boosts and 
ISCOMATRIX™ adjuvant (c-d).  Naïve mice were immunized with saline injections.  
Env-specific endpoint IgG titer was determined by ELISA on individual serum samples 
collected 7 days after final protein boost from immunized (a) wildtype or (b) MyD88 
deficient mice. Temporal Env-specific IgG response was determined by ELISA using 
pooled sera samples from each group collected at two-week intervals from immunized (c) 
wildtype or (d) MyD88 deficient mice. Statistical significance was determined by a 
student’s t test (*: p < 0.05, **: p < 0.01, ***: p < 0.001).  (IMX = ISCOMATRIX™ 
adjuvant)   
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Serum cytokines and chemokines were quantified by Luminex array in mice 
immunized with DP6-001 protein-ISCOMATRIX™ adjuvant in the absence of DNA 
priming.  As we have previously noted, serum cytokines levels were typically most 
strongly induced in the 6 hours following the first protein immunization.  In comparison 
to mice receiving the complete DP6-001/ISCOMATRIX™ adjuvant vaccine, overall 
serum cytokines were notably lower in mice following only two protein-
ISCOMATRIX™ adjuvant immunizations (Fig. 4.8a, c).  Serum KC, G-CSF, and MCP-
1, were significantly reduced in MyD88 deficient mice immunized with DP6-001 protein 
formulated with ISCOMATRIX™ adjuvant as compared to wildtype mice immunize 
with protein-ISCOMATRIX™ adjuvant vaccine (Fig. 4.8c-d).  In comparison, these 
characteristic cytokines were unchanged in wildtype and MyD88 deficient mice 
immunized with DP6-001/ISCOMATRIX™ adjuvant (Fig. 4.8a-b).  Moderate reductions 
in serum IL-2, Eotaxin, IL-1β were observed in MyD88 deficient mice only in the 
absence of any DNA prime (Fig. 4.8c-d).    
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(a)      (b) 
 
(c)      (d) 
 
Figure 4.8.  Serum cytokine levels after first protein boost in wildtype or MyD88 
deficient mice vaccinated with DP6-001 and ISCOMATRIX™ adjuvant in the 
presence or absence of DNA priming.  In the absence of DNA priming, wildtype (solid) 
and MyD88 deficient (checkered) mice were immunized with two DP6-001 protein 
boosts and ISCOMATRIX™ adjuvant (a-b). DNA primed wildtype and MyD88 deficient 
mice were immunized with DP6-001 DNA prime-protein boost and ISCOMATRIX™ 
adjuvant (c-d). Sera were collected pre-immunization and 6 hours following both protein-
adjuvant boosts.  Cytokines were quantified in the serum of individual mice at a 1:4 
dilution using a custom 12-plex Luminex panel.  Shown are serum cytokine panels in (a) 
wildtype and (b) MyD88 deficient mice immunized with DP6-001 protein formulated 
with ISCOMATRIX™ adjuvant, or (c) wildtype and (d) MyD88 deficient mice 
immunized with DP6-001 DNA prime-protein boost formulated with ISCOMATRIX™ 
adjuvant.  Statistical significance was determined with a One-way ANOVA and Tukey 
post-test (*: p < .05, **: p < .01, ***: p < .001).    
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DP6-001 formulated with ISCOMATRIX™ adjuvant produced Env-specific IgG 
and robust neutralizing antibody responses in rabbit 
In a study scaled up from mouse immunization studies, White New Zealand 
rabbits received the DP6-001 DNA prime-protein boost vaccine adjuvanted by either 
Al(OH)3 or ISCOMATRIX™ adjuvant.  Controls rabbits received an empty vector DNA 
prime followed by a DP6-001 protein boost formulated with ISCOMATRIX™ adjuvant.  
Naïve animals received saline injections.  Sera were collected at biweekly and monthly 
intervals throughout the immunization schedule.  Env-specific endpoint IgG titer was 
measured in sera collected 7 days following the final protein boost.  Rabbits immunized 
with DP6-001/Al(OH)3 and DP6-001/ISCOMATRIX™ adjuvant demonstrated 
comparable Env-specific IgG induction by temporal OD, with serum IgG levels 
increasing slightly during DNA priming (Fig. 4.9a).  Both groups demonstrated a notable 
rise in specific antibody response following first protein boost, and these levels were 
maintained by subsequent protein boosting.  In rabbits immunized with vector prime and 
protein-ISCOMATRIX™ adjuvant boost, Env-specific IgG in the sera was not detectable 
until the first protein boost; however, Env-specific IgG was substantially boosted by the 
second protein-ISCOMATRIX™ adjuvant immunization, rising to levels comparable to 
rabbits immunized with the complete DP6-001 regimen.  End-point titers of Env-specific 
IgG were not statistically different between immunization groups (Fig. 4.9b).   
Previous formulations of the polyvalent Env DP6-001 vaccine in small animal 
and clinical models were capable of eliciting broadly neutralizing antibody responses.  
NAb titer, defined as the serum dilution at which it is possible to neutralize 50% of virus 
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infection, was performed as previously described (178, 179).  Immunized rabbit sera 
were assessed for neutralizing activity against sensitive viral isolates SF162 and ss1196 
(Fig. 4.10).  No significant difference was observed between immunization groups in 
neutralizing antibody titers against either sensitive viral isolate.  Rabbits receiving DP6-
001 and either Al(OH)3 or ISCOMATRIX™ adjuvant, as well as those receiving vector 
prime followed by DP6-001 protein boost formulated with ISCOMATRIX™ adjuvant, 
were similarly able to neutralize SF162 (Fig. 4.10a) and ss1196 (Fig. 4.10b).  
Notable differences emerged upon further dissecting the quality of vaccine-
induced antibody responses.  Immunized sera were examined for neutralizing ability 
against a previously described NIH tier 2 clade B standardized panel of 12 primary viral 
isolates (98) (Fig. 4.10c).  Sera from rabbits immunized with either DP6-001/Al(OH)3 or 
vector prime and protein-ISCOMATRIX™ adjuvant boost failed to elicit greater than 5% 
of positive neutralizing events against the less sensitive Tier 2 panel.  Rabbits immunized 
with DP6-001/ISCOMATRIX™ adjuvant demonstrated a much broader neutralizing 
response, averaging 20% positive neutralizing events against Tier 2 viral isolates (Fig. 
4.10c).  These results identify the importance of both DNA priming as well as choice of 
adjuvant in inducing an effective, broad and potent neutralizing antibody response against 
HIV-1. 
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(a) 
 
(b) 
 
Figure 4.9.  HIV-1 Env-specific induction of total IgG in rabbits immunized with 
DP6-001 and ISCOMATRIX™ adjuvant.  Rabbits were immunized with DP6-001 
DNA prime-protein boost and either Al(OH)3 (D+P-Al(OH)3) or ISCOMATRIX™ 
adjuvant (D+P-IMX).  As a control, rabbits were immunized with empty vector DNA 
prime followed by DP6-001 protein boosts formulated with ISCOMATRIX™ adjuvant 
(V+P-IMX).  Naïve animals received saline injection in lieu of immunization (black).  (a) 
Temporal Env-specific IgG response was determined by ELISA using pooled sera 
samples from each group collected at two-week intervals from immunized rabbits.  (b) 
Env-specific endpoint IgG titer was determined by ELISA using individual serum 
samples collected in week 20 after the final protein-adjuvant boost.  (IMX = 
ISCOMATRIX™ adjuvant) 
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(a)      (b)   
 
(c) 
 
 
Figure 4.10.  ISCOMATRIX™ adjuvant improves breadth of neutralizing antibody 
response in rabbits immunized with DP6-001.  Rabbits were immunized with DP6-001 
DNA prime-protein boost and either Al(OH)3 (D+P-Al(OH)3) or ISCOMATRIX™ 
adjuvant (D+P-IMX).  Control rabbits were immunized with empty vector DNA prime 
followed by DP6-001 protein boosts formulated with ISCOMATRIX™ adjuvant (V+P-
IMX).  NAb titer is defined as the serum dilution at which it is possible to inhibit 50% of 
viral infection.  Neutralizing antibody titers were determined against two Clade B viral 
isolates sensitive to neutralization: (a) SF162 and (b) ss1196.  (c) Neutralization of a 
previously described Tier 2B panel of 12 primary viruses by serum from rabbits 
immunized with DP6-001 and different adjuvants.  (IMX = ISCOMATRIX™ adjuvant) 
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Discussion 
Protective immunity against complex pathogens such as HIV-1 requires a vaccine 
that is capable of inducing a diverse and potent immune response consisting of both 
humoral and cell-mediated immunity.  The importance of polyfunctional CD4+ helper T 
cells, CD8+ T cells, and broad neutralizing antibodies have been clearly defined in the 
effective prophylaxis against HIV-1 challenge.  In several clinical trials, including the 
widely publicized Thailand RV144 trial and our lab’s own trial of the DP6-001 vaccine, a 
DNA or viral vector prime followed by a protein boost has been employed as an effective 
and potent strategy to strongly activate both arms of the immune response and confer 
some level of protective immunity.  The choice of adjuvant to be paired with the protein 
boost component critically impacts the immunogenicity an efficacy of a vaccine.   
In recent years, the integrated adjuvant system ISCOMATRIX™ adjuvant has 
emerged as an ideal candidate for inclusion in future formulations of HIV-1 vaccines, due 
to its ability to serve as a delivery system for vaccine adjuvant, and also have a 
substantial and diverse immunomodulatory effect on innate immune cell recruitment and 
function, and subsequent cross-presentation by dendritic cells and a potent CD8+ T cell 
response.  ISCOMATRIX™ adjuvant-based vaccines have been demonstrated to induce 
potent humoral and cell-mediated immunity while remaining well tolerated and safe in 16 
Phase I trials of prophylactic and therapeutic vaccines.   
While ISCOMATRIX™ adjuvant has been clinically evaluated with recombinant 
protein-based vaccines, and pre-clinically in the context of recombinant protein-based 
vaccines against HIV-1, the current study is the first report of ISCOMATRIX™ adjuvant 
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in the context of an HIV-1 Env DNA prime-protein boost vaccine strategy.   The primary 
objectives of this study were to confirm the immunogenicity of ISCOMATRIX™ 
adjuvant formulated with the previously described DP6-001 in preclinical models, and 
also identify the impact of DNA priming on an ISCOMATRIX™ adjuvant-based protein 
boost.   
In the current study, we demonstrated in both mouse and rabbit models, the ability 
of an Env DNA prime-protein boost vaccine formulated with ISCOMATRIX™ to 
generate strong Env-specific IgG responses comparable to levels associated with DP6-
001/Al(OH)3 immunization or vector prime and protein-ISCOMATRIX™ adjuvant 
boost.  In rabbits, vaccine-induced antibodies generated with DP6-001/Al(OH)3, DP6-
001/ISCOMATRIX™ adjuvant, or vector prime and protein-ISCOMATRIX™ adjuvant 
were similarly able to neutralize sensitive HIV-1 viral isolates SF162 and ss1196.   The 
superior immunogenicity of the DP6-001/ISCOMATRIX™ adjuvant vaccine formulation 
was evident upon more in-depth evaluation of the neutralizing antibody response 
generated in immunized rabbits.  Animals immunized with DP6-001/ISCOMATRIX™ 
adjuvant were able to generate broadly neutralizing antibodies against 20% of a clade B 
Tier 2 panel of more resistant viral isolates, while those immunized with DP6-
001/Al(OH)3, or with vector prime and protein-ISCOMATRIX™ adjuvant boost in the 
absence of DNA priming, performed poorly.  These data highlight not only the potent 
immunogenicity of the ISCOMATRIX™ adjuvant, but also the substantial impact of a 
multiclade DNA prime encoding Env antigen on the breadth and potency of vaccine-
induced humoral immunity.   
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We also evaluated the ability of DP6-001/ISCOMATRIX™ adjuvant vaccine to 
generate characteristic serum cytokines in comparison to DP6-001/Al(OH)3 vaccine or an 
empty vector DNA prime.  In the current study we identified that 6 hours following the 
first protein boost yielded the most robust serum cytokine response.  In a recent study by 
Wilson et al., a serum cytokine profile was developed for ISCOMATRIX™ adjuvant 6 
hours after subcutaneous administration, with the Th1 and Th2 cytokines, as well as the 
chemokines G-CSF, KC, and MIP-1α, standing out over background levels (191).   
Wilson et al. correlated this rapid but transient induction of a unique serum cytokine 
signature with activation of DCs and NKs in the draining lymph node, suggesting that the 
generation of a potent and unique systemic cytokine response facilitates the innate and 
adaptive immune response to vaccination with ISCOMATRIX™ adjuvant (191).  In 
concurrent work by our lab, we have defined a profile of serum markers associated with 
DP6-001/ISCOMATRIX™ adjuvant immunization (Buglione-Corbett et al., unpublished 
data), including IL-2, MCP-1, Eotaxin, and G-CSF, as well as markers commonly 
induced by all of our vaccine formulations, IL-6, KC, and MIP-1α.  In the current study, 
we demonstrated DP6-001/Al(OH)3 and, to a greater extent, DP6-001/ISCOMATRIX™ 
adjuvant, were able to induce strong non-antigen specific Th1 and Th2 serum cytokines 
following the first protein boost.   In these groups, serum cytokine levels typically fell 
following the second protein-adjuvant boost, and returned to background levels by 
termination 7 days after the second protein-adjuvant boost. 
In contrast, wildtype animals primed with empty vector DNA generated low to 
background levels of IFNγ, IL-2, and IL-6 following either of two DP6-001 protein-
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ISCOMATRIX™ adjuvant boosts.  This trend was also observed for TNF and IL-10 in a 
broader CBA panel focusing on serum cytokine levels 6 hours after the first protein-
adjuvant boost only.  Similarly, non-antigen specific serum cytokines and chemokines 
analyzed by multiplex array following only two immunizations with DP6-001 protein 
formulated with ISCOMATRIX™ adjuvant in absence of DNA priming were reduced 
across the board in comparison to DNA-primed animals.  These results indicate the 
critical impact of Env DNA priming in the generation of an ISCOMATRIX™ adjuvant-
associated potent and diverse inflammatory cytokine profile.   
In this study, we also examined the dependence of the DP6-001/ISCOMATRIX™ 
adjuvant vaccine on the broadly utilized innate immune signaling adaptor, MyD88.  In a 
recent study by Wilson et al. utilizing a recombinant protein tumor antigen vaccine 
formulated with ISCOMATRIX™ adjuvant, MyD88 was found to be essential for 
adaptive immune responses such as CD8+ T cell responses, NK cell function, and 
vaccine-specific antibody responses, while other TLR deficiencies did not compromise 
adaptive immunity.  However, MyD88 appeared to be dispensable for activation of 
dendritic cells and cross-presentation to CD8+ T cells (191).  Wilson et al. suggest that 
ISCOMATRIX™ adjuvant produces an indirect effect on innate signaling pathways via 
the generation of a pro-inflammatory cytokine and chemokine environment, and propose 
the coexistence of both MyD88-dependent and independent mechanisms of action for the 
ISCOMATRIX™ adjuvant (191).  Our current study of the role of MyD88 in 
ISCOMATRIX™ adjuvant focused on its impact on adaptive immunity and sera cytokine 
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profiles, as well as its changing function in the context of a DNA prime-protein boost 
vaccine strategy. 
Env-specific IgG endpoint titers associated with DP6-001/Al(OH)3, DP6-
001/ISCOMATRIX™ adjuvant, or vector prime and DP6-001 protein boost formulated 
with ISCOMATRIX™ adjuvant, were minimally impacted in MyD88 deficient mice.  
Initial serum cytokine analysis by CBA indicated some reduction in Th1 and Th2 
responses associated with DP6-001/ISCOMATRIX™ adjuvant in MyD88 deficient mice, 
while serum cytokines induced by vector prime and protein-ISCOMATRIX™ adjuvant 
boost were overall low.  An expanded multiplex panel of serum cytokines and 
chemokines indicated that mice immunized with only DP6-001 protein formulated with 
ISCOMATRIX™ adjuvant also generated a reduced serum cytokine response in 
comparison to DP6-001/ISCOMATRIX™ adjuvant immunizations.   
Follow-up studies employing immunization with two DP6-001 protein boosts 
formulated with ISCOMATRIX™ adjuvant, however, indicated a dependence of 
vaccine-induced humoral responses on MyD88 in the absence of DNA priming.  In 
addition, by a multiplex array, MyD88 deficiency had a much more significant impact on 
sera cytokine and chemokine profiles in protein-ISCOMATRIX™ adjuvant immunized 
mice that was observed in DP6-001/ISCOMATRIX™ adjuvant groups.  These data 
highlight the significant impact of a DNA priming component on the innate and adaptive 
immune responses, showing that DNA primed vaccines generate not only improved 
humoral immunity and pro-inflammatory response.  However, we also demonstrate that 
the use of a DNA prime reduces the dependence of these responses on MyD88 signaling 
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in comparison to our protein-only vaccine, or the recombinant protein-based vaccine with 
ISCOMATRIX™ adjuvant employed by Wilson et al. (191). 
While an evident but poorly understood role for MyD88 has been identified in the 
adjuvanticity of ISCOMATRIX™ adjuvant, the mechanism of this integrated adjuvant 
system remains unclear.  Studies of other particulate adjuvants have implicated 
inflammasome pathways such as NLRP3, either directly or indirectly, in their mechanism 
of action (169).  In addition, recent work by Duewell et al. introduced the secretion of 
mature IL-1β by DCs in vitro in response to stimulation with ISCOMATRIX™ adjuvant 
in a caspase-1-dependent manner, indicating stimulation of any number of caspase-1-
dependent inflammasome pathways (42).  The further elucidation of the signaling 
pathways involved in ISCOMATRIX™ adjuvant-induced adaptive immunity, with a 
particular focus on the unique impact of DNA priming on these mechanisms, are a 
component of ongoing research by this lab.   
In conclusion, the ISCOMATRIX™ adjuvant system is a promising prospect for 
inclusion in future formulations of HIV-1 Env vaccines.  In the context of a DNA prime-
protein boost strategy, ISCOMATRIX™ adjuvant was associated with improved 
neutralizing antibody responses, as well as a potent pro-inflammatory cytokine and 
chemokine environment that contributes to the NK cell and DC activation, cross-
presentation, and potent CD8+ T cell response characteristic of ISCOMATRIX™ 
adjuvant.  The data presented in the current study contributes to our selection of an 
adjuvant for future optimized HIV-1 Env DNA prime-protein boosts, and also expands 
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our understanding of both the impact of a DNA prime component and also the underlying 
mechanisms of ISCOMATRIX™ adjuvant in the context of a novel vaccine strategy. 
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CHAPTER V:  
Materials and Methods 
HIV-1 gp120 DNA vaccine 
The gp120-expressing DNA vaccine component of the DP6-001 formulation was 
composed of equal amounts of five plasmids encoding codon-optimized gp120 genes 
from primary HIV-1 isolates: A (92UG037.8), B (92US715.6), Ba-L, Czm (96ZM651), 
and E (93TH976.17) in the common vector pSW3891 as previously described (138).  
DNA vaccine plasmids were grown up in HB101 strain of E. coli, and prepared using a 
Plasmid Giga Kit (Qiagen, Valencia, CA).  Endotoxin-free DNA plasmids were prepared 
using EndoFree Plasmid Mega Kit (Qiagen).  A colorimetric test of the endotoxin levels 
in individual DNA preparations confirmed that EndoFree plasmids were associated with 
an average of 12.1 EU/ml, while standard DNA plasmid preparations were associated 
with 1000-fold greater EU/ml (ranging from 1460 EU/ml to greater than 25,000 EU/ml).  
DNA plasmid expression was confirmed by transient expression in 293T cells and 
Western blot.   
HIV-1 gp120 Protein Production  
The protein component of DP6-001 was composed of equal parts of five recombinant 
gp120 proteins homologous to DNA vaccine components.  These gp120 proteins were 
produced in CHO cell lines by Advanced Bioscience Laboratory, Inc. (ABL) as 
previously described (186).  Final protein product consisted of 7 µg/ per gp120 protein at 
each immunization, in Dulbecco’s phosphate buffered saline (DPBS) (Gibco, Invitrogen, 
Grand Islands, NY).   
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Formulation of DP6-001 gp120 Protein With Adjuvants 
Protein mixes were formulated prior to immunization with the candidate adjuvants 
immediately prior to immunization.  35 µg total gp120 protein was simply mixed with 5 
µg QS-21 in DPBS.  35 µg total gp120 protein was adsorbed onto 175 µg aluminum 
hydroxide gel [Al(OH)3 gel] (Sigma Aldrich Corp., St. Louis, MO) by mixing, followed 
by a 20 minute incubation at room temperature.  Protein and Al(OH)3 mixtures were then 
spun down at 12,000 rpm for 10 minutes, the supernatant was removed, and the pellet 
was resuspended in the final volume of DPBS for immunization.  Stock synthetic MPLA 
(Avanti Polar Lipids, Inc., Alabaster, AL) was dissolved in 1 ml DMSO, followed by 9 
ml dH2O, and opsonized for complete dissolution.  35 µg total gp120 protein was simply 
mixed with 25 µg MPLA.  35 µg total gp120 protein was simply mixed in DBPS with 1.5 
ISCO™ Units of ISCOMATRIX™ adjuvant (CSL Limited, Parkville, Victoria, 
Australia).  1.5 ISCO™ Units is equivalent to 1.5 µg of ISCOPREP™ saponin and to 
allow easier comparison with other adjuvants the µg measurement is used in this 
dissertation.   
Mouse Immunizations 
BALB/c (6-8 weeks old, mixed sex) and C57Bl/6 (6-8 weeks old, mixed sex) mice were 
obtained from Taconic Farms and maintained in Department of Animal Medicine animal 
facility at University of Massachusetts Medical School, according to an IACUC-
approved protocol.  Mice received i.m. DNA immunizations of total 120 µg gp120 DNA 
plasmid, divided between each quadriceps at weeks 0, 2, and 4.  Sera were collected at 
each immunization time point.  After the third DNA immunization, sera were collected 6 
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hours following immunization.  Mice were bled at week 6.  Mice received protein boosts 
of 7 µg/mouse per gp120 protein for a total protein immunization of 35 µg at each 
immunization.  Protein boosts were formulated with candidate adjuvants as described 
above, and administered via two i.m. injections divided between each quadriceps at 
weeks 8 and 12.  Mice were bled multiple times for serum antibody and cytokine analysis 
(Fig. 1).  Mice were terminated 7 days after the final protein boost according to an 
IACUC approved procedure, at which time sera and spleens were collected. 
Rabbit Immunizations 
New Zealand White (NZW) rabbits (6-8 weeks) were purchased from Millbrook Farm 
(Amherst, MA).  Rabbits were house in the Department of Animal Medicine animal 
facility at University of Massachusetts Medical School, according to an IACUC-
approved protocol.  Rabbits received i.m. DNA immunizations of total 400 µg gp120 
DNA plasmid in each lumbar muscle at weeks 0, 2, and 4.  Rabbits received i.m. protein 
boost for of total 100 µg gp120 protein formulated with candidate adjuvants at weeks 8 
and 12. Rabbit protein immunizations consisted of 500 µg/rabbit of Al(OH3) gel (Sigma) 
or 50 µg/rabbit ISCOMATRIX™ adjuvant (CSL Ltd.).  Protein and adjuvant 
formulations were prepared as described above.  1.5 ISCO™ Units is equivalent to 1.5 µg 
of ISCOPREP™ saponin and to allow easier comparison with other adjuvants the µg 
measurement is used in this article.  Sera were collected biweekly throughout the 
immunization schedule.   
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Enzyme Linked Immunosorbent Assay (ELISA) 
gp120-specific antibody responses were assessed by ELISA, performed as previously 
described with some modifications (179).  Briefly, 96-well EIA/RIA microtiter plates 
(Costar, Corning, NY) were coated with 5 µg/well ConA diluted in PBS for 1 hr.  
Between each step, plates were washed with PBS and 0.1% Triton X-100 five times using 
AquaMax2000 automatic plate washer (Molecular Devices, Sunnyvale, CA).  Plates were 
coated with 1 µg/ml of the five recombinant gp120 protein mix used in immunizations.  
Wells were blocked overnight (4% whey by weight whey dilution buffer and 5% 
powdered milk) at 4oC.  Plates were incubated with 100 µl of serially diluted mouse sera 
in duplicate for 1 hr.  Biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, 
CA) was added at 1.5 µg/ml for 1 hr.  Horseradish-peroxidase (HRP)-conjugated 
streptavidin (Vector Laboratories) at 0.5 µg/ml was added and incubated for 1 hr.  Plates 
were developed with TMB substrate (Sigma-Aldrich, St. Louis, MO) for 5 minutes, 
followed by the addition of 2 N H2SO4.  Optical density (OD) of 450 nm (OD450) minus 
the background of plate absorbance at 630 nm, was read on a Multiskan FC (Thermo 
Fischer Scientific, Waltham, MA).  The endpoint titer was determined as the highest 
dilution at which the OD450 equaled twice the OD450 of negative control wells.  
Statistically significant differences between titers were analyzed using Student’s t test. 
 For temporal antibody responses, pooled mouse sera dilutions of 1:250 or 1:500 
were prepared for each collection time point.  For mouse IgG isotyping ELISA, standard 
curve wells were coated with 0.5 µg/ml IgG2c or IgG1 coating antibody (Southern 
Biotech, Birmingham, AL) at 1:3 serial dilutions from a starting dilution of 1:1000.  
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Biotin-conjugated IgG2c or IgG1 detection antibody (Southern Biotech) was applied at 
0.5 µg/ml.  Plates were washed, developed, and endpoint titers were determined as 
described above.  Env-specific antibody ELISAs were performed on rabbit sera as 
described above. 
HIV-1 Neutralization Assay 
Neutralization assays on rabbit sera were performed as previously described (124, 178, 
179).  Briefly, HIV-1 pseudovirus was produced in HEK293T cells by cotransfection 
with pSG3Δenv backbone (NIH AIDS Research References and Reagent Program) and a 
plasmid encoding gp160.  Pseudovirus was titered out using TZM-bl cell line.  Rabbit 
sera were incubated for 1 hr at 37oC with 200 TCID50 of pseudovirus.   This mixture was 
added to 1x105 TZM-bl cells in 20 µg/ml DEAE Dextran, for 48 hr at 37oC.  Plates were 
developed with luciferase reagent (Promega, Madison, WI).  Percent change in luciferase 
activity in the presence of pre-immune sera compared to in the presence of sera from 
immunized mice was used to calculate percent neutralization.  
Splenocyte Preparation 
Spleens were harvested 7 days following the second protein boost.  Spleens were 
homogenized in complete RPMI media, with 10% heat-inactivated FBS (HyClone, 
Logan, UT), and 1% Penicillin-Streptomycin.  Single-cell suspensions were made by 
pressing each spleen through a screen, and washing with media.  Red blood cells were 
lysed with Red Blood Cell Lysis Buffer (Sigma).  Cells were washed, counted, and 
diluted to a final concentration of 1x107 cells/ml. 
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Intracellular Cytokine Staining 
All fluorophore-conjugated antibodies, unless otherwise noted, were obtained from BD 
Pharmingen (San Diego, CA).  Splenocytes were cultured in 96-well cell culture round-
bottom plates (Costar) at 1x106 cells per well.  Splenocytes were co-incubated with 2 
µg/ml human IL-2, GolgiPlug (BD Biosciences, San Diego, CA), and peptide.  Positive 
controls were stimulated with BD Leukocyte Activating Cocktail (BD Pharmingen, San 
Diego, CA).  Antigen-specific stimulation consisted peptides 8771-8886 from a 
consensus clade B peptide pool (Cat. No. 9480, NIH AIDS Research & Reference 
Program, Germantown, MD) covering the region of gp120, composed of 115 15mer 
peptides overlapping by 11 amino acids each, at an individual peptide concentration of 2 
µg/ml.  Mock-stimulated splenocytes were treated with media, hIL-2, and GolgiPlug 
alone.  Splenocytes were incubated at 37oC for 5 hr, after which cells were washed in 2% 
FBS/PBS staining buffer.  Non-specific binding was blocked by incubating with 5 µg/ml 
α-Fcγ R III/II (2.4 G2) antibody (BD Pharmingen) at 4oC for 10 minutes.  Cells were 
washed in staining buffer, and then incubated with LIVE/DEAD Fixable Blue 
(Invitrogen, Carlsbad, CA).  Cells were washed in staining buffer, and then incubated 
with anti-CD4-Alexa700 and anti-CD8-PerCPCy5.5 at 0.4 µg/ml for 20 minutes at 4oC.  
Cells were washed in staining buffer, and were then fixed and permeabilized in 
Cytofix/Cytoperm (BD Biosciences) in the dark at 4oC for 20 minutes.  Cells were 
washed in 1X PermWash (BD Biosciences).  Cells were stained with anti-IFNγ-FITC, 
anti-IL-2-PECy7, anti-IL-4-APC, anti-IL-5-APC, anti-IL-6-PE, and anti-IL-17-Pacific 
Blue, diluted in 1X Permwash, for 30 minutes at 4oC.  Cells were washed in Permwash, 
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and resuspended in staining buffer.  Stained splenocytes were analyzed on an LSRII 
FACS machine (BD Biosciences, San Jose, CA), and data was analyzed using FlowJo 
software (Treestar, Ashland, OR).   
T Cell ELISpot 
ELISpot reagents (IL-2, IL-4 IFNγ) were obtained from Mabtech (Mariemont, OH) or 
from BD Biosciences (IL-6) (San Diego, CA).  ELISpots were performed according to 
manufacturer’s instructions.  Pre-coated MSIP PVDF-plates (Millipore, Billerica, MA) 
were seeded with splenocytes from immunized mice (prepared as above) at a 2.5x105 
cells/well.  Positive controls were stimulated with 20 ng/ml phorbol 12-myristate 13-
acetate (PMA) (Sigma-Aldrich, St. Louis, MO) and 500 ng/ml ionomycin (Sigma-
Aldrich).  Antigen-specific stimulation was performed with truncated peptide pools 
derived from clade B consensus Env including the V2/V3 pool (8836-8844) (19) 
(provided by NIH AIDS Reagent Repository), at an individual peptide concentration of 2 
µg/ml.  .  Mock-stimulated wells received media only.  Plates were incubated 18-20 hr at 
37oC in 5% CO2.  Positive spots were visualized on a CTL Imager and counting was 
performed with ImmunospotTM software (Cellular Technology Ltd., Shaker Heights, OH) 
Cytometric Bead Array (CBA)  
Cytokines were quantified in sera collected before immunization, and 6 hr following each 
protein boost, using a Th1/Th2/Th17 CBA kit from BD Biosciences (San Diego, CA).  
The panel included: IFNγ, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17, TNFα.  Prior to 
assay, sera were diluted 1:6 in sample diluent.  Samples were read using an LSRII FACS 
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machine (BD Biosciences), and the data was analyzed using FCAP Array Software v3.0 
(BD Bioscience).   
Luminex 
Cytokines and chemokines were quantified in serum collected before immunization, and 
6 hr following each protein boost, using a custom Bio-Plex cytokine assay (Bio-Rad, 
Hercules, CA) according to manufacturer’s instructions.  The panel of cytokines and 
chemokines included: IFNγ, IL-1β, IL-2, IL-4, IL-6, Eotaxin, G-CSF, KC, MIP-1α, MIP-
1β, MCP-1, and RANTES.  Prior to assay, serum samples were diluted 1:4 in sample 
diluent.  Samples were read on a Bio-Plex 200 system with Bio-Plex Manager software 
(Bio-Rad).   
BMDC Preparation 
Bl6.129 wildtype or AIM2 deficient mice were used to prepare BMDCs, as previously 
described (148, 191).  Briefly bone marrow cells were plated at 1x106 cells per 10 cm 
plate in 10 ml, and grown for 10-12 days in 10% GM-CSF (Invitrogen) in complete 
RPMI (Gibco) containing 10% FBS and 1% penicillin and streptomycin at 37oC.  At days 
3, 6, and 8, cells were fed at with 5 ml/plate fresh complete media.  At day 10-12, cells 
were harvested, counted, and replated in 96-well plates (Corning) at 2x105 cells/well in 
complete media.  Cells were rested overnight.   
BMDC Adjuvant Stimulation 
Cells were primed for 2 hours with 1 µg/ml LPS prior to adjuvant stimulation as 
previously described (191).  After priming, supernatant and stimulation were removed 
and replaced with adjuvant stimulations.  Cells were stimulated with adjuvants in the 
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following concentrations: 10 µg/ml QS-21, 100 µg/ml Al(OH)3, 20 µg/ml MPLA, or 10 
µg/ml ISCOMATRIX™ adjuvant.  As a positive control, 1.25 mM ATP was added to 
LPS-primed wells in the last hour of the overnight adjuvant stimulation.  Select samples 
were co-incubated with 2 mM Z-Vad-fmk pan-caspase inhibitor.  After 18-hour 
incubation at 37oC, supernatants were harvested and stored at -20oC for downstream 
application.   
IL-1β  ELISA 
Stimulated cell supernatant were assayed for production of IL-1β by ELISA (BD 
Biosciences) according to manufacturer’s instructions.   
Statistical Analysis 
All data is presented as the mean of individual mice +/- standard error of the mean 
(SEM).  Statistical analysis was performed using a Student’s t test, a one-way ANOVA 
followed by a Tukey post-test, or a two-way ANOVA followed by a Bonferroni post-test.   
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CHAPTER VI: 
Final Comments and Conclusions 
For the last three decades since the emergence of HIV-1 onto the global stage, a 
primary focus of HIV-1 research has been the design of an effective vaccine that is 
capable of eliciting sufficient virus-specific immune responses to confer protection 
against viral infection.  Until very recently, clinical attempts have not been successful, 
but have contributed valuable insight into immune correlates of protective immunity.  
Based on the failures of the VaxGen trials, which targeted on the induction of humoral 
immunity, and the Merck STEP trial, which instead focused on eliciting T cell responses, 
we have learned the importance of vaccine induction of both humoral and cell-mediated 
immune responses.  The unprecedented, albeit modest, protection elicited in the RV144 
trial demonstrated the improved efficacy of a prime-boost strategy in both vaccine-
specific antibody and T cell responses.  Still, while 31% protection is a promising 
advancement, substantial effort is still necessary to develop a vaccine capable of 
protecting the entire population against HIV-1 infection.   
 In addition to lessons about immune correlates of protective immunity, clinical 
trials of novel HIV-1 vaccine strategies have also emphasized the importance of adjuvant 
selection in vaccine design.  The use of a conventional, antibody-biased adjuvant like 
aluminum hydroxide gel in the RV144 trial, may well have contributed to the limitations 
to vaccine-induced immunogenicity.  In contrast, our own clinical studies of an HIV-1 
DNA prime-protein boost vaccine, DP6-001, utilized an adjuvant that potently stimulates 
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vaccine-specific antibodies, helper T cells, and cytotoxic T cells, but at the cost of 
clinical tolerability.   
 In the work presented in this dissertation, I attempted to characterize several 
conventional and novel adjuvant systems in the unique context of the DP6-001 DNA 
prime-protein boost vaccine.  Specifically, I aimed to define the adaptive immune 
responses associated with mice immunized with DP6-001 and adjuvants in terms of 
vaccine induction of Env-specific T cells and IgG antibody responses.  In these studies I 
also established distinct profiles of pro-inflammatory serum cytokines and chemokines 
associated with each adjuvant.   Additionally, I confirmed that these were unique to the 
DNA primed DP6-001 vaccine strategy, implicating a role for DNA priming in the 
inflammatory response to subsequent immunization with protein and adjuvants.   
 In terms of adaptive immunity, the select adjuvants Al(OH)3, QS-21, MPLA, and 
ISCOMATRIX™ adjuvant all comparably induced humoral responses in immunized 
mice, and while QS-21 most potently induced Env-specific Th1 cytokine production, 
both MPLA and ISCOMATRIX™ adjuvant also induced positive responses.  However, 
distinct patterns associated with each adjuvant emerged upon evaluation of a panel of 
non-antigen specific pro-inflammatory serum cytokines and chemokines at time points 6 
hours after protein-adjuvant immunization.  These studies identified several biomarkers 
induced shortly after protein-adjuvant induction in all immunization groups, including 
IL-6, KC, and MIP-1α.  DP6-001/Al(OH)3 demonstrated an overall low serum cytokine 
and chemokine profile.  DP6-001/QS-21 was characterized by Th1 cytokine IFNγ, Th2 
cytokine IL-4, as well as pro-inflammatory factors IL-1β and MIP-1β.  DP6-001/MPLA 
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was uniquely characterized by the broadly acting chemokines G-CSF and RANTES.  
DP6-001/ISCOMATRIX™ adjuvant was associated with potent induction of IL-2, 
Eotaxin, and MCP-1.  These distinct profiles are not only characteristic of each adjuvant, 
but are also unique to the context of the DP6-001 DNA prime-protein boost vaccine 
strategy itself.  The adjuvant profiles described in this dissertation provide insight into 
 A secondary aim of the research presented in this dissertation was to further 
explore the innate immune mechanisms utilized by the examined adjuvants, particularly 
given that the mechanisms of even widely employed adjuvants like Al(OH)3 remain 
undefined.  Adjuvants must be evaluated in the context of each new vaccine formulation, 
and the DNA prime-protein boost may provide a unique environment for the action of 
adjuvants on innate immune pathways.  With plans in mind to move forward with an 
optimized HIV-1 prime boost vaccine formulated with an improved adjuvant, these 
mechanistic studies focused on MPLA and ISCOMATRIX™ adjuvant specifically.   
In the context of DP6-001, I confirmed a critical role for TLR4 signaling in the 
antibody and T cell responses enhanced by MPLA.  In addition, intact TLR4 activation 
was required to generate serum cytokines and chemokines associated with DP6-
001/MPLA, chiefly RANTES and G-CSF, as well as IL-6, which was associated with all 
adjuvants.  More interestingly, in light of literature reports suggesting that MPLA induces 
weak MyD88 signaling and TRIF-biased activation downstream of TLR4, I also 
identified a critical role for MyD88 in the adaptive immune response to DP6-001/MPLA.  
Serum cytokine profiles were more variably affected by MyD88 deficiency.  I also 
reported reduced adaptive and innate inflammatory responses to immunization with 
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empty vector prime and DP6-001 protein-MPLA boost, highlighting the improved 
immunogenicity and inflammatory response provided by the DNA prime component.   
The studies presented in these chapters also evaluated the novel adjuvant system 
ISCOMATRIX™ adjuvant formulated with DP6-001 vaccine in both mice and rabbit 
models.  In both animal models, the induction of vaccine-specific serum IgG antibody 
responses were similar between adjuvant groups, the superiority of ISCOMATRIX™ 
adjuvant emerged in the rabbit model upon evaluation of the breadth and strength of 
neutralizing ability against a panel of Tier 2 viruses.  I also observed enhanced induction 
of serum cytokines and chemokines associated with DP6-001/ISCOMATRIX™ 
adjuvant, which was reduced in the absence of DNA priming.  Of particular note, while I 
did not observe a critical role for MyD88 signaling in the adaptive or inflammatory 
immune responses to DP6-001/ISCOMATRIX™ adjuvant, MyD88 deficiency had a 
significant negative impact on the adaptive and inflammatory profiles to immunization 
with protein and ISCOMATRIX™ adjuvant in the absence of DNA priming.  These 
results not only demonstrate the strong immune response induced by DP6-
001/ISCOMATRIX™ adjuvant, but also strongly indicate a role for DNA priming in 
shaping the inflammatory response to subsequent immunizations with antigen and 
adjuvant.   
As a final note, I began preliminary in vitro work drawing on recent trends in the 
literature exploring roles for innate inflammasome signaling in the mechanism of all of 
the adjuvants described in this dissertation.  While this work was performed in vitro and 
only in the absence of antigen, I confirmed the ability of Al(OH)3 and ISCOMATRIX™ 
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adjuvant to induce the production of IL-1β in LPS-primed BMDCs, and also indicated 
that QS-21 induces a similar response and may thus owe its adjuvanticity to a similar 
mechanism.  Furthermore, this IL-1β response was completely and significantly 
diminished with the inhibition of capase-1, and modestly but significantly reduced in 
cells generated from AIM2 deficient mice.  While these experiments were preliminary in 
nature, they lay the groundwork for the future directions for our lab, exploring more 
deeply in the innate mechanisms for vaccine adjuvants.  Our in vivo experiments clearly 
suggest a role for DNA priming not only in the enhancement of vaccine-specific 
immunogenicity, but also in providing a unique setting for the innate immune pathways 
harnessed by subsequent vaccine and adjuvant immunizations.   
In summary, in this dissertation I have established a method by which unique 
adjuvant profiles in the context of our vaccine can be defined, based on adaptive immune 
responses and serum cytokine and chemokine induction.  Furthermore, these profiles are 
unique to the setting of a DNA prime-protein boost immunization regimen utilizing HIV-
1 Env antigens, rather than being characteristic of a protein-adjuvant vaccine in the 
absence of DNA priming.  Finally, we have identified roles for both TLR4 and MyD88 
signaling in the generation of adaptive and pro-inflammatory immune responses to DP6-
001 and MPLA adjuvant; meanwhile, any role for MyD88 signaling in the immune 
responses to other adjuvants appears to vary based on the vaccine regimen.  This body of 
work clearly warrants further investigation of the impact of DNA priming on subsequent 
immunization and adjuvant use, sheds additional light on the involvement of our selected 
adjuvants in innate inflammasome pathways that are increasingly the focus of adjuvant 
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research, and provides an opportunity to make a critical clinically relevant link between 
innate immune responses to adjuvants and the adaptive immune responses to which they 
contribute.   
 The original impetus for our study of adjuvants was a clinical case of 
leukocytoclastic vasculitis, and other, milder adverse effects associated with our DP6-001 
vaccine and the QS-21 adjuvant (86).  We aimed to explore the causes of inflammation 
and adverse effects of vaccine adjuvants, and also identify markers indicative of 
inflammation and of immunogenicity, which might better inform us in our selection of an 
ideal adjuvant from a panel of candidates.  However, this question is not so clear cut, as 
samples from human subjects immunized with DP6-001 and QS-21 were not assessed for 
correlates of reactogenicity.  Furthermore, there is mounting evidence that the reliable 
animal models upon which so much preclinical work is based may not be truly predictive 
of clinical outcomes.  Indeed, preclinical toxicology and immunogenicity studies of DP6-
001 and QS-21 in rabbits did not reveal local or systemic reactogenicity associated with 
the vaccine, encouraging the move towards a clinical application (140).   
This issue may particularly evident in the case of inbred mice used for models of 
inflammation and immunological responses.  A recent article by Seok et al. summarizes 
results of published models of acute inflammatory stresses in murine and human models, 
with a focus on the gene response patterns in mice and compared to humans in the 
context of varied sources of acute inflammation, including endotoxemia, trauma, and 
burns (168).  Given the dominance of the mouse model in preclinical research, it was 
surprisingly to find that at the transcriptional level, the response in mice to endotoxemia 
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and acute injury and inflammation varied so greatly from the human response.  It has 
been established that mice tolerate a substantially higher challenge of endotoxin in 
comparison to humans, although the kinetics of cytokine induction in response to 
endotoxin are not wholly disparate between the two models (33).  Why then, if such a 
basic immunological response is so different at the genetic level, do we rely so heavily on 
the mouse model in the study of human immunological responses?  Clearly new 
approaches sounds be explored to improve the quality of animal models, perhaps moving 
towards humanized mouse models, or to develop alternative ways to simulate the human 
model (68).   
Still, the preclinical adjuvant research presented in this dissertation is not without 
significance.  We clearly identified superior immunogenicity of novel adjuvant systems 
compared to classical adjuvants, and also established unique profiles of inflammatory 
markers consistently associated with each candidate adjuvant.  In addition, we have 
demonstrated the substantial impact of a DNA priming component on the 
immunogenicity and inflammatory cytokine profiles elicited upon subsequent 
immunization.  Certainly we may observe the impact of different adjuvants on the 
immunogenicity of the DP6-001 vaccine in a preclinical model in a clinically relevant 
way, particularly in terms of the improved neutralizing antibodies elicited by MPLA and 
ISCOMATRIX™ adjuvant compared to classical adjuvants.   
In the absence of clear human correlates of reactogenicity, it is difficult to 
characterize the nature of adverse effects that might be predicted by these inflammatory 
markers, or indeed to define the specific qualities of an ideal adjuvant.  Given what we 
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know about the balanced humoral and cell-mediated immunity (Th1/Th2 responses as 
well as CTLs) necessitated by a complex pathogen such as HIV-1, and evidence from 
clinical studies of each adjuvant, we can speculate that the novel adjuvants MPLA and 
ISCOMATRIX™ are better candidates for inclusion in future HIV-1 vaccine 
formulations that aluminum hydroxide adjuvants or QS-21.   
Our preclinical work with multiplex analysis of serum cytokines suggests that 
strong and balanced induction of Th1 and Th2 cytokines may be favorable and associated 
with improved immunogenicity; potent pro-inflammatory cytokines such as the elevated 
IL-1β associated with QS-21, may be of predictive value for reactogenicity.  We might 
also speculate that cytokine and chemokine profiles suggestive of a diverse and rapid 
recruitment of innate immune cells, resulting in improved antigen trafficking and 
presentation.  This would be best further studied by studying the temporal immune cell 
recruitment at the sites of immunization and at draining lymph nodes, alongside serum 
cytokines and chemoattractants in both preclinical and clinical models.  Further still, the 
mechanisms of these adjuvants on the innate and adaptive immune systems remain poorly 
defined.  More thorough elucidation of the signaling pathways activated by these 
candidate adjuvants would help to define the relationship of these serum marker profiles 
to the innate and adaptive immune responses shaped by each adjuvant.   
Definition of mechanisms of action of these adjuvants as well as the mechanism 
of DNA priming and its impact on subsequent immunizations, will likely be the focus of 
future preclinical investigation by this lab, based on the data described herein.    In 
addition, optimized vaccine formulations including ISCOMATRIX™ adjuvant are 
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moving towards clinical trials. The preclinical work in this dissertation has laid the 
groundwork for future development of the DNA prime-protein boost HIV-1 vaccine.     
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Preface to Appendix I 
 
 
R. Buglione-Corbett designed, performed, and analyzed the preliminary in vitro 
experiments presented in this chapter, Fig. AI.1. 
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Appendix I: 
Preliminary in vitro studies exploring innate pathways to guide future adjuvant 
studies 
Introduction 
 In light of our in vivo findings regarding the impact of DNA priming on the 
MyD88 dependency of adaptive immune responses and serum cytokine profiles to 
ISCOMATRIX™ adjuvant, and considering the current direction of research into 
adjuvant mechanisms, we decided to further explore our candidate adjuvants in vitro.  
Bone marrow-derived dendritic cells (BMDCs) derived from wildtype mice or mice 
deficient in immune signaling pathways were stimulated with candidate adjuvants, and 
IL-1β secretion was quantified as a determination of inflammasome activation.  We 
examined adjuvant activity in the presence or absence of a caspase-1 inhibitor molecule, 
in order to generally evaluate the dependence of adjuvant-induced IL-1β secretion on 
caspase-1-dependent inflammasome complexes such as NLRs and AIM2.  The work 
described in this Appendix highlights simple pilot in vitro studies, which serve mainly to 
confirm a future direction for the adjuvant work to be performed by our lab.   
As described in previous chapters, the NLRP3 inflammasome has been the most 
widely investigated inflammasome protein complex in the context of adjuvants, 
especially aluminum salts and to a lesser extent, ISCOMATRIX™ adjuvant.  In both 
cases, it remains unclear whether the particulate adjuvants themselves stimulate assembly 
of the inflammasome complex and subsequent secretion of pro-inflammatory cytokines, 
or if administration of adjuvant results in tissue and cellular damage, the products of 
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which are inflammasome ligands.  It is the latter hypothesis that suggests the potential 
importance of nucleic acid sensing pathways in adjuvant mechanisms.  As described in 
Chapter I, while many nucleic acid sensing pathways result in the production of type I 
IFNs, the AIM2 inflammasome, like NLRP3, recruits caspase-1 and results in the 
secretion of IL-1β and IL-18 in response to dsDNA.  Recent studies by Marichal et al. 
suggest that aluminum salts induce cell death, resulting in the release of host cell DNA.  
The host DNA activates innate nucleic acid sensors, and the subsequent secretion of pro-
inflammatory cytokines helps shape the adaptive immune response to immunization with 
aluminum salt-based adjuvants (111).   
A novel role for cell damage products in the adjuvanticity of alumimun salts 
suggest that these pathways may also be relevant for our other adjuvants of interest, in 
particular the saponin adjuvants QS-21 and ISCOMATRIX™ adjuvant.  QS-21 is a 
known hemolytic agent with reactogenic characteristics and strong induction of 
inflammatory cytokines including IL-1β, but very little is known about its mechanism.  
While our in vivo data does not suggest a dependence on TLR4 or MyD88 signaling for 
the generation of adaptive immunity or serum cytokine profiles, at least in the context of 
DP6-001, QS-21 may directly or indirectly act on inflammasome pathways.  While 
ISCOMATRIX™ adjuvant is considerably more tolerable than QS-21, it also contains a 
saponin fraction and is also particulate in nature, characteristics that may cause cell 
damage upon administration.  Therefore, with the recent work on Al(OH)3 in mind, we 
aimed to take an exploratory approach and investigate the activation of the AIM2 
inflammasome by our candidate adjuvant in vitro in the absence of antigen.   
 158 
Results 
Generation of BMDCs and Adjuvant Stimulations 
In these pilot experiments, bone marrow-derived dendritic cells (BMDCs) were generated 
from naïve wildtype or mice deficinent in innate immune signaling pathways as 
previously described (10, 149).  Bone marrow was harvested from individual mice, and 
the cells were grown in complete RPMI with 10% FBS and 1% penicillin and 
streptomycin for 12 days in the presence of 10% GM-CSF for the selective growth of 
BMDCs.  After maturation, cells were counted and seeded into 96-well plates for 
stimulation the next day.  Cells were washed with complete media and BMDCs were 
incubated for 18 hours, with either QS-21, Al(OH)3, MPLA, or ISCOMATRIX™ 
adjuvant in the absence of antigen.  
Adjuvant induction of IL-1β  production in wildtype BMDCs  
BMDCs generated from Bl6.129 wildtype mice were primed with LPS for 2 hours, 
before being stimulated with adjuvant overnight (42, 149).  Based on previous methods 
described in the literature, BMDCs were stimulated with 10 µg/ml of QS-21 or 
ISCOMATRIX™ adjuvant, 20 µg/ml of MPLA, or 100 µg/ml of Al(OH)3.  As a read-out 
of inflammasome activation, IL-1β was measured in the supernatant by ELISA.  LPS-
primed BMDCs stimulated with either QS-21, Al(OH)3, or ISCOMATRIX™ adjuvant 
produced comparably robust IL-1β.  As previously described in Chapter I, a first signal 
via MyD88 and NFκB activation is required for production of pro-cytokines and 
assembly of inflammasome components (10).   Thus, as we would expect, adjuvant 
stimulations in the absence of LPS priming resulted in poor IL-1β production.  
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Furthermore, LPS priming alone was insufficient for induction of IL-1β.  As it has been 
previously established that the LPS derivative, MPLA, has impaired activation of the 
NLRP3 inflammasome, MPLA alone also did not induce IL-1β (Fig AI.1). 
Adjuvant-induced IL-1β  production in wildtype BMDCs requires caspase-1 
The small molecule z-VAD-fmk (z-VAD) binds to the catalytic site of caspases and 
inhibits their enzymatic function.  While z-VAD inhibits several caspases, it very 
strongly inhibits caspase-1 and is frequently used in studies of the NLRP3 
inflammasome.  Wildtype BMDCs were primed with LPS for 2 hours and then stimulated 
with adjuvant in the presence and absence of z-VAD.  Addition of the caspase-1 inhibitor 
completely abrograted the IL-1β induction by QS-21, Al(OH)3 and ISCOMATRIX™ 
adjuvant (Fig AI.1).  
Reduction of IL-1β  in AIM2 deficient BMDCs stimulated by adjuvant 
In order to explore a potential role for the AIM2 inflammasome in the mechanism of each 
candidate adjuvant, the in vitro stimulations described above were performed in parallel 
in BMDCs generated from AIM2 deficient mice.  Interestingly, AIM2 deficiency 
significantly reduced IL-1β production in response to Al(OH)3 or ISCOMATRIX™ 
adjuvant, but this negative impact was only partial.  In AIM2 deficient BMDCs 
stimulated with QS-21, there was a modest reduction in IL-1β induction compared to 
wildtype.  However, the addition of z-VAD to adjuvant stimulations in AIM2 deficient 
mice completely eliminated the IL-1β response to QS-21, Al(OH)3, and 
ISCOMATRIX™ adjuvant, similar to the effect observed in wildtype BMDCs (Fig AI.1). 
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Figure AI.1.  Adjuvants induced IL-1β  production in LPS-primed BMDCs from 
wildtype and AIM2 deficient mice in the absence of antigen.  BMDCs were generated 
from the bone marrow of Bl6.129 wildtype (WT) or AIM2 deficient (KO) mice.  After 
maturation, BMDCs were plated at 2x105 cells/well, and primed with 1 µg/ml LPS for 2 
hours.  After priming, BMDCs were incubated with adjuvants for 18 hours overnight at 
the following concentrations (grey): 10 µg/ml QS-21, 100 µg/ml Al(OH)3, 20 µg/ml 
MPLA, or 10 µg/ml ISCOMATRIX™ adjuvant.  As a control, BMDCs were incubated 
with adjuvants in the absence of LPS priming (white).  Select adjuvant stimulations of 
BMDCs were co-incubated with the pan-caspase-1 inhibitor Z-vad (checkered).  
Statistical differences were determined by a two-way ANOVA and a Bonferroni post-
test.  (*: p < .05, **: p < .01, ***: p < .001).  (IMX = ISCOMATRIX™ adjuvant)  
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Discussion 
 Innate signaling pathways, and inflammasomes in particular, are the primary 
focus in current adjuvant research.  Though the goal of adjuvants in vaccine design is to 
harness the innate immune response and promote inflammatory responses in order to 
promote antigen presentation and generation of adaptive immunity, the mechanism by 
which these adjuvants accomplish these immunomodulatory effects remains unclear.  
Aluminum salts in particular have been extensively evaluated for activation of the 
NLRP3 inflammasome, and while it is clear that alum-based adjuvants induce pro-
inflammatory cytokines in an NLRP3-dependent manner, a clear link between this 
response and adaptive immunity subsequent to vaccination with antigen in vivo remains 
tenuous (45, 53, 77, 92, 97, 119, 169).   
Our in vivo experience with select adjuvants in the context of DP6-001 DNA 
prime-protein boost, in comparison to empty vector primed immunizations or protein-
only immunizations, demonstrate that the DNA priming component itself may uniquely 
affect the immunogenicity and inflammatory profiles of adjuvants in subsequent protein 
immunizations.  The influence of DNA priming may even be to the extent of reduced 
dependence on innate pathways involving MyD88, for example, for the generation of 
adaptive immunity.   
 Consistent with previous reports, LPS-primed BMDCs stimulated with aluminum 
hydroxide gel or ISCOMATRIX™ adjuvant induced IL-1β in a caspase-1-dependent 
manner (42).  QS-21 also induced IL-1β in a caspase-1-dependent manner.  While this 
has not to our knowledge been previously demonstrated in this model, it is not 
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unexpected for several reasons: serum IL-1β associated with QS-21 in the context of 
DP6-001, the similarities between QS-21 and ISCOMATRIX™ adjuvant, and the likely 
cell damage caused by QS-21 administration.  However, the complete inhibition of IL-1β 
in the presence of a caspase-1 inhibitor suggests that, like Al(OH)3 and ISCOMATRIX™ 
adjuvant, QS-21 may be acting via a caspase-1-dependent inflammasome complex. 
 Based on recent reports that aluminum hydroxide induces cell death and 
subsequent release of host DNA, which is responsible for shaping the adaptive immune 
response to alum-adjuvanted vaccination (111), we chose to evaluate a potential role for 
the caspase-1-dependent dsDNA sensor AIM2 in the IL-1β response to adjuvant 
stimulations.  We hypothesized that, similarly to aluminum hydroxide adjuvants, the 
saponins QS-21 and ISCOMATRIX™ adjuvant may also cause cell damage and 
subsequently activate nucleic acid sensing pathways.  While we did observe a reduction 
in the IL-1β response in AIM2 deficient BMDCs with all candidate adjuvants, the effect 
was only partial.  Adjuvant-induced IL-1β was completely absent in AIM2 deficient 
BMDCs with the addition of z-VAD.  These results suggest that while AIM2 signaling 
may contribute to the IL-1β response to stimulation with QS-21, ISCOMATRIX™ 
adjuvant or Al(OH)3, it is not required.  However, intact caspase functionality is required 
for the induction of IL-1β for each of these adjuvants, indicating the possible 
involvement of multiple inflammasome pathways. 
In the preliminary experiments described in this chapter, we sought to define 
potential future directions for our group’s continued adjuvant research.  As we move 
forward with optimized HIV-1 DNA prime-protein boost vaccines, and with the 
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ISCOMATRIX™ adjuvant selected for use in future vaccine formulations, we aim to 
better understand both the mechanism of ISCOMATRIX™ adjuvant itself, and also how 
its mechanism may be impacted by the unique context of DNA priming.  In addition, 
inclusion of QS-21 in these experiments may provide greater insight into the mechanism 
of action of saponins in general, and also a potential mechanism for the reactogenicity 
associated with QS-21 in comparison to more tolerable saponins-related systems like 
ISCOMATRIX™ adjuvant.   
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